drug	genes	question	answer	incorrect_recommendations	concurring_recommendation	llm_answer	oai_embedding_ref_vs_llm	oai_embedding_ref_vs_concurring	oai_embedding_adversarial_vs_llm	oai_embedding_concurring_vs_llm	negation_mpnet_ref_vs_llm	negation_mpnet_ref_vs_concurring	negation_mpnet_adversarial_vs_llm	negation_mpnet_concurring_vs_llm	base_mpnet_ref_vs_llm	base_mpnet_ref_vs_concurring	base_mpnet_adversarial_vs_llm	base_mpnet_concurring_vs_llm	roberta_ref_vs_llm	roberta_ref_vs_concurring	roberta_adversarial_vs_llm	roberta_concurring_vs_llm	gte_ref_vs_llm	gte_ref_vs_concurring	gte_adversarial_vs_llm	gte_concurring_vs_llm	gpt4_ref_vs_llm
abacavir	HLA-B	What would be the clinical guidance for someone who is HLA-B*57:01 positive for HLA-B with regards to taking abacavir? Give a 2-3 sentence summary.	Abacavir is not recommended	['Proceed taking abacavir as normal. There is no recommendation.', 'Take abacavir with a reduced dose.', 'Take abacavir with an increased dose.']	Avoid abacavir. Take an alternate therapy.	Individuals who are HLA-B*57:01 positive should not be prescribed abacavir due to a significantly increased risk of developing a hypersensitivity reaction to the drug. Clinical guidelines recommend performing HLA-B*57:01 screening before initiating abacavir therapy to ensure patient safety.	0.6769935912817803	0.7590662809135725	0.7479400437640393	0.6170525121879807	0.733724	0.7781517	0.69347507	0.58527726	0.68127954	0.83611435	0.7775479	0.62955344	0.56740725	0.8141054	0.7101602	0.52350014	0.64126277	0.8348719	0.68388987	0.6368246	1
abacavir	HLA-B	What would be the clinical guidance for someone who is HLA-B*57:01 negative for HLA-B with regards to taking abacavir? Give a 2-3 sentence summary.	Use abacavir per standard dosing guidelines	['Avoid abacavir. Take an alternate therapy.', 'Take abacavir with a reduced dose.', 'Take abacavir with an increased dose.']	Proceed taking abacavir as normal. There is no recommendation.	If an individual tests negative for the HLA-B*57:01 allele, they are at a significantly reduced risk of developing abacavir hypersensitivity syndrome. Therefore, abacavir can be prescribed for the treatment of HIV without the heightened risk of this potentially severe reaction. Nonetheless, patients should still be monitored for any adverse effects as with any antiretroviral therapy.	0.601061570034174	0.7423717712059391	0.739037784899372	0.5734117092044021	0.55983853	0.615938	0.6371864	0.60572374	0.6469512	0.81842077	0.70092964	0.63771385	0.55826133	0.77097464	0.7008068	0.44589424	0.6177647	0.677821	0.6862624	0.5697221	1
allopurinol	HLA-B	What would be the clinical guidance for someone who is HLA-B*58:01 positive for HLA-B with regards to taking allopurinol? Give a 2-3 sentence summary.	Allopurinol is contraindicated	['Proceed taking allopurinol as normal. There is no recommendation.', 'Take allopurinol with a reduced dose.', 'Take allopurinol with an increased dose.']	Avoid allopurinol. Take an alternate therapy.	Individuals who are HLA-B*58:01 positive should avoid allopurinol due to an increased risk of severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Clinical guidelines recommend using alternative medications to manage conditions like gout in these patients to prevent these potentially life-threatening reactions.	0.6565354895323575	0.7545026572256232	0.7085925768723073	0.6242201621126844	0.777525	0.76679975	0.6530145	0.69019747	0.7317428	0.82667464	0.66951466	0.7019686	0.52227724	0.7028648	0.59876686	0.61225516	0.7169271	0.6549111	0.61749643	0.6994311	1
allopurinol	HLA-B	What would be the clinical guidance for someone who is HLA-B*58:01 negative for HLA-B with regards to taking allopurinol? Give a 2-3 sentence summary.	Use allopurinol per standard dosing guidelines	['Avoid allopurinol. Take an alternate therapy.', 'Take allopurinol with a reduced dose.', 'Take allopurinol with an increased dose.']	Proceed taking allopurinol as normal. There is no recommendation.	For individuals who test negative for the HLA-B*58:01 allele, the risk of developing allopurinol-induced severe cutaneous adverse reactions (SCAR) is significantly lower. Therefore, standard guidelines recommend that allopurinol can be prescribed to these patients without the heightened concern for SCAR related to this genetic marker. Regular monitoring for adverse reactions is still advised, but the absence of the HLA-B*58:01 allele allows for a more routine use of allopurinol in managing conditions like gout.	0.6385142519658511	0.7484076173506446	0.718666789370288	0.5907692048870204	0.5527396	0.68156767	0.6525745	0.5708001	0.59296864	0.83289593	0.7034952	0.54854226	0.54367805	0.7821047	0.68069845	0.49726045	0.6379913	0.7153088	0.64258885	0.6226481	1
amikacin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking amikacin as normal. There is no recommendation.', 'Take amikacin with a reduced dose.', 'Take amikacin with an increased dose.']	Avoid amikacin. Take an alternate therapy.	For patients identified with a genetic variant in MT-RNR1 that increases their risk of aminoglycoside-induced hearing loss, clinical guidance would typically recommend avoiding aminoglycosides, such as amikacin, whenever possible. If the use of amikacin is essential and no appropriate alternatives are available, it is crucial to monitor hearing function closely throughout the treatment and consider the lowest effective dose to mitigate the risk.	0.7578111457747674	0.5695090963475564	0.4649105976259993	0.5315693991690866	0.8014889	0.6022638	0.47815537	0.6176495	0.74198914	0.48981172	0.4896748	0.6003747	0.75019896	0.5031079	0.4638221	0.5373512	0.6497968	0.66144204	0.53816634	0.6095261	1
amikacin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid amikacin. Take an alternate therapy.', 'Take amikacin with a reduced dose.', 'Take amikacin with an increased dose.']	Proceed taking amikacin as normal. There is no recommendation.	For individuals who have normal risk of aminoglycoside-induced hearing loss according to their MT-RNR1 genotype, standard dosing and monitoring practices for amikacin can be followed. It is still important to ensure appropriate dosing, therapeutic drug monitoring, and renal function assessment to minimize the risk of ototoxicity and nephrotoxicity, as these adverse effects can still occur even in genetically low-risk individuals.	0.6844916722850259	0.4757929502291946	0.48585757741050034	0.5660157815837399	0.70228153	0.46694177	0.49092147	0.55804527	0.6643421	0.5265164	0.54872555	0.63597393	0.7140554	0.51020634	0.4997115	0.48684165	0.62213016	0.54797643	0.58697814	0.5749011	1
amikacin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking amikacin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid amikacin. Take an alternate therapy.', 'Take amikacin with a reduced dose.', 'Take amikacin with an increased dose.']	Proceed taking amikacin as normal. There is no recommendation.	For individuals who are at uncertain risk of aminoglycoside-induced hearing loss due to variations in the MT-RNR1 gene, it is advisable to exercise caution when prescribing amikacin. Alternative antibiotics should be considered to avoid potential ototoxicity. Genetic testing for MT-RNR1 variants (e.g., m.1555A>G) can provide more definitive guidance, as carriers of certain variants are at a significantly higher risk of hearing loss from aminoglycosides.	0.6029046292061288	0.4757929502291946	0.48585757741050034	0.47925965728458136	0.54625267	0.46694177	0.49092147	0.519681	0.65418476	0.5265164	0.54872555	0.56091726	0.7113856	0.51020634	0.4997115	0.45866463	0.5839224	0.54797643	0.58697814	0.5284351	0
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking aminosalicylic acid? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid aminosalicylic acid. Take an alternate therapy.', 'Take aminosalicylic acid with a reduced dose.', 'Take aminosalicylic acid with an increased dose.']	Proceed taking aminosalicylic acid as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), the use of aminosalicylic acid is generally not recommended due to the risk of hemolytic anemia. G6PD deficiency can impair the red blood cells' ability to handle oxidative stress, leading to increased susceptibility to hemolysis when exposed to certain medications and chemicals, including aminosalicylic acid. Therefore, clinicians usually advise against the use of this medication in G6PD-deficient patients and may consider alternative treatments.	0.6238958135545675	0.44187849526037787	0.3204646679621956	0.5568506541678523	0.5815627	0.57132846	0.38750115	0.6162487	0.60430974	0.4840476	0.32936192	0.6262674	0.59149814	0.42687216	0.34347177	0.53629816	0.5351056	0.48436832	0.38195387	0.5245647	0
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking aminosalicylic acid? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid aminosalicylic acid. Take an alternate therapy.', 'Take aminosalicylic acid with a reduced dose.', 'Take aminosalicylic acid with an increased dose.']	Proceed taking aminosalicylic acid as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, it's advisable to exercise caution with medications that can induce hemolysis. Aminosalicylic acid is known to potentially trigger hemolytic anemia in patients with G6PD deficiency. Therefore, alternative treatments should be considered, and close monitoring for signs of hemolysis is recommended if the use of aminosalicylic acid is deemed necessary.	0.6518655723445024	0.3651483317780353	0.29022834635833417	0.5041672762314449	0.55384535	0.276957	0.30954546	0.59504694	0.60533595	0.35385734	0.3112883	0.5830423	0.5645357	0.23289989	0.22736818	0.54805166	0.4943999	0.39969903	0.3975959	0.538847	0
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking aminosalicylic acid? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid aminosalicylic acid. Take an alternate therapy.', 'Take aminosalicylic acid with a reduced dose.', 'Take aminosalicylic acid with an increased dose.']	Proceed taking aminosalicylic acid as normal. There is no recommendation.	In individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, especially those with Chronic Non-Spherocytic Hemolytic Anemia (CNSHA), caution is advised when considering the use of aminosalicylic acid. This drug has been associated with hemolysis in G6PD-deficient patients, and thus, alternative treatments should be considered to avoid potential hemolytic events. Clinical guidance typically involves careful risk assessment and monitoring if the use of this drug is deemed necessary.	0.5170884549126985	0.4007958015421879	0.41787655467330515	0.559381380447059	0.57872844	0.46784836	0.48777103	0.5829394	0.5237429	0.44924873	0.45345184	0.5608764	0.5720337	0.41248104	0.39447233	0.5158317	0.5849181	0.37057313	0.4644724	0.5394651	1
aminosalicylic acid	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking aminosalicylic acid? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid aminosalicylic acid. Take an alternate therapy.', 'Take aminosalicylic acid with a reduced dose.', 'Take aminosalicylic acid with an increased dose.']	Proceed taking aminosalicylic acid as normal. There is no recommendation.	For individuals with normal G6PD activity, there is no specific contraindication for the use of aminosalicylic acid related to G6PD deficiency. Therefore, these patients can generally take aminosalicylic acid without an increased risk of hemolysis that is associated with G6PD deficiency. Always consult with a healthcare provider for personalized medical advice.	0.6332607586460717	0.3818308064162856	0.2535010698233842	0.6288105904901095	0.5513823	0.3969791	0.20935772	0.7106618	0.5252825	0.27556524	0.16035242	0.700514	0.4420359	0.17489591	0.108316936	0.61672926	0.5298134	0.40799674	0.2952974	0.57225573	1
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline? Give a 2-3 sentence summary.	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking amitriptyline as normal. There is no recommendation.', 'Take amitriptyline with a reduced dose.', 'Take amitriptyline with an increased dose.']	Avoid amitriptyline. Take an alternate therapy.	For an individual who is an Ultrarapid Metabolizer (UM) for CYP2D6 with an activity score of ≥3.0 and an Intermediate Metabolizer (IM) for CYP2C19, clinical guidance suggests avoiding the use of amitriptyline due to significantly reduced efficacy and potential for subtherapeutic levels. Monitoring is advised if use is necessary, with consideration of an alternative medication not primarily metabolized by CYP2D6, such as nortriptyline or another non-tricyclic antidepressant.	0.7322392671892523	0.6949160559521141	0.6515407280902098	0.654773492820532	0.64321506	0.65050745	0.5732425	0.65324867	0.63086694	0.6533343	0.5974688	0.6979806	0.536312	0.56317353	0.5388899	0.58636266	0.60641146	0.6366815	0.5333409	0.6200774	1
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking amitriptyline? Give a 2-3 sentence summary.	Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking amitriptyline as normal. There is no recommendation.', 'Take amitriptyline with a reduced dose.', 'Take amitriptyline with an increased dose.']	Avoid amitriptyline. Take an alternate therapy.	For a patient who is a Poor Metabolizer (activity score = 0.0) for CYP2D6 and an Intermediate Metabolizer for CYP2C19, it is recommended to avoid using amitriptyline due to the increased risk of side effects and reduced drug efficacy. If amitriptyline is necessary, consider starting with a lower dose and monitoring plasma concentrations and clinical response closely, or selecting an alternative medication not metabolized by CYP2D6 and CYP2C19.	0.7446104123343709	0.6987435362115095	0.6955513903005647	0.6334379532824097	0.7332978	0.67975414	0.6347178	0.63222885	0.7409122	0.72943026	0.67952085	0.70410126	0.6430812	0.63382924	0.60919553	0.5920212	0.7188738	0.6415289	0.546624	0.66167724	1
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking amitriptyline? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	['Proceed taking amitriptyline as normal. There is no recommendation.', 'Take amitriptyline with a reduced dose.', 'Take amitriptyline with an increased dose.']	Avoid amitriptyline. Take an alternate therapy.	For a patient who is an Ultrarapid Metabolizer with an activity score ≥4.0 for CYP2D6 and has no result for CYP2C19 regarding amitriptyline use, clinicians should consider prescribing an alternative medication not metabolized by CYP2D6 due to the likelihood of subtherapeutic drug levels and reduced efficacy. If amitriptyline is necessary, careful monitoring and potential dose adjustments are essential to achieve therapeutic response and mitigate the risk of adverse effects.	0.6894337321320892	0.5743874390717245	0.5259300554648737	0.6399326318310498	0.74855316	0.5125287	0.48056576	0.6489454	0.67077893	0.39688078	0.40023708	0.64759105	0.66785204	0.38163447	0.41306105	0.5727667	0.63893557	0.49497023	0.44446453	0.58823687	1
amitriptyline	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking amitriptyline? Give a 2-3 sentence summary.	Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking amitriptyline as normal. There is no recommendation.', 'Take amitriptyline with a reduced dose.', 'Take amitriptyline with an increased dose.']	Avoid amitriptyline. Take an alternate therapy.	For an individual who is an Ultrarapid Metabolizer (UM) with an activity score of 2.5 for CYP2D6 and a Rapid Metabolizer for CYP2C19, the dose of amitriptyline may need to be adjusted, as these metabolic profiles can lead to reduced drug efficacy and increased risk of side effects. Clinical guidelines suggest considering a lower starting dose and closely monitoring the patient's response, potentially using therapeutic drug monitoring to optimize the dose. Alternatively, the use of a different antidepressant that is not primarily metabolized by CYP2D6 or CYP2C19 could be considered.	0.7189177565890478	0.6949160559521141	0.6515407280902098	0.606425069462934	0.63821054	0.65050745	0.5732425	0.5462981	0.6440818	0.6533343	0.5974688	0.7004309	0.55355364	0.56317353	0.5388899	0.58300036	0.5836525	0.6366815	0.5333409	0.55712384	0
aspirin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking aspirin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid aspirin. Take an alternate therapy.', 'Take aspirin with a reduced dose.', 'Take aspirin with an increased dose.']	Proceed taking aspirin as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), taking aspirin should be approached with caution. Aspirin can potentially cause hemolysis (destruction of red blood cells) in G6PD-deficient patients, especially at higher doses. It is advisable for these individuals to consult their healthcare provider before taking aspirin to carefully weigh the risks and consider alternative treatments if necessary.	0.5873908377592305	0.4459659687897329	0.34427394878059303	0.5105157288354822	0.5535624	0.5056575	0.297689	0.5565311	0.57955813	0.389984	0.2018512	0.5598378	0.4385571	0.3024909	0.20275877	0.50611305	0.481702	0.4712979	0.35572085	0.53595525	0
aspirin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking aspirin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid aspirin. Take an alternate therapy.', 'Take aspirin with a reduced dose.', 'Take aspirin with an increased dose.']	Proceed taking aspirin as normal. There is no recommendation.	For individuals with an indeterminate glucose-6-phosphate dehydrogenase (G6PD) status, caution is advised when prescribing aspirin, as G6PD deficiency can lead to hemolysis, particularly at high doses. Clinical guidance should involve assessing the risks versus benefits and considering alternative therapies or conducting further diagnostic tests to determine G6PD activity before using aspirin for treatment.	0.6403260451629742	0.33288404041990965	0.2828415120114278	0.5173722127550695	0.5570447	0.15246576	0.1356938	0.5431322	0.6425647	0.14822087	0.043561477	0.5055261	0.6189415	0.10093928	0.07276488	0.47462314	0.6074869	0.3910955	0.37708566	0.53679913	0
aspirin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking aspirin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid aspirin. Take an alternate therapy.', 'Take aspirin with a reduced dose.', 'Take aspirin with an increased dose.']	Proceed taking aspirin as normal. There is no recommendation.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those who have chronic non-spherocytic hemolytic anemia (CNSHA), the use of aspirin is generally advised with caution. Aspirin can induce hemolysis in G6PD-deficient individuals, so it should either be avoided or closely monitored, with alternative pain relievers being considered when necessary. Always consult with a healthcare provider for personalized medical advice.	0.47259858444334396	0.36301316023426117	0.4317639476515504	0.49004298425078296	0.59410673	0.5096382	0.4923276	0.5438011	0.5807741	0.5230756	0.43451056	0.5690123	0.5412181	0.37750235	0.35231486	0.5373409	0.548218	0.46096963	0.49368575	0.5522812	1
aspirin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking aspirin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid aspirin. Take an alternate therapy.', 'Take aspirin with a reduced dose.', 'Take aspirin with an increased dose.']	Proceed taking aspirin as normal. There is no recommendation.	For an individual who has normal glucose-6-phosphate dehydrogenase (G6PD) activity, taking aspirin generally does not pose an increased risk for hemolytic anemia, which is a concern in individuals with G6PD deficiency. Therefore, standard clinical guidelines and dosing recommendations for aspirin can be followed, considering any other underlying health conditions or contraindications the patient may have. It is always advisable to use aspirin under the guidance of a healthcare provider to ensure it is appropriate for the individual's overall health status.	0.6052653297983634	0.38012272463083585	0.2635640942934305	0.5859662516990247	0.50211984	0.3738107	0.16683589	0.5744885	0.44670162	0.24273354	0.09404412	0.58225024	0.31762654	0.088122874	0.028731184	0.53928745	0.5431746	0.41270486	0.29584396	0.5981466	1
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Normal Metabolizer for UGT1A1 with regards to taking atazanavir? Give a 2-3 sentence summary.	There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).	['Avoid atazanavir. Take an alternate therapy.', 'Take atazanavir with a reduced dose.', 'Take atazanavir with an increased dose.']	Proceed taking atazanavir as normal. There is no recommendation.	For a person who is a normal metabolizer (extensive metabolizer) of UGT1A1, clinical guidance suggests that they can take atazanavir without any requirement for dose adjustment. This is because their UGT1A1 enzyme activity is typical, allowing for the standard metabolism and clearance of atazanavir, thereby minimizing the risk of drug toxicity or reduced efficacy.	0.7510851438576457	0.571195637874032	0.5767795902919776	0.648671579061782	0.65962553	0.6421217	0.52521545	0.54126215	0.7056792	0.6135973	0.54535025	0.6281878	0.63386655	0.45971867	0.41235915	0.5383093	0.6381608	0.46626982	0.53889376	0.60779005	1
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Poor Metabolizer for UGT1A1 with regards to taking atazanavir? Give a 2-3 sentence summary.	Consider an alternative agent particularly where jaundice would be of concern to the patient. If atazanavir is to be prescribed, there is a high likelihood of developing jaundice that will result in atazanavir discontinuation (at least 20% and as high as 60%).	['Proceed taking atazanavir as normal. There is no recommendation.', 'Take atazanavir with a reduced dose.', 'Take atazanavir with an increased dose.']	Avoid atazanavir. Take an alternate therapy.	For patients identified as UGT1A1 poor metabolizers, clinical guidance suggests caution with the use of atazanavir due to an increased risk of hyperbilirubinemia. It may be advisable to consider alternative antiretroviral therapy to avoid potential adverse effects. Monitoring bilirubin levels and assessing tolerance to the drug is crucial if atazanavir is used.	0.7454968887479664	0.6537545665161384	0.6051531068415327	0.6519683019953224	0.669227	0.6311699	0.5104937	0.59205383	0.65165704	0.70257473	0.5682922	0.6136747	0.56954294	0.51187515	0.44552958	0.54109657	0.63080233	0.61695784	0.556464	0.6527782	1
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Indeterminate for UGT1A1 with regards to taking atazanavir? Give a 2-3 sentence summary.	No recommendation	['Avoid atazanavir. Take an alternate therapy.', 'Take atazanavir with a reduced dose.', 'Take atazanavir with an increased dose.']	Proceed taking atazanavir as normal. There is no recommendation.	For individuals who are indeterminate for UGT1A1 regarding atazanavir use, clinicians should monitor for signs of increased bilirubin levels, such as jaundice, since UGT1A1 is involved in bilirubin metabolism. If significant hyperbilirubinemia occurs, dose adjustments or alternative medications might be considered, guided by clinical evidence of the patient's tolerance and response. Genetic testing to clarify UGT1A1 status could also be beneficial for personalized treatment planning.	0.19817864561411036	0.48164300115128733	0.23324705632833734	0.5252071851558946	0.1369622	0.39350736	0.213448	0.46034145	0.073047966	0.2589199	0.13633978	0.57807875	-0.058153223	0.32848233	0.1147574	0.33074823	0.2272222	0.5132342	0.36977795	0.4974917	0
atazanavir	UGT1A1	What would be the clinical guidance for someone who is Intermediate Metabolizer for UGT1A1 with regards to taking atazanavir? Give a 2-3 sentence summary.	There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient's genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).	['Avoid atazanavir. Take an alternate therapy.', 'Take atazanavir with a reduced dose.', 'Take atazanavir with an increased dose.']	Proceed taking atazanavir as normal. There is no recommendation.	For individuals who are intermediate metabolizers (IM) for UGT1A1, caution is advised when prescribing atazanavir. Such patients may have an increased risk for hyperbilirubinemia due to reduced metabolism of the drug. Clinicians should monitor bilirubin levels closely and consider potential alternative treatments if significant jaundice or other side effects occur.	0.8054245101641259	0.571195637874032	0.5767795902919776	0.5651362452909171	0.7030086	0.6421217	0.52521545	0.50557786	0.7545221	0.6135973	0.54535025	0.5982798	0.7001892	0.45971867	0.41235915	0.5117438	0.7016992	0.46626982	0.53889376	0.5134272	0
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking atomoxetine? Give a 2-3 sentence summary.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	['Proceed taking atomoxetine as normal. There is no recommendation.', 'Avoid atomoxetine. Take an alternate therapy.']	Take atomoxetine with an altered dose.	For someone who is a Normal Metabolizer with an activity score of 1.25 for CYP2D6, standard dosing of atomoxetine is generally appropriate. Normal metabolizers typically process medications as expected, meaning there should be no need for dose adjustments based on CYP2D6 activity. However, it is always essential to monitor the patient's response and any side effects, adjusting the dosage if necessary.	0.5081327667733135	0.42708426441753283	0.40226531097076434	0.6158300976667447	0.5163862	0.36949787	0.3471993	0.45973328	0.48665363	0.28713924	0.31679466	0.49598873	0.52090317	0.48509085	0.42077214	0.5307191	0.36522368	0.4046722	0.2915557	0.6342916	0
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking atomoxetine? Give a 2-3 sentence summary.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	['Proceed taking atomoxetine as normal. There is no recommendation.', 'Avoid atomoxetine. Take an alternate therapy.']	Take atomoxetine with an altered dose.	For an individual identified as an ultrarapid metabolizer with an activity score of ≥3.75 for CYP2D6, taking atomoxetine may result in subtherapeutic drug levels due to accelerated metabolism. Clinical guidance typically suggests considering an alternative medication that is not predominantly metabolized by CYP2D6 or closely monitoring the patient's response and side effects, potentially adjusting the dose accordingly.	0.5107572776327873	0.42708426441753283	0.40226531097076434	0.6416391333563026	0.427715	0.36949787	0.3471993	0.59974426	0.3951586	0.28713924	0.31679466	0.56240857	0.42725468	0.48509085	0.42077214	0.5304437	0.40730733	0.4046722	0.2915557	0.67575693	0
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking atomoxetine? Give a 2-3 sentence summary.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	['Proceed taking atomoxetine as normal. There is no recommendation.', 'Avoid atomoxetine. Take an alternate therapy.']	Take atomoxetine with an altered dose.	For individuals who are ultrarapid metabolizers (activity score ≥ 4.0) of CYP2D6, the clinical guidance suggests that there may be an increased risk of subtherapeutic plasma concentrations of atomoxetine, potentially leading to reduced efficacy. It may be recommended to consider alternative medications that are not metabolized by CYP2D6, or to closely monitor the individual's response to atomoxetine and adjust the dose accordingly.	0.5241749421933046	0.42708426441753283	0.40226531097076434	0.6465826435029802	0.40339014	0.36949787	0.3471993	0.5928864	0.39409044	0.28713924	0.31679466	0.5734308	0.43549627	0.48509085	0.42077214	0.5100064	0.43326548	0.4046722	0.2915557	0.68174565	0
atomoxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking atomoxetine? Give a 2-3 sentence summary.	Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.	['Proceed taking atomoxetine as normal. There is no recommendation.', 'Avoid atomoxetine. Take an alternate therapy.']	Take atomoxetine with an altered dose.	For a patient identified as a normal metabolizer with an activity score of 1.5 for the CYP2D6 enzyme, standard dosing of atomoxetine is generally recommended. Patients with this metabolic profile typically process the medication at an expected rate, reducing the risk of side effects associated with slower metabolism. However, ongoing monitoring is advised to ensure therapeutic effectiveness and tolerability.	0.49268045036253183	0.42708426441753283	0.40226531097076434	0.604428720122322	0.5082006	0.36949787	0.3471993	0.5032667	0.46749285	0.28713924	0.31679466	0.53869426	0.5178149	0.48509085	0.42077214	0.5188482	0.3766823	0.4046722	0.2915557	0.6354019	0
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking atorvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid atorvastatin. Take an alternate therapy.', 'Take atorvastatin with a reduced dose.', 'Take atorvastatin with an increased dose.']	Proceed taking atorvastatin as normal. There is no recommendation.	For someone with increased function of the SLCO1B1 gene, the clinical guidance for taking atorvastatin is generally favorable, as increased SLCO1B1 function is associated with enhanced hepatic uptake of atorvastatin. This may result in lower circulating levels of the drug, potentially reducing the risk of statin-associated side effects such as myopathy. Therefore, standard dosing regimens are typically appropriate, but as with any medication, individual response should be monitored.	0.36451865604265926	0.35227414895120357	0.366379998311126	0.5584010893272585	0.4302316	0.2798628	0.39841756	0.48826241	0.42241293	0.47312066	0.35083425	0.6392893	0.38471904	0.3790906	0.3231633	0.5554972	0.49484345	0.53293127	0.5909062	0.5668394	1
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking atorvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid atorvastatin. Take an alternate therapy.', 'Take atorvastatin with a reduced dose.', 'Take atorvastatin with an increased dose.']	Proceed taking atorvastatin as normal. There is no recommendation.	For individuals with normal function SLCO1B1, the clinical guidance for taking atorvastatin typically suggests that they can use standard dosing regimens. These individuals have average transport function of the SLCO1B1 protein, which is associated with a typical risk for atorvastatin-related side effects, including myopathy. Therefore, standard dosing without special adjustments is generally recommended.	0.3924315933777545	0.35227414895120357	0.366379998311126	0.6366044135525676	0.4142976	0.2798628	0.39841756	0.502581	0.44801167	0.47312066	0.35083425	0.6767358	0.43897304	0.3790906	0.3231633	0.5928837	0.46164474	0.53293127	0.5909062	0.5813131	1
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking atorvastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid atorvastatin. Take an alternate therapy.', 'Take atorvastatin with a reduced dose.', 'Take atorvastatin with an increased dose.']	Proceed taking atorvastatin as normal. There is no recommendation.	For individuals with an indeterminate SLCO1B1 genotype taking atorvastatin, clinical guidance generally follows standard dosing and monitoring protocols, as their genetic status does not provide clear information on increased risk for statin-induced myopathy. However, it remains important to monitor for symptoms of muscle pain or weakness and consider periodic measurement of creatine kinase levels, adjusting the dose or switching to another statin if necessary.	0.2141099663080158	0.47632664585291085	0.21802801408409103	0.5261654772497443	0.11516841	0.3040144	0.14507084	0.5297916	0.051693767	0.20310935	0.07865126	0.5789015	-0.016931541	0.27278814	0.06812027	0.4901361	0.22967839	0.5326432	0.41531745	0.5579079	0
atorvastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking atorvastatin? Give a 2-3 sentence summary.	Prescribe ≤40mg as a starting dose and adjust doses of atorvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for 40mg dose. If dose >40mg needed for desired efficacy, consider combination therapy (i.e., atorvastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	['Proceed taking atorvastatin as normal. There is no recommendation.', 'Avoid atorvastatin. Take an alternate therapy.']	Take atorvastatin with an altered dose.	Clinical guidance for individuals with a Possible Decreased Function (often indicated by the *1/*5 or similar genotypes) variant of the SLCO1B1 gene when taking atorvastatin suggests exercising caution due to an increased risk of statin-associated muscle symptoms (SAMS). It is generally recommended to consider prescribing atorvastatin at a lower dose or choosing an alternative statin that is metabolized differently, while closely monitoring the patient for any signs of muscle toxicity.	0.6551145788468391	0.6587863375783103	0.6056510334007199	0.5967725641197459	0.607758	0.6618069	0.5980638	0.5482263	0.5819185	0.61707485	0.67316854	0.54288334	0.5255667	0.57333755	0.5444894	0.5323681	0.60467076	0.6692238	0.5752126	0.6389127	0
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking azathioprine? Give a 2-3 sentence summary.	For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).	['Proceed taking azathioprine as normal. There is no recommendation.', 'Take azathioprine with a reduced dose.', 'Take azathioprine with an increased dose.']	Avoid azathioprine. Take an alternate therapy.	For a patient who is a normal metabolizer of TPMT and a poor metabolizer of NUDT15, the clinical guidance for taking azathioprine would be to start at a reduced dose. Specifically, recommendations suggest using alternative agents if possible, or if azathioprine is necessary, starting at a reduced dose by 30-80% and closely monitoring for signs of toxicity, particularly myelosuppression. Regular blood count monitoring is essential to adjust the dosage appropriately.	0.7547718136717178	0.6419303066897288	0.6083785431767134	0.6190449219035482	0.6616478	0.67134595	0.5922713	0.61234105	0.6534579	0.6836007	0.5990633	0.5890829	0.67356026	0.63224703	0.5839283	0.6580384	0.6219589	0.62126034	0.57314605	0.6049881	0
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking azathioprine? Give a 2-3 sentence summary.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	['Proceed taking azathioprine as normal. There is no recommendation.', 'Avoid azathioprine. Take an alternate therapy.']	Take azathioprine with an altered dose.	For a patient who is a Possible Intermediate Metabolizer for TPMT and a Normal Metabolizer for NUDT15, clinical guidelines suggest starting azathioprine at 30-80% of the target dose with close monitoring for myelosuppression. Adjustments to the dosage should be guided by the patient's tolerance and blood count monitoring to minimize the risk of toxicity.	0.7344624906088774	0.6416324090280345	0.5998968854446683	0.5930210924534989	0.74260736	0.5624114	0.4738117	0.5381378	0.7157267	0.59944165	0.6505487	0.47560748	0.73400337	0.57822484	0.5763184	0.55894846	0.7438992	0.6076962	0.53516483	0.5952009	1
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking azathioprine? Give a 2-3 sentence summary.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	['Proceed taking azathioprine as normal. There is no recommendation.', 'Avoid azathioprine. Take an alternate therapy.']	Take azathioprine with an altered dose.	For a patient who is a normal metabolizer for TPMT and an intermediate metabolizer for NUDT15, clinical guidelines typically recommend starting azathioprine at 30-80% of the standard dose, while monitoring closely for myelosuppression and other adverse effects. Adjustments in dose may be necessary based on the patient’s tolerance and laboratory results. Continuous monitoring of blood counts is important due to the increased risk of toxicity related to NUDT15 intermediate metabolization.	0.7067657317304827	0.6416324090280345	0.5998968854446683	0.5856508843516369	0.7548262	0.5624114	0.4738117	0.5600737	0.7074984	0.59944165	0.6505487	0.48634285	0.6579714	0.57822484	0.5763184	0.5437482	0.7241649	0.6076962	0.53516483	0.62185466	1
azathioprine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking azathioprine? Give a 2-3 sentence summary.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 – 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).	['Proceed taking azathioprine as normal. There is no recommendation.', 'Avoid azathioprine. Take an alternate therapy.']	Take azathioprine with an altered dose.	For patients identified as intermediate metabolizers for TPMT and likely intermediate metabolizers for NUDT15, it is recommended to initiate azathioprine at a reduced dose to avoid toxicity. Close monitoring of blood counts and adjusting the dose based on clinical response and tolerance is also advised due to their potential increased risk for myelosuppression.	0.6646728684821943	0.6416324090280345	0.5998968854446683	0.6091481056857634	0.7137836	0.5624114	0.4738117	0.54944307	0.6435905	0.59944165	0.6505487	0.4893247	0.5883334	0.57822484	0.5763184	0.5636351	0.6357369	0.6076962	0.53516483	0.6400114	1
capecitabine	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for DPYD with regards to taking capecitabine? Give a 2-3 sentence summary.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).	['Proceed taking capecitabine as normal. There is no recommendation.', 'Avoid capecitabine. Take an alternate therapy.']	Take capecitabine with an altered dose.	For a patient who is an intermediate metabolizer with a DPYD activity score of 1.5, it is generally recommended to reduce the starting dose of capecitabine by 25-50% to mitigate the risk of severe toxicity. Close monitoring for adverse effects is also advised, with subsequent dose adjustments based on individual tolerance and clinical response. Consulting with a healthcare professional and potentially considering alternative therapies may also be appropriate.	0.5816677756674836	0.47857442059978317	0.4084707444114843	0.6846647328180184	0.6516405	0.42999873	0.33372462	0.59192175	0.5977898	0.40511245	0.36830682	0.6297081	0.6166003	0.48803955	0.39713836	0.64624953	0.6161197	0.606386	0.41908053	0.736993	0
capecitabine	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for DPYD with regards to taking capecitabine? Give a 2-3 sentence summary.	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	['Proceed taking capecitabine as normal. There is no recommendation.', 'Take capecitabine with a reduced dose.', 'Take capecitabine with an increased dose.']	Avoid capecitabine. Take an alternate therapy.	For individuals who are categorized as Poor Metabolizers with an activity score of 0.0 for the DPYD gene, clinical guidelines recommend avoiding the use of capecitabine. This is because these individuals have a significantly increased risk of severe or life-threatening toxicity due to impaired drug metabolism. Alternative chemotherapeutic agents that do not depend on DPYD metabolism should be considered for treatment.	0.4678223809589002	0.5413839430270553	0.4966813616061092	0.5724764684174432	0.65968275	0.6247765	0.4920832	0.6248804	0.49927446	0.58513063	0.5618896	0.5907553	0.4311922	0.51412886	0.5186717	0.560755	0.5501538	0.7149978	0.6033117	0.67762077	0
capecitabine	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for DPYD with regards to taking capecitabine? Give a 2-3 sentence summary.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.	['Proceed taking capecitabine as normal. There is no recommendation.', 'Avoid capecitabine. Take an alternate therapy.']	Take capecitabine with an altered dose.	For patients identified as intermediate metabolizers with an activity score of 1.0 for the DPYD gene, it is recommended to reduce the starting dose of capecitabine to 50% of the typical dose. This adjustment is advised to mitigate the risk of severe toxicity, given that these patients have a partial deficiency in dihydropyrimidine dehydrogenase (DPD) enzyme activity, which is crucial for metabolizing capecitabine.	0.6368879520915431	0.5325349575953107	0.45306111633679613	0.6521208550930322	0.7358792	0.47069123	0.39925283	0.5232784	0.59762913	0.41999748	0.4116537	0.48704055	0.62619317	0.4618656	0.3852154	0.5609422	0.5527212	0.44198048	0.31433266	0.6915302	1
capecitabine	DPYD	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for DPYD with regards to taking capecitabine? Give a 2-3 sentence summary.	Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.	['Avoid capecitabine. Take an alternate therapy.', 'Take capecitabine with a reduced dose.', 'Take capecitabine with an increased dose.']	Proceed taking capecitabine as normal. There is no recommendation.	For a patient who is a normal metabolizer with an activity score of 2.0 for dihydropyrimidine dehydrogenase (DPYD), no dosage adjustments of capecitabine are necessary according to clinical guidelines. Such individuals can proceed with standard dosing as they are unlikely to have increased risk of severe toxicity from the drug due to normal DPYD enzyme activity.	0.4605118123179768	0.5113062159188908	0.4293982451302812	0.6073340510255142	0.68115294	0.6932473	0.4216878	0.6468289	0.555024	0.60176563	0.42015576	0.6240144	0.497986	0.54416364	0.49926734	0.54731923	0.4558732	0.60580343	0.44000748	0.5990046	1
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine? Give a 2-3 sentence summary.	Use carbamazepine per standard dosing guidelines.	['Avoid carbamazepine. Take an alternate therapy.', 'Take carbamazepine with a reduced dose.', 'Take carbamazepine with an increased dose.']	Proceed taking carbamazepine as normal. There is no recommendation.	For a patient who tests negative for both HLA-A*31:01 and HLA-B*15:02, there is a significantly reduced risk of developing serious adverse reactions to carbamazepine, such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). As a result, carbamazepine can be considered a suitable therapeutic option for this patient, with less stringent monitoring compared to those testing positive for these alleles. However, as with all medications, the patient should still be monitored for other potential side effects.	0.5320513791484962	0.7278216505356311	0.7106176081405602	0.5364565377844925	0.46276614	0.7026913	0.746233	0.52620935	0.50165594	0.8420273	0.8618571	0.53350127	0.34364796	0.7945943	0.7449587	0.38258308	0.54050857	0.76734257	0.779682	0.50714993	1
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine? Give a 2-3 sentence summary.	Use carbamazepine per standard dosing guidelines.	['Avoid carbamazepine. Take an alternate therapy.', 'Take carbamazepine with a reduced dose.', 'Take carbamazepine with an increased dose.']	Proceed taking carbamazepine as normal. There is no recommendation.	For a patient who tests negative for HLA-A*31:01 and HLA-B*15:02, the risk of serious adverse reactions such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) from carbamazepine is significantly reduced. Therefore, clinical guidance would generally not contraindicate the use of carbamazepine in these individuals, allowing them to proceed with this medication under standard monitoring protocols.	0.5838469246847505	0.7278216505356311	0.7106176081405602	0.5697971156429485	0.45273426	0.7026913	0.746233	0.57366115	0.55928105	0.8420273	0.8618571	0.5861267	0.41496485	0.7945943	0.7449587	0.44977272	0.5827489	0.76734257	0.779682	0.5415737	1
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is HLA-A*31:01 negative for HLA-A and No HLA-B Result for HLA-B with regards to taking carbamazepine? Give a 2-3 sentence summary.	Use carbamazepine per standard dosing guidelines.	['Avoid carbamazepine. Take an alternate therapy.', 'Take carbamazepine with a reduced dose.', 'Take carbamazepine with an increased dose.']	Proceed taking carbamazepine as normal. There is no recommendation.	For a patient who is HLA-A*31:01 negative with no available HLA-B result, the risk of carbamazepine-induced hypersensitivity reactions, such as Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN), is reduced but not completely eliminated. Current clinical guidelines advise using caution and consider monitoring for any signs of hypersensitivity, while also considering the genotype and clinical context for individualized decision-making.	0.5205331219005255	0.7278216505356311	0.7106176081405602	0.5193370445139883	0.53140795	0.7026913	0.746233	0.61354125	0.5169124	0.8420273	0.8618571	0.5306174	0.37384486	0.7945943	0.7449587	0.4208758	0.512828	0.76734257	0.779682	0.52702534	0
carbamazepine	HLA-A;HLA-B	What would be the clinical guidance for someone who is No HLA-A Result for HLA-A and HLA-B*15:02 negative for HLA-B with regards to taking carbamazepine? Give a 2-3 sentence summary.	Use carbamazepine per standard dosing guidelines.	['Avoid carbamazepine. Take an alternate therapy.', 'Take carbamazepine with a reduced dose.', 'Take carbamazepine with an increased dose.']	Proceed taking carbamazepine as normal. There is no recommendation.	For an individual who has no HLA-A result and is negative for HLA-B*15:02, the clinical guidance generally suggests that the risk of developing carbamazepine-induced Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) is not significantly elevated. Therefore, carbamazepine can be prescribed, but standard monitoring for adverse reactions should still be conducted, especially during the initial stages of therapy.	0.5936283741355496	0.7278216505356311	0.7106176081405602	0.6065323975027798	0.4880953	0.7026913	0.746233	0.670225	0.56833845	0.8420273	0.8618571	0.63211393	0.38765386	0.7945943	0.7449587	0.47339168	0.60537267	0.76734257	0.779682	0.60523885	1
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking celecoxib? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid celecoxib. Take an alternate therapy.', 'Take celecoxib with a reduced dose.', 'Take celecoxib with an increased dose.']	Proceed taking celecoxib as normal. There is no recommendation.	Individuals who are normal metabolizers with an activity score of 2.0 for CYP2C9 can follow standard dosing guidelines for celecoxib, as their enzyme activity for metabolizing the drug is typical. This means they should experience the expected therapeutic effects and side effect profiles without requiring dose adjustments based on CYP2C9 metabolic considerations. However, clinicians should still monitor for any adverse effects as they would with any patient.	0.3926959283302872	0.4056743122010449	0.42770056399710876	0.6243990315156255	0.44984466	0.3863871	0.3947883	0.5513534	0.4076566	0.45445696	0.360486	0.6727457	0.34995818	0.37312856	0.3606197	0.54363126	0.41511413	0.46683082	0.4570136	0.6472248	1
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking celecoxib? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid celecoxib. Take an alternate therapy.', 'Take celecoxib with a reduced dose.', 'Take celecoxib with an increased dose.']	Proceed taking celecoxib as normal. There is no recommendation.	For an individual who is an intermediate metabolizer (activity score = 1.5) for CYP2C9 taking celecoxib, clinical guidance suggests cautious use. A decrease in the initial dose by 25-50% may be considered to mitigate the risk of adverse effects, as intermediate metabolizers tend to have reduced clearance of the drug. Regular monitoring of therapeutic response and side effects is also recommended to adjust dosing as necessary.	0.4679842870266442	0.4056743122010449	0.42770056399710876	0.6069230170393433	0.51962626	0.3863871	0.3947883	0.6018834	0.46148002	0.45445696	0.360486	0.7154014	0.4111775	0.37312856	0.3606197	0.5746537	0.442915	0.46683082	0.4570136	0.5638926	0
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking celecoxib? Give a 2-3 sentence summary.	No recommendation	['Avoid celecoxib. Take an alternate therapy.', 'Take celecoxib with a reduced dose.', 'Take celecoxib with an increased dose.']	Proceed taking celecoxib as normal. There is no recommendation.	For an individual with an indeterminate CYP2C9 genotype taking celecoxib, clinical guidance suggests caution, as their metabolic capacity is uncertain. It may be advisable to start with a lower dose and monitor the patient's response closely, adjusting the dose as needed based on clinical efficacy and tolerability, while paying attention to any adverse effects. It is also important to consider alternative therapies if the patient's response is inadequate or if they experience significant side effects.	0.2445691420621872	0.4503981395995981	0.20412885924565036	0.6248751379412383	0.115085155	0.30769533	0.16489124	0.5723058	0.05457791	0.16374877	0.082905255	0.6720868	0.009112848	0.31693676	0.075233966	0.62248594	0.33158273	0.5483505	0.43558243	0.6072368	0
celecoxib	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking celecoxib? Give a 2-3 sentence summary.	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	['Avoid celecoxib. Take an alternate therapy.', 'Take celecoxib with a reduced dose.', 'Take celecoxib with an increased dose.']	Proceed taking celecoxib as normal. There is no recommendation.	For patients identified as Intermediate Metabolizers with an activity score of 1.0 for the CYP2C9 enzyme, clinical guidance typically suggests initiating celecoxib therapy at the lowest recommended dose. This is due to their reduced metabolic capacity to process the drug, which could increase the risk of adverse effects. Close monitoring for efficacy and adverse reactions is recommended, with dose adjustments made based on clinical response and tolerability.	0.5524544496447555	0.3893482446171051	0.42445896258188026	0.5914313113141492	0.60133517	0.51510775	0.48573783	0.58527493	0.47744438	0.47427765	0.36415282	0.66779757	0.47030368	0.37362063	0.35958543	0.5773668	0.582943	0.37028438	0.40010858	0.6621813	1
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking chloramphenicol? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid chloramphenicol. Take an alternate therapy.', 'Take chloramphenicol with a reduced dose.', 'Take chloramphenicol with an increased dose.']	Proceed taking chloramphenicol as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, caution is advised when prescribing chloramphenicol. Chloramphenicol has the potential to cause hemolysis in patients with G6PD deficiency, so it is recommended to assess other treatment options or carefully monitor the patient for signs of hemolysis. Genetic testing or a G6PD enzyme activity test may be warranted for a more definitive diagnosis before proceeding with chloramphenicol therapy.	0.6650556881664683	0.39242395620984727	0.3245262367607318	0.5199126039835226	0.553525	0.19861548	0.20102334	0.5333168	0.62389576	0.20685655	0.117397934	0.50094044	0.57929057	0.21180913	0.1714455	0.5328233	0.5162075	0.4550125	0.41476405	0.5104402	0
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking chloramphenicol? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid chloramphenicol. Take an alternate therapy.', 'Take chloramphenicol with a reduced dose.', 'Take chloramphenicol with an increased dose.']	Proceed taking chloramphenicol as normal. There is no recommendation.	For individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, particularly those who also have Chronic Non-Spherocytic Hemolytic Anemia (CNSHA), the use of chloramphenicol should be approached with caution. Chloramphenicol is known to potentially precipitate hemolytic anemia in G6PD-deficient patients. Patients should consult with healthcare providers to evaluate alternative antibiotics and carefully monitor for signs of hemolysis if chloramphenicol use is necessary.	0.4828206089000134	0.41795938612948774	0.4561797351493316	0.5065665756464206	0.6038666	0.51649565	0.5009657	0.5275499	0.571403	0.504123	0.42528477	0.5126613	0.499426	0.39991054	0.35830268	0.526511	0.53204346	0.47981244	0.49699664	0.5348976	1
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking chloramphenicol? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid chloramphenicol. Take an alternate therapy.', 'Take chloramphenicol with a reduced dose.', 'Take chloramphenicol with an increased dose.']	Proceed taking chloramphenicol as normal. There is no recommendation.	For individuals who have normal G6PD levels, there is no increased risk of hemolytic anemia when taking chloramphenicol. Clinicians can prescribe chloramphenicol without additional precautions specifically related to G6PD deficiency. However, as with any medication, it is important to monitor for other potential side effects and ensure the drug is appropriate for the patient's overall clinical condition.	0.616466184968372	0.4331837656526784	0.2924148023734498	0.5927654476986576	0.48726884	0.36942506	0.17954539	0.5180214	0.46011114	0.25685406	0.10079092	0.47570774	0.40480268	0.17106262	0.09560957	0.53468627	0.5358368	0.42804214	0.31084254	0.601832	1
chloramphenicol	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking chloramphenicol? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid chloramphenicol. Take an alternate therapy.', 'Take chloramphenicol with a reduced dose.', 'Take chloramphenicol with an increased dose.']	Proceed taking chloramphenicol as normal. There is no recommendation.	For individuals who have a variant or deficient glucose-6-phosphate dehydrogenase (G6PD) enzyme, clinicians generally advise caution with drugs like chloramphenicol. Chloramphenicol can induce hemolysis in G6PD-deficient individuals, potentially leading to acute hemolytic anemia. Therefore, alternative antibiotics should be considered, especially for those known to have significant G6PD deficiency.	0.5988405214998692	0.4899241011317448	0.36507805227022655	0.5144739105882592	0.5867479	0.49345425	0.2918489	0.4905001	0.58305156	0.38766322	0.18482669	0.46669412	0.5497588	0.4114269	0.3062875	0.52612156	0.56855977	0.5183809	0.38959745	0.54009885	0
chloroquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking chloroquine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid chloroquine. Take an alternate therapy.', 'Take chloroquine with a reduced dose.', 'Take chloroquine with an increased dose.']	Proceed taking chloroquine as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) and suffer from chronic non-spherocytic hemolytic anemia (CNSHA) should avoid taking chloroquine. The drug can induce hemolysis, leading to potentially severe, life-threatening hemolytic anemia in these patients. Clinical guidance typically recommends alternative antimalarial treatments that do not carry the same risk for G6PD-deficient individuals.	0.4288311516789243	0.3715973201810518	0.43912172209419414	0.5019333792314739	0.5198271	0.48956987	0.48323813	0.64782274	0.49694195	0.4598891	0.42643932	0.5877175	0.4928838	0.35736457	0.28844616	0.5429414	0.5439293	0.47051492	0.50144756	0.5213946	0
chloroquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking chloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid chloroquine. Take an alternate therapy.', 'Take chloroquine with a reduced dose.', 'Take chloroquine with an increased dose.']	Proceed taking chloroquine as normal. There is no recommendation.	For a person who is identified as normal for Glucose-6-Phosphate Dehydrogenase (G6PD) activity, taking chloroquine generally does not present a significant risk of hemolytic anemia, a condition that can occur in individuals who are G6PD deficient. Therefore, chloroquine can be prescribed without the need for specific precautions related to G6PD deficiency. However, as with all medications, monitoring for general adverse effects of chloroquine is recommended.	0.648652944704594	0.4151668493473421	0.2925580608924934	0.5835084078447954	0.53173745	0.3835857	0.19254188	0.606809	0.45046398	0.2540764	0.12516862	0.6157162	0.30172256	0.12736985	0.05926104	0.5675919	0.5508186	0.44536725	0.3172803	0.5402735	1
chloroquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking chloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid chloroquine. Take an alternate therapy.', 'Take chloroquine with a reduced dose.', 'Take chloroquine with an increased dose.']	Proceed taking chloroquine as normal. There is no recommendation.	For individuals with a variable or intermediate G6PD deficiency, the use of chloroquine requires caution. Clinical guidance would generally advise to avoid chloroquine due to the increased risk of hemolytic anemia, and alternative treatments should be considered. A comprehensive evaluation by a healthcare provider is essential to tailor the safest and most effective treatment strategy.	0.6251827557616662	0.46974184204440894	0.36500251793320215	0.5448628371608846	0.6719387	0.5186053	0.31381702	0.6452094	0.68966085	0.41052726	0.23366328	0.6514332	0.6519154	0.3348915	0.21829458	0.6003696	0.5845779	0.50255436	0.3728219	0.50976396	0
chloroquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking chloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid chloroquine. Take an alternate therapy.', 'Take chloroquine with a reduced dose.', 'Take chloroquine with an increased dose.']	Proceed taking chloroquine as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), taking chloroquine can pose a significant risk of hemolytic anemia. Clinical guidance typically advises against the use of chloroquine or recommends careful medical supervision, along with alternative treatment options to avoid triggering hemolysis.	0.5700433500839489	0.46974184204440894	0.36500251793320215	0.5496047301372212	0.55881137	0.5186053	0.31381702	0.6163638	0.52247864	0.41052726	0.23366328	0.6333527	0.4414834	0.3348915	0.21829458	0.5734872	0.51912004	0.50255436	0.3728219	0.5697339	0
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking ciprofloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid ciprofloxacin. Take an alternate therapy.', 'Take ciprofloxacin with a reduced dose.', 'Take ciprofloxacin with an increased dose.']	Proceed taking ciprofloxacin as normal. There is no recommendation.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, the use of ciprofloxacin is typically advised with caution or avoided if possible. Ciprofloxacin can induce oxidative stress, increasing the risk of hemolytic anemia in G6PD-deficient patients. Clinical alternatives that do not pose this risk should be considered.	0.6098477434111848	0.44387351345166826	0.325814649987456	0.49524042464870144	0.6112653	0.4902243	0.29601064	0.55187905	0.61341006	0.3560121	0.17014767	0.5370175	0.61154217	0.41386536	0.28979298	0.52660865	0.5153378	0.48706704	0.3765311	0.5604565	0
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking ciprofloxacin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid ciprofloxacin. Take an alternate therapy.', 'Take ciprofloxacin with a reduced dose.', 'Take ciprofloxacin with an increased dose.']	Proceed taking ciprofloxacin as normal. There is no recommendation.	For a patient with an indeterminate G6PD status, careful consideration is required before prescribing ciprofloxacin, as this medication can potentially cause oxidative stress, leading to hemolysis in G6PD-deficient individuals. It may be advisable to confirm G6PD status with further testing or consider alternative antibiotics with a safer profile in this context to avoid potential complications.	0.626814045734205	0.33584667851278394	0.2598635630575957	0.48724917352594155	0.5615405	0.17799821	0.18765672	0.5609404	0.58368075	0.19115618	0.0898493	0.5860573	0.6196472	0.21838924	0.17383744	0.5576627	0.5630139	0.4234594	0.4001079	0.5542581	0
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking ciprofloxacin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid ciprofloxacin. Take an alternate therapy.', 'Take ciprofloxacin with a reduced dose.', 'Take ciprofloxacin with an increased dose.']	Proceed taking ciprofloxacin as normal. There is no recommendation.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those classified as having chronic non-spherocytic hemolytic anemia (CNSHA), ciprofloxacin is generally recommended to be avoided. This antibiotic can induce oxidative stress, leading to hemolysis (the destruction of red blood cells), and thus poses a significant risk for these patients. Alternative antibiotics with a safer profile should be considered for treating infections in this population.	0.4597012183126223	0.38213536054111447	0.4292523297875717	0.4978201974386134	0.54441583	0.5047884	0.5085552	0.5865754	0.50257945	0.50199807	0.4082689	0.5698012	0.5232075	0.42412642	0.3632442	0.5698621	0.52862716	0.40185246	0.46376395	0.5538802	0
ciprofloxacin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking ciprofloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid ciprofloxacin. Take an alternate therapy.', 'Take ciprofloxacin with a reduced dose.', 'Take ciprofloxacin with an increased dose.']	Proceed taking ciprofloxacin as normal. There is no recommendation.	For individuals with normal glucose-6-phosphate dehydrogenase (G6PD) levels, there are generally no specific restrictions regarding the use of ciprofloxacin. These patients are not at increased risk for hemolytic anemia, which can be a concern in those with G6PD deficiency. Therefore, ciprofloxacin can be prescribed and used according to standard clinical guidelines.	0.59681851984307	0.38276770892615186	0.25176780460633214	0.5324756315961431	0.51788324	0.3702135	0.19452888	0.54018456	0.4730022	0.22637808	0.10209323	0.5229832	0.3861687	0.14614058	0.06894932	0.4895956	0.5207133	0.42934158	0.32436523	0.5839413	1
citalopram	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking citalopram? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	['Avoid citalopram. Take an alternate therapy.', 'Take citalopram with a reduced dose.', 'Take citalopram with an increased dose.']	Proceed taking citalopram as normal. There is no recommendation.	For patients who are Rapid Metabolizers of CYP2C19, clinical guidance typically advises caution when prescribing citalopram. This is because rapid metabolizers may have lower blood levels of the drug, potentially reducing its efficacy. Healthcare providers might consider an alternative medication that is less dependent on CYP2C19 for metabolism or monitor the patient closely for therapeutic response and side effects, adjusting the dose as necessary.	0.6436772563229486	0.5315722729307916	0.5966859007071413	0.5916764697258325	0.6698137	0.5391675	0.54738754	0.6101364	0.66707873	0.580556	0.46466866	0.6798089	0.6002132	0.5730629	0.5569536	0.56919146	0.6805759	0.57986754	0.6025488	0.6487878	0
citalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking citalopram? Give a 2-3 sentence summary.	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.	['Proceed taking citalopram as normal. There is no recommendation.', 'Take citalopram with a reduced dose.', 'Take citalopram with an increased dose.']	Avoid citalopram. Take an alternate therapy.	For individuals identified as Likely Poor Metabolizers (PMs) for CYP2C19, clinical guidelines suggest using caution with citalopram due to the risk of increased drug levels, which may lead to a higher risk of adverse effects such as QT prolongation. It might be recommended to consider alternative antidepressants that do not rely on CYP2C19 metabolism, or to start citalopram at a lower dose with careful monitoring. Consulting with a healthcare provider for personalized advice is crucial.	0.7924727482811497	0.6399936309335847	0.6272070139560425	0.6732531419328025	0.7495032	0.6283731	0.5453087	0.61346227	0.8503736	0.6433694	0.5497702	0.6742088	0.82473135	0.6504354	0.58428746	0.6245163	0.8125101	0.6719739	0.6417777	0.68798697	1
citalopram	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking citalopram? Give a 2-3 sentence summary.	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.	['Proceed taking citalopram as normal. There is no recommendation.', 'Take citalopram with a reduced dose.', 'Take citalopram with an increased dose.']	Avoid citalopram. Take an alternate therapy.	For individuals identified as Ultrarapid Metabolizers of CYP2C19, the clinical guidance for prescribing citalopram typically includes considering an alternative medication, as these patients may experience reduced therapeutic effects due to increased drug metabolism. If citalopram is prescribed, close monitoring for efficacy and potential side effects is recommended, with possible dose adjustments depending on clinical response.	0.7520507050486446	0.6727939441295636	0.6058114862647214	0.6780431081487264	0.7718401	0.6530691	0.54373735	0.6424981	0.763828	0.6210098	0.54659027	0.6578375	0.76835674	0.67460674	0.61359966	0.5663595	0.80041313	0.7099127	0.6516633	0.6874344	1
citalopram	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking citalopram? Give a 2-3 sentence summary.	No recommendation	['Avoid citalopram. Take an alternate therapy.', 'Take citalopram with a reduced dose.', 'Take citalopram with an increased dose.']	Proceed taking citalopram as normal. There is no recommendation.	For individuals with an indeterminate CYP2C19 genotype, there isn't specific guidance tailored to that genotype regarding the use of citalopram. Clinicians typically follow standard dosing protocols, while closely monitoring for potential side effects or therapeutic efficacy. Regular follow-up evaluations are important to ensure optimal treatment outcomes and to adjust the dose if necessary.	0.22871300981738021	0.430570198178423	0.19712969802967897	0.6174962254797246	0.16075145	0.31391826	0.1523509	0.58143497	0.056300744	0.1933321	0.09381481	0.60584813	-0.054282907	0.31026798	0.077434726	0.52691	0.24394254	0.5449866	0.4306179	0.57907736	1
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine? Give a 2-3 sentence summary.	Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking clomipramine as normal. There is no recommendation.', 'Take clomipramine with a reduced dose.', 'Take clomipramine with an increased dose.']	Avoid clomipramine. Take an alternate therapy.	For an individual who is an Intermediate Metabolizer (activity score = 1.0) for CYP2D6 and a Rapid Metabolizer for CYP2C19, the clinical guidance for clomipramine would suggest starting at a lower dose with careful titration. Clomipramine is metabolized by both CYP2D6 and CYP2C19; therefore, such a metabolic profile may affect drug levels and increase the risk for side effects. Regular monitoring for efficacy and adverse effects is recommended to adjust dosing as needed.	0.8041197406367151	0.7431669404312972	0.6899612460031118	0.6527075974986848	0.667085	0.62268287	0.5216867	0.50866723	0.8212418	0.64054334	0.5394547	0.6410772	0.79149246	0.63897115	0.61448556	0.58862156	0.7612406	0.6680724	0.629466	0.62096095	0
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking clomipramine? Give a 2-3 sentence summary.	Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking clomipramine as normal. There is no recommendation.', 'Take clomipramine with a reduced dose.', 'Take clomipramine with an increased dose.']	Avoid clomipramine. Take an alternate therapy.	For an individual who is an Intermediate Metabolizer (activity score of 0.5) for CYP2D6 and a Poor Metabolizer for CYP2C19, caution is advised when prescribing clomipramine. Due to their impaired metabolic capacity for processing the medication, clinicians are recommended to consider starting at a lower dose and closely monitor the patient for adverse effects or toxicity, adjusting the dosage as needed based on clinical response and tolerability. Alternative treatments might also be considered if appropriate.	0.7734053954608736	0.7583298035184052	0.7236291555680938	0.6823893651433623	0.6453393	0.6844405	0.5856778	0.5512146	0.68766356	0.70384324	0.61055046	0.66791487	0.5996126	0.6568455	0.61605936	0.60122687	0.6158962	0.65558445	0.5484403	0.6460165	0
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking clomipramine? Give a 2-3 sentence summary.	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking clomipramine as normal. There is no recommendation.', 'Take clomipramine with a reduced dose.', 'Take clomipramine with an increased dose.']	Avoid clomipramine. Take an alternate therapy.	For clomipramine, a tricyclic antidepressant metabolized primarily by CYP2D6 and, to a lesser extent, by CYP2C19, the lack of results for CYP2D6 and the designation of a rapid metabolizer status for CYP2C19 complicates the guidance. Generally, without specific CYP2D6 information, it would be important to closely monitor the patient for efficacy and side effects, as CYP2D6 poor metabolizers might experience higher drug levels and increased risk of side effects. Rapid metabolism through CYP2C19 could potentially reduce clomipramine effectiveness, necessitating possible dose adjustments depending on clinical response.	0.6277964879992065	0.5670136149495657	0.49534048956494553	0.6369892030749766	0.63763475	0.54132766	0.46458402	0.5397749	0.579999	0.46163177	0.40879238	0.65157145	0.54709214	0.45651048	0.44743288	0.6106019	0.5666743	0.5431978	0.45833245	0.6023293	0
clomipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking clomipramine? Give a 2-3 sentence summary.	Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking clomipramine as normal. There is no recommendation.', 'Take clomipramine with a reduced dose.', 'Take clomipramine with an increased dose.']	Avoid clomipramine. Take an alternate therapy.	For a patient identified as a Poor Metabolizer (activity score = 0.0) for CYP2D6 and a Normal Metabolizer for CYP2C19, clinical guidance would recommend considering a reduction in the starting dose of clomipramine. This is because clomipramine is metabolized primarily by CYP2D6, and poor metabolism could lead to increased plasma levels and higher risk of side effects. Frequent monitoring and potential dose adjustments based on clinical response and tolerability should be conducted.	0.7834908838747549	0.7752765815460128	0.7533057224230446	0.6489676528253078	0.7037401	0.7208366	0.63050437	0.5141254	0.7102964	0.75810325	0.6774829	0.65645087	0.61428744	0.703527	0.65726733	0.6236213	0.64321417	0.692356	0.59332854	0.64866376	0
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel? Give a 2-3 sentence summary.	No recommendation	['Avoid clopidogrel. Take an alternate therapy.', 'Take clopidogrel with a reduced dose.', 'Take clopidogrel with an increased dose.']	Proceed taking clopidogrel as normal. There is no recommendation.	For individuals identified as Ultrarapid Metabolizers (UMs) of CYP2C19, they may metabolize clopidogrel very efficiently, potentially resulting in higher levels of the active metabolite. Clinical guidelines generally suggest that these individuals may have enhanced response to clopidogrel therapy, leading to an increased risk of bleeding. Careful monitoring and potential dose adjustment may be considered, or alternatively, the use of an antiplatelet drug not predominantly metabolized by CYP2C19, such as prasugrel or ticagrelor, may be recommended.	0.19182076171683918	0.4568320877872956	0.21617818466059988	0.53785653647643	0.0909975	0.3181639	0.1744972	0.50309825	0.11313404	0.21856643	0.11721451	0.58956355	-0.016919198	0.28515065	0.089936554	0.58642256	0.2662903	0.5262831	0.4034878	0.58375424	0
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel? Give a 2-3 sentence summary.	No recommendation	['Avoid clopidogrel. Take an alternate therapy.', 'Take clopidogrel with a reduced dose.', 'Take clopidogrel with an increased dose.']	Proceed taking clopidogrel as normal. There is no recommendation.	For individuals who are ultrarapid metabolizers (UMs) of CYP2C19, clopidogrel is generally considered effective because their bodies convert the prodrug to its active form more efficiently. Clinical guidelines typically recommend standard dosing of clopidogrel for CYP2C19 UMs, as they can achieve optimal platelet inhibition and clinical outcomes. However, careful monitoring is advised to ensure there are no adverse events related to excessive platelet inhibition.	0.2173555231639055	0.4568320877872956	0.21617818466059988	0.5646090222054888	0.1173182	0.3181639	0.1744972	0.4806204	0.13670313	0.21856643	0.11721451	0.63803905	0.016392447	0.28515065	0.089936554	0.6057761	0.3065774	0.5262831	0.4034878	0.6031001	0
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking clopidogrel? Give a 2-3 sentence summary.	If considering clopidogrel, use at standard dose (75 mg/day)	['Avoid clopidogrel. Take an alternate therapy.', 'Take clopidogrel with a reduced dose.', 'Take clopidogrel with an increased dose.']	Proceed taking clopidogrel as normal. There is no recommendation.	For individuals identified as Ultrarapid Metabolizers (UMs) of CYP2C19, they may metabolize clopidogrel very efficiently, potentially resulting in higher levels of the active metabolite. Clinical guidelines generally suggest that these individuals may have enhanced response to clopidogrel therapy, leading to an increased risk of bleeding. Careful monitoring and potential dose adjustment may be considered, or alternatively, the use of an antiplatelet drug not predominantly metabolized by CYP2C19, such as prasugrel or ticagrelor, may be recommended.	0.5972995550719642	0.6525744964666061	0.6819326195711565	0.53785653647643	0.55543256	0.66459435	0.63991123	0.50309825	0.5519383	0.8041712	0.6743166	0.58956355	0.6066962	0.8246283	0.7503503	0.58642256	0.56293106	0.63629514	0.6103576	0.58375424	0
clopidogrel	CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2C19 with regards to taking clopidogrel? Give a 2-3 sentence summary.	If considering clopidogrel, use at standard dose (75 mg/day)	['Avoid clopidogrel. Take an alternate therapy.', 'Take clopidogrel with a reduced dose.', 'Take clopidogrel with an increased dose.']	Proceed taking clopidogrel as normal. There is no recommendation.	For an individual identified as a Normal Metabolizer of CYP2C19, standard clinical guidance suggests that clopidogrel can be administered at the usual recommended dosage. Normal Metabolizers demonstrate effective conversion of clopidogrel into its active form, ensuring optimal antiplatelet effect and reducing the risk of adverse cardiovascular events.	0.6625176433878964	0.6525744964666061	0.6819326195711565	0.6326198564036789	0.6776654	0.66459435	0.63991123	0.56574845	0.64303255	0.8041712	0.6743166	0.65441865	0.69792646	0.8246283	0.7503503	0.6127212	0.66949487	0.63629514	0.6103576	0.65717	1
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking codeine? Give a 2-3 sentence summary.	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	['Proceed taking codeine as normal. There is no recommendation.', 'Take codeine with a reduced dose.', 'Take codeine with an increased dose.']	Avoid codeine. Take an alternate therapy.	For individuals identified as Ultrarapid Metabolizers with a CYP2D6 activity score of ≥3.75, the clinical guidance is generally to avoid codeine. These patients are at risk of rapid conversion of codeine to morphine, which can lead to potentially life-threatening levels of morphine in the blood, posing serious risks for toxicity including respiratory depression. An alternative analgesic that is not metabolized by CYP2D6 should be considered.	0.620274826162179	0.6600617720125046	0.5874021115540122	0.5728047860937209	0.7037429	0.68523324	0.6014888	0.5426747	0.65186775	0.705423	0.61934114	0.5410011	0.648732	0.69261056	0.6553333	0.53813225	0.6457916	0.7587914	0.66517645	0.6450402	1
codeine	CYP2D6	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 with regards to taking codeine? Give a 2-3 sentence summary.	Avoid codeine use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-tramadol opioid.	['Proceed taking codeine as normal. There is no recommendation.', 'Take codeine with a reduced dose.', 'Take codeine with an increased dose.']	Avoid codeine. Take an alternate therapy.	For individuals who are Poor Metabolizers (PM) with an activity score of 0.0 for CYP2D6, clinical guidelines recommend avoiding the use of codeine. These individuals lack the necessary enzyme activity to convert codeine into its active metabolite, morphine, resulting in insufficient analgesic effect and potentially no pain relief. Alternative pain management strategies or medications that do not rely on CYP2D6 metabolism should be considered.	0.59098614690433	0.6712361220820907	0.6158185299111913	0.5657140714327077	0.68937355	0.70070213	0.61401534	0.5427593	0.6584986	0.7190799	0.6269817	0.5654186	0.66767174	0.70038223	0.6592577	0.57936096	0.63511753	0.7284867	0.6182027	0.6312051	1
codeine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.25 for CYP2D6 with regards to taking codeine? Give a 2-3 sentence summary.	Use codeine label recommended age- or weight-specific dosing.	['Avoid codeine. Take an alternate therapy.', 'Take codeine with a reduced dose.', 'Take codeine with an increased dose.']	Proceed taking codeine as normal. There is no recommendation.	For a patient who is a Normal Metabolizer (activity score around 1.25) for CYP2D6, standard dosing of codeine can generally be used. This phenotype suggests typical enzyme activity, leading to expected analgesic effects with normal risk for adverse effects. Regular monitoring is still recommended to tailor the treatment to the patient's response.	0.534640897313331	0.5709753514784908	0.5999104471235336	0.5683149256444849	0.55067617	0.4908734	0.48797455	0.54179025	0.532485	0.6813122	0.5592585	0.6371932	0.6302459	0.6714885	0.5974271	0.58294594	0.59568816	0.5969221	0.6480748	0.63148546	1
codeine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking codeine? Give a 2-3 sentence summary.	Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.	['Proceed taking codeine as normal. There is no recommendation.', 'Take codeine with a reduced dose.', 'Take codeine with an increased dose.']	Avoid codeine. Take an alternate therapy.	For an individual who is an ultrarapid metabolizer (activity score ≥5.0) of CYP2D6, clinical guidance generally recommends avoiding codeine due to the risk of rapid conversion to morphine, which can cause potentially severe or life-threatening toxicity. Alternative pain management strategies that do not rely on CYP2D6 metabolism should be considered.	0.6384106212295747	0.6600617720125046	0.5874021115540122	0.5832081262332867	0.76431674	0.68523324	0.6014888	0.5942222	0.69322693	0.705423	0.61934114	0.5975627	0.7141043	0.69261056	0.6553333	0.6369311	0.6873542	0.7587914	0.66517645	0.66951245	1
dapsone	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking dapsone? Give a 2-3 sentence summary.	Avoid use	['Proceed taking dapsone as normal. There is no recommendation.', 'Take dapsone with a reduced dose.', 'Take dapsone with an increased dose.']	Avoid dapsone. Take an alternate therapy.	For an individual with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly in the context of chronic non-spherocytic hemolytic anemia (CNSHA), taking dapsone is generally contraindicated. Dapsone can induce oxidative stress in red blood cells, leading to hemolysis, which is particularly dangerous in G6PD-deficient individuals. Therefore, alternative medications should be considered, and a healthcare provider should be consulted for personalized treatment options.	0.2127702385287101	0.3185228175255057	0.2652104728944961	0.6284034902470264	0.2595427	0.37868103	0.32521656	0.5707959	0.15238091	0.21554656	0.25289634	0.6068365	0.18043865	0.2495044	0.23950265	0.54704434	0.42064443	0.57492006	0.4758322	0.5951933	1
dapsone	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking dapsone? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid dapsone. Take an alternate therapy.', 'Take dapsone with a reduced dose.', 'Take dapsone with an increased dose.']	Proceed taking dapsone as normal. There is no recommendation.	For patients with an indeterminate G6PD status, caution is advised when prescribing dapsone due to the risk of hemolysis. It is recommended to either confirm G6PD status through additional testing or consider alternative treatments that do not carry the same risk of hemolytic anemia. Regular monitoring for signs of hemolysis is essential if dapsone is used.	0.6363153638560067	0.4075762841377638	0.33591847054498863	0.594386483054103	0.5582998	0.28339818	0.30463555	0.5988943	0.55184925	0.35237056	0.29692063	0.62964016	0.5834394	0.2382147	0.19378124	0.52245855	0.5446162	0.41301396	0.40812758	0.5062724	0
dapsone	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking dapsone? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid dapsone. Take an alternate therapy.', 'Take dapsone with a reduced dose.', 'Take dapsone with an increased dose.']	Proceed taking dapsone as normal. There is no recommendation.	For a patient with normal glucose-6-phosphate dehydrogenase (G6PD) levels, there are no specific contraindications to using dapsone. However, routine monitoring is still recommended due to potential side effects such as hemolysis, methemoglobinemia, and other hematologic reactions. Regular clinical follow-up and monitoring of blood counts are advised to promptly identify and manage any adverse effects.	0.6354006830248861	0.43546080089256645	0.3210704505886514	0.6280030653138999	0.5131555	0.4154106	0.21241462	0.6372896	0.47825497	0.33054858	0.17866248	0.704014	0.4117193	0.20539321	0.12723543	0.54033905	0.5078204	0.44612324	0.31890652	0.54297286	0
dapsone	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking dapsone? Give a 2-3 sentence summary.	Avoid use	['Proceed taking dapsone as normal. There is no recommendation.', 'Take dapsone with a reduced dose.', 'Take dapsone with an increased dose.']	Avoid dapsone. Take an alternate therapy.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), taking dapsone is generally contraindicated due to the increased risk of hemolytic anemia. Clinical guidelines typically recommend avoiding dapsone in G6PD-deficient patients or using it with extreme caution, coupled with regular monitoring of hemoglobin levels and signs of hemolysis if its use is absolutely necessary.	0.24663259139544808	0.3185228175255057	0.2652104728944961	0.6396501429992378	0.31517315	0.37868103	0.32521656	0.5933564	0.19158348	0.21554656	0.25289634	0.6605043	0.23830171	0.2495044	0.23950265	0.5236022	0.42961195	0.57492006	0.4758322	0.60986274	1
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking desflurane? Give a 2-3 sentence summary.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid desflurane. Take an alternate therapy.', 'Take desflurane with a reduced dose.', 'Take desflurane with an increased dose.']	Proceed taking desflurane as normal. There is no recommendation.	For an individual with Uncertain Susceptibility to RYR1 and No Result for CACNA1S regarding desflurane use, clinical guidance typically recommends caution due to the potential risk of malignant hyperthermia (MH). While specific guidance should be personalized based on a comprehensive clinical evaluation, the use of desflurane may be avoided, or alternative anesthetics with a lower MH risk profile might be preferred. It is advisable to consult with a specialist in anesthesiology and genetics for tailored recommendations.	0.6347738515860236	0.385834688039794	0.33077034267208694	0.6239640930872575	0.5949575	0.4609393	0.30815092	0.59215754	0.6580865	0.30849737	0.28907695	0.57061136	0.53142524	0.34629637	0.27809048	0.60759807	0.67855287	0.42528602	0.36341128	0.6191599	0
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and No Result for CACNA1S with regards to taking desflurane? Give a 2-3 sentence summary.	Based on RYR1 status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking desflurane as normal. There is no recommendation.', 'Take desflurane with a reduced dose.', 'Take desflurane with an increased dose.']	Avoid desflurane. Take an alternate therapy.	Individuals diagnosed with Malignant Hyperthermia Susceptibility (MHS) related to RYR1 mutations should avoid the use of inhaled anesthetics like desflurane, as it can trigger a life-threatening hypermetabolic response. Clinical guidance emphasizes the use of alternative anesthetic agents and vigilant perioperative monitoring to prevent malignant hyperthermia episodes.	0.8094525152389184	0.4875794289579271	0.40736910973699153	0.4785747303329189	0.8595388	0.54020315	0.44405663	0.5660747	0.8234387	0.4002831	0.3446006	0.46185225	0.8143163	0.41017166	0.3942164	0.4897234	0.76477975	0.5312534	0.5231835	0.58129334	1
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking desflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking desflurane as normal. There is no recommendation.', 'Take desflurane with a reduced dose.', 'Take desflurane with an increased dose.']	Avoid desflurane. Take an alternate therapy.	For a patient with Malignant Hyperthermia Susceptibility (MHS) related to the RYR1 gene, and Uncertain Susceptibility related to the CACNA1S gene, desflurane should be avoided due to the increased risk of malignant hyperthermia, a severe and potentially fatal reaction. Alternative anesthetic agents that do not trigger malignant hyperthermia should be considered, and a thorough anesthetic plan should be discussed with the healthcare team.	0.7485742313798616	0.48248692546559196	0.40656850991419313	0.5813920186528078	0.8127503	0.5509429	0.45515454	0.6351641	0.7847033	0.41915086	0.36819223	0.60483587	0.7740945	0.4211804	0.4045284	0.5417958	0.673088	0.5364593	0.52825373	0.57100886	1
desflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking desflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid desflurane. Take an alternate therapy.', 'Take desflurane with a reduced dose.', 'Take desflurane with an increased dose.']	Proceed taking desflurane as normal. There is no recommendation.	For a patient with no result for RYR1 and uncertain susceptibility for CACNA1S, clinical guidance would be to proceed with caution when using desflurane. The uncertain status of CACNA1S may elevate the risk of malignant hyperthermia, although not conclusively. It is generally advisable to consider alternative anesthetic agents or have rigorous monitoring and preparedness for malignant hyperthermia management if desflurane is used.	0.705832872779348	0.3960784389824267	0.34400603829419935	0.5967535453560779	0.6212581	0.46003896	0.29448935	0.57822335	0.64532226	0.30627376	0.28438208	0.5105861	0.52880335	0.3839381	0.3179077	0.50019896	0.71356815	0.4284475	0.36899486	0.53283703	0
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking desipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking desipramine as normal. There is no recommendation.', 'Take desipramine with a reduced dose.', 'Take desipramine with an increased dose.']	Avoid desipramine. Take an alternate therapy.	For individuals identified as Ultrarapid Metabolizers with a CYP2D6 activity score of ≥3.5, significant caution is generally advised when prescribing desipramine. Due to their increased metabolic capacity, these individuals may have substantially lower blood levels of desipramine, potentially resulting in reduced efficacy. It is recommended to consider an alternative medication not metabolized by CYP2D6 or to use vigilant therapeutic drug monitoring and possibly higher doses to achieve the desired therapeutic effect.	0.6182551982496285	0.579242695095738	0.5378209773905221	0.6221246105849191	0.67046255	0.44016334	0.40424857	0.536579	0.6471648	0.29443675	0.290827	0.58694685	0.60544705	0.42456952	0.4261879	0.5883	0.59375936	0.4605885	0.4113097	0.61412966	1
desipramine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking desipramine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose	['Avoid desipramine. Take an alternate therapy.', 'Take desipramine with a reduced dose.', 'Take desipramine with an increased dose.']	Proceed taking desipramine as normal. There is no recommendation.	For an individual who is classified as a Normal Metabolizer (with an activity score of 1.75) for CYP2D6, standard dosing of desipramine is generally appropriate. This metabolizer status suggests that they have typical CYP2D6 enzyme activity, which should lead to expected drug metabolism and efficacy. Nonetheless, it is essential to monitor the patient for therapeutic effectiveness and potential side effects, adjusting the dose if necessary.	0.4482474657542719	0.49698700990059946	0.499519631731222	0.6529785944039695	0.39049613	0.32793343	0.33902708	0.49439365	0.3518688	0.371532	0.26033124	0.631965	0.33759087	0.3783284	0.36477092	0.57736886	0.4227896	0.5207515	0.54124117	0.5930756	1
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking desipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking desipramine as normal. There is no recommendation.', 'Take desipramine with a reduced dose.', 'Take desipramine with an increased dose.']	Avoid desipramine. Take an alternate therapy.	For individuals identified as Ultrarapid Metabolizers (UMs) of CYP2D6 with an activity score of 2.75, taking desipramine could result in significantly lower plasma concentrations of the drug, reducing its efficacy. Clinical guidance typically recommends considering alternative medications that are not metabolized by CYP2D6 or adjusting the desipramine dosage carefully while monitoring therapeutic drug levels and clinical response closely.	0.6034537085434515	0.579242695095738	0.5378209773905221	0.6172968727199949	0.6544883	0.44016334	0.40424857	0.58494854	0.6393779	0.29443675	0.290827	0.5882819	0.55857974	0.42456952	0.4261879	0.56485033	0.58178335	0.4605885	0.4113097	0.61324936	1
desipramine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking desipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking desipramine as normal. There is no recommendation.', 'Take desipramine with a reduced dose.', 'Take desipramine with an increased dose.']	Avoid desipramine. Take an alternate therapy.	For individuals identified as Ultrarapid Metabolizers (UMs) with a CYP2D6 activity score of ≥6.0, taking desipramine is typically not recommended. This is because UMs rapidly metabolize desipramine, leading to subtherapeutic drug levels and potential treatment failure. Alternative medications not primarily metabolized by CYP2D6 are often advised.	0.5900175266024563	0.579242695095738	0.5378209773905221	0.6256280628990329	0.6202933	0.44016334	0.40424857	0.6191378	0.5859405	0.29443675	0.290827	0.63885766	0.5555548	0.42456952	0.4261879	0.5913192	0.56317025	0.4605885	0.4113097	0.6082235	1
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking dexlansoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.	['Proceed taking dexlansoprazole as normal. There is no recommendation.', 'Avoid dexlansoprazole. Take an alternate therapy.']	Take dexlansoprazole with an altered dose.	For a patient who is a rapid metabolizer for CYP2C19, dexlansoprazole, a proton pump inhibitor (PPI), does not typically require dosage adjustment. Rapid metabolizers may have decreased plasma exposure to the drug, but clinical studies have generally shown that the therapeutic efficacy of dexlansoprazole is maintained. Monitoring clinical response and symptoms can help guide any necessary adjustments.	0.4321296559361462	0.4319382910073833	0.4223590568212565	0.6563406970705975	0.4594225	0.5244643	0.42311606	0.54880404	0.47092155	0.45668063	0.45661741	0.5821542	0.3341257	0.39340094	0.36267304	0.55471057	0.37880185	0.5162315	0.4036599	0.6533447	0
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking dexlansoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking dexlansoprazole as normal. There is no recommendation.', 'Avoid dexlansoprazole. Take an alternate therapy.']	Take dexlansoprazole with an altered dose.	For individuals identified as likely poor metabolizers of CYP2C19 taking dexlansoprazole, no specific dosage adjustment is recommended. Dexlansoprazole metabolism primarily involves CYP2C19, but its pharmacokinetics suggest that standard dosing can generally be safe and effective even in poor metabolizers. It is still prudent for healthcare providers to monitor for efficacy and adverse reactions, adjusting treatment as needed based on clinical response.	0.3700089585883588	0.42527032175724366	0.42686208773348144	0.6433301024398086	0.4040414	0.44282907	0.4213407	0.5411789	0.45715785	0.4142662	0.4479006	0.54375637	0.42355916	0.4067165	0.42262483	0.5700021	0.41437736	0.5007438	0.40314388	0.6317827	0
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking dexlansoprazole? Give a 2-3 sentence summary.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	['Proceed taking dexlansoprazole as normal. There is no recommendation.', 'Avoid dexlansoprazole. Take an alternate therapy.']	Take dexlansoprazole with an altered dose.	For an individual identified as an Ultrarapid Metabolizer of CYP2C19, standard dosing of dexlansoprazole is generally appropriate because the metabolism of dexlansoprazole is not significantly affected by variations in CYP2C19 activity. Clinical guidelines suggest that dosage adjustments are not necessary for these patients.	0.3828759139293854	0.4634739907440425	0.4026063255530932	0.6616701654635663	0.39767787	0.6592625	0.50002605	0.47114798	0.4403657	0.6434663	0.5377309	0.52557623	0.39403245	0.5398695	0.46074864	0.5465729	0.401359	0.5422964	0.3703694	0.617377	0
dexlansoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking dexlansoprazole? Give a 2-3 sentence summary.	No recommendation	['Avoid dexlansoprazole. Take an alternate therapy.', 'Take dexlansoprazole with a reduced dose.', 'Take dexlansoprazole with an increased dose.']	Proceed taking dexlansoprazole as normal. There is no recommendation.	For an individual with an indeterminate CYP2C19 genotype, standard clinical guidelines typically recommend proceeding with caution due to the uncertainty in metabolic activity. However, since dexlansoprazole is metabolized by multiple pathways and does not solely rely on CYP2C19, the patient can generally use the standard dosing without significant concerns for efficacy or safety. It is always advisable to monitor the patient's response and adjust the dosage if necessary based on clinical judgment and therapeutic outcomes.	0.2834672186763513	0.4862845712999244	0.24034438024374494	0.6761608955630138	0.13828978	0.31074387	0.17201185	0.60675967	0.0712995	0.20862255	0.10475824	0.62867564	-0.028992064	0.2978908	0.08362041	0.6027016	0.34841523	0.51009244	0.38946715	0.64159185	1
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking dibekacin as normal. There is no recommendation.', 'Take dibekacin with a reduced dose.', 'Take dibekacin with an increased dose.']	Avoid dibekacin. Take an alternate therapy.	For individuals who possess genetic variants in the MT-RNR1 gene associated with an increased risk of aminoglycoside-induced hearing loss, the use of dibekacin, an aminoglycoside, should be avoided. Alternative antibiotics not associated with ototoxicity should be considered to prevent hearing loss. Genetic screening for MT-RNR1 variants is recommended before initiating aminoglycoside therapy.	0.7070667638491472	0.3573562598777829	0.2734919241015345	0.40049208811436915	0.72229326	0.48581642	0.4086357	0.4949475	0.7187463	0.2858537	0.31050733	0.46140364	0.7595344	0.35697496	0.36481392	0.4129529	0.6395347	0.5829945	0.43764806	0.50966436	1
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid dibekacin. Take an alternate therapy.', 'Take dibekacin with a reduced dose.', 'Take dibekacin with an increased dose.']	Proceed taking dibekacin as normal. There is no recommendation.	For an individual with a normal risk of aminoglycoside-induced hearing loss based on their MT-RNR1 genetic profile, there are no specific contraindications or increased risks associated with taking dibekacin, an aminoglycoside antibiotic. The clinical guidance would be to proceed with standard dosing and monitoring protocols appropriate to their clinical condition while continuing routine auditory monitoring, as aminoglycosides in general can pose a risk of ototoxicity.	0.6064336598326722	0.27613267482373927	0.3249954609615821	0.4643819588922071	0.67734504	0.44967842	0.43793797	0.5699549	0.6977634	0.46886262	0.3952757	0.53598505	0.7332535	0.4393011	0.41773668	0.4800422	0.6100552	0.4293274	0.48268962	0.5145016	1
dibekacin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking dibekacin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid dibekacin. Take an alternate therapy.', 'Take dibekacin with a reduced dose.', 'Take dibekacin with an increased dose.']	Proceed taking dibekacin as normal. There is no recommendation.	For individuals with uncertain risk of aminoglycoside-induced hearing loss due to variants in the MT-RNR1 gene, the clinical guidance would generally advise caution in prescribing aminoglycosides like dibekacin. Alternative antibiotics should be considered if possible to mitigate the risk, as MT-RNR1 variants can predispose individuals to ototoxicity. Genetic testing for MT-RNR1 variants may be recommended to better assess risk.	0.6007829740850502	0.27613267482373927	0.3249954609615821	0.3765688891785182	0.5226515	0.44967842	0.43793797	0.48391876	0.64321405	0.46886262	0.3952757	0.4432417	0.7116642	0.4393011	0.41773668	0.4120248	0.5978217	0.4293274	0.48268962	0.45092747	0
dimercaprol	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking dimercaprol? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid dimercaprol. Take an alternate therapy.', 'Take dimercaprol with a reduced dose.', 'Take dimercaprol with an increased dose.']	Proceed taking dimercaprol as normal. There is no recommendation.	For individuals with normal G6PD (glucose-6-phosphate dehydrogenase) enzyme activity, there are no specific contraindications or additional precautions required when taking dimercaprol. These patients can generally adhere to standard dosage and administration guidelines for dimercaprol without increased risk of hemolytic anemia, which is a concern in G6PD-deficient individuals.	0.6147992243817576	0.45045604730651795	0.31459926736754545	0.6975695589251305	0.56257635	0.43337488	0.25049803	0.66758657	0.5328661	0.36993852	0.22432743	0.6883463	0.39536023	0.16816781	0.09049007	0.55766183	0.57717335	0.42321077	0.31795505	0.5836355	1
dimercaprol	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking dimercaprol? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid dimercaprol. Take an alternate therapy.', 'Take dimercaprol with a reduced dose.', 'Take dimercaprol with an increased dose.']	Proceed taking dimercaprol as normal. There is no recommendation.	Clinical guidance for individuals with an indeterminate Glucose-6-phosphate dehydrogenase (G6PD) status regarding dimercaprol administration advises caution. Since G6PD deficiency can lead to hemolytic anemia when exposed to certain oxidative agents, including dimercaprol, a confirmed G6PD status is recommended prior to treatment. If G6PD status remains indeterminate, alternative chelation therapies that are safer for potential G6PD deficient individuals should be considered.	0.6441779963324882	0.4110218716588707	0.34659774537242577	0.6102090793476954	0.61548805	0.29013324	0.33482394	0.56784934	0.6757542	0.40234432	0.33091682	0.5952311	0.5802731	0.20922047	0.15902184	0.5068479	0.57626367	0.4211849	0.4146048	0.5016373	0
dimercaprol	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking dimercaprol? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid dimercaprol. Take an alternate therapy.', 'Take dimercaprol with a reduced dose.', 'Take dimercaprol with an increased dose.']	Proceed taking dimercaprol as normal. There is no recommendation.	For individuals who have glucose-6-phosphate dehydrogenase (G6PD) deficiency combined with chronic nonspherocytic hemolytic anemia (CNSHA), clinical guidelines typically advise against using dimercaprol. This is because dimercaprol can induce oxidative stress leading to hemolysis in G6PD-deficient patients, thus posing serious health risks. Alternative chelating agents that do not provoke hemolysis should be considered under the guidance of a healthcare professional.	0.48331990629535415	0.4423198008813404	0.47737019236724665	0.6241200480126733	0.5305468	0.5141985	0.5208659	0.61092937	0.55552846	0.5395808	0.48958287	0.62634414	0.52346075	0.37105843	0.3260891	0.53589815	0.5405566	0.43311274	0.5046956	0.5118751	0
dimercaprol	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking dimercaprol? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid dimercaprol. Take an alternate therapy.', 'Take dimercaprol with a reduced dose.', 'Take dimercaprol with an increased dose.']	Proceed taking dimercaprol as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), the use of dimercaprol is generally contraindicated. G6PD deficiency increases the risk of hemolytic anemia when exposed to oxidative stress, which can be triggered by dimercaprol. Therefore, clinicians should avoid prescribing dimercaprol to patients with G6PD deficiency and seek alternative treatments.	0.5755892308187938	0.5036694757714525	0.3951741947354286	0.6229453339722099	0.6410753	0.58485603	0.41781464	0.5900926	0.66461504	0.56316566	0.39363754	0.6225415	0.61172324	0.42734602	0.30470765	0.5243276	0.57900363	0.5044765	0.4008882	0.5530118	0
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin? Give a 2-3 sentence summary.	Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking doxepin as normal. There is no recommendation.', 'Take doxepin with a reduced dose.', 'Take doxepin with an increased dose.']	Avoid doxepin. Take an alternate therapy.	For an individual who is an intermediate metabolizer of CYP2D6 with an activity score of 0.25 and a rapid metabolizer of CYP2C19, caution is advised when prescribing doxepin, as the drug is primarily metabolized by CYP2D6. The impaired CYP2D6 function can lead to elevated drug levels and a higher risk of side effects, so a lower starting dose or an alternative medication less dependent on CYP2D6 metabolism might be considered. Close monitoring is recommended to adjust the dose based on clinical response and tolerability.	0.8198854467592811	0.7151100858554056	0.6847204259099641	0.6366537062135477	0.7586383	0.6404855	0.52827096	0.5751231	0.8604858	0.6326014	0.5126578	0.69580555	0.8357221	0.6350476	0.6258845	0.6253514	0.72083676	0.6596958	0.6257884	0.6337314	1
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin? Give a 2-3 sentence summary.	Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking doxepin as normal. There is no recommendation.', 'Avoid doxepin. Take an alternate therapy.']	Take doxepin with an altered dose.	For a patient identified as an Intermediate Metabolizer with an activity score of 0.75 for CYP2D6 and a Normal Metabolizer for CYP2C19, caution is advised when prescribing doxepin due to potential alterations in drug metabolism. Consider starting with a lower dose and closely monitoring for efficacy and adverse effects, as reduced CYP2D6 activity may lead to higher plasma levels of doxepin and increased risk of side effects. Adjustments can be made based on the patient’s clinical response and tolerability.	0.5276776609670356	0.5067466235046885	0.4216244877459596	0.7016597119868253	0.48472953	0.316517	0.27954158	0.5361715	0.49105182	0.3510678	0.36093313	0.5226955	0.45190287	0.44490954	0.36865884	0.5564135	0.6572801	0.69863266	0.53988624	0.6813675	1
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking doxepin? Give a 2-3 sentence summary.	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking doxepin as normal. There is no recommendation.', 'Take doxepin with a reduced dose.', 'Take doxepin with an increased dose.']	Avoid doxepin. Take an alternate therapy.	If an individual has no result for CYP2D6 and an activity score of no result, standard dosing recommendations for doxepin should be followed due to the lack of specific metabolic information. However, being a rapid metabolizer for CYP2C19 suggests increased metabolism through that pathway, which could potentially reduce the therapeutic efficacy of the drug. Close monitoring for therapeutic effect and side effects is advisable, with dose adjustments made based on clinical response.	0.5352404247712496	0.5239165573926827	0.4262741157941501	0.609044523098449	0.67480385	0.5059307	0.43306765	0.5616403	0.60452086	0.38745198	0.36487627	0.67115265	0.49449062	0.3161476	0.3471447	0.59249145	0.57241297	0.5577875	0.46976256	0.6068604	0
doxepin	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2D6 and Normal Metabolizer for CYP2C19 with regards to taking doxepin? Give a 2-3 sentence summary.	Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking doxepin as normal. There is no recommendation.', 'Take doxepin with a reduced dose.', 'Take doxepin with an increased dose.']	Avoid doxepin. Take an alternate therapy.	For a patient identified as a Poor Metabolizer (activity score = 0.0) for CYP2D6 and a Normal Metabolizer for CYP2C19, alternative medications to doxepin should be considered due to the risk of increased side effects and toxicity from elevated plasma levels of doxepin. If doxepin therapy is deemed necessary, a significantly reduced dose should be utilized, along with careful monitoring for adverse effects.	0.7150600980503359	0.7373002280903281	0.7537521238382743	0.6486757383976314	0.63744193	0.65722954	0.57175666	0.6209685	0.68294317	0.67009485	0.61654526	0.6384873	0.5906403	0.66437507	0.66686153	0.6260591	0.5907981	0.72831243	0.64521545	0.70656204	1
doxorubicin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking doxorubicin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid doxorubicin. Take an alternate therapy.', 'Take doxorubicin with a reduced dose.', 'Take doxorubicin with an increased dose.']	Proceed taking doxorubicin as normal. There is no recommendation.	For patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, careful consideration is needed when prescribing doxorubicin, as G6PD deficiency may increase the risk of hemolytic anemia. Clinicians should monitor these patients closely for hemolysis and consider alternative chemotherapeutic agents if necessary. It's essential to balance the potential benefits and risks, and involve a hematologist in the treatment plan if there are concerns about hemolysis.	0.624054111425805	0.49740764674371774	0.3870102566740276	0.5415977233020697	0.55569065	0.5219781	0.34363055	0.5247203	0.60790306	0.43614927	0.2692185	0.5706414	0.59394985	0.40620273	0.29904434	0.5466217	0.5081189	0.4858471	0.36839136	0.52844113	0
doxorubicin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking doxorubicin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid doxorubicin. Take an alternate therapy.', 'Take doxorubicin with a reduced dose.', 'Take doxorubicin with an increased dose.']	Proceed taking doxorubicin as normal. There is no recommendation.	Patients with an indeterminate G6PD (glucose-6-phosphate dehydrogenase) status should be closely monitored for hemolytic anemia when taking doxorubicin, although doxorubicin is not typically a strong inducer of hemolysis in G6PD-deficient individuals. It is recommended to discuss the potential risks with a healthcare provider, who may decide on additional testing or monitoring strategies based on the patient's overall clinical context.	0.6345932097005977	0.3767176624653358	0.30288402081207894	0.5486952835168956	0.57415897	0.24444602	0.24107246	0.5783842	0.60344714	0.28558224	0.19955267	0.585331	0.5764148	0.19736038	0.17089063	0.44518927	0.5704729	0.4402822	0.4201783	0.5488736	0
doxorubicin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking doxorubicin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid doxorubicin. Take an alternate therapy.', 'Take doxorubicin with a reduced dose.', 'Take doxorubicin with an increased dose.']	Proceed taking doxorubicin as normal. There is no recommendation.	Individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, specifically those experiencing chronic non-spherocytic hemolytic anemia (CNSHA), should use caution when taking doxorubicin. Doxorubicin is an oxidative agent that can exacerbate hemolysis in G6PD-deficient patients. It is recommended to monitor closely for signs of hemolysis and consider alternative therapies if feasible.	0.48348660720756453	0.3752351044697244	0.4064388903359554	0.5087024924094157	0.5796032	0.50134087	0.47825202	0.5967235	0.5237388	0.45784476	0.39459077	0.6211688	0.4883168	0.4253103	0.38260403	0.5319154	0.54902184	0.46916935	0.49619803	0.5553764	1
doxorubicin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking doxorubicin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid doxorubicin. Take an alternate therapy.', 'Take doxorubicin with a reduced dose.', 'Take doxorubicin with an increased dose.']	Proceed taking doxorubicin as normal. There is no recommendation.	For individuals with normal G6PD enzyme activity, standard clinical guidelines for doxorubicin administration apply. No specific dosage adjustments or additional precautions related to G6PD status are necessary because these individuals do not have an increased risk of hemolytic anemia associated with doxorubicin. It is important, however, to monitor for other known toxicities associated with doxorubicin, such as cardiotoxicity and myelosuppression.	0.6551596911073234	0.43742168966948886	0.3199832829298244	0.6321499496180452	0.52309895	0.39323202	0.22587407	0.65811676	0.43995947	0.286873	0.17024358	0.68892854	0.4107994	0.1300933	0.06187092	0.55518234	0.6032911	0.4238915	0.3085551	0.5975552	1
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 with regards to taking efavirenz? Give a 2-3 sentence summary.	Initiate efavirenz with standard dosing (600 mg/day)	['Avoid efavirenz. Take an alternate therapy.', 'Take efavirenz with a reduced dose.', 'Take efavirenz with an increased dose.']	Proceed taking efavirenz as normal. There is no recommendation.	For individuals identified as Ultrarapid Metabolizers (UMs) of CYP2B6, clinical guidelines typically suggest caution when prescribing efavirenz. These patients are likely to metabolize efavirenz very quickly, which can lead to subtherapeutic drug levels and potential treatment failure. Dose adjustment or considering alternative therapies may be recommended to ensure effective treatment.	0.6439211112398148	0.7058875282266428	0.7464471255757467	0.6039606135656084	0.6503757	0.68188524	0.71472186	0.55131453	0.63895303	0.830931	0.7367101	0.5914545	0.6214081	0.73547643	0.7257293	0.5784017	0.5841883	0.64531857	0.6786317	0.60707396	0
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 with regards to taking efavirenz? Give a 2-3 sentence summary.	Initiate efavirenz with standard dosing (600 mg/day)	['Avoid efavirenz. Take an alternate therapy.', 'Take efavirenz with a reduced dose.', 'Take efavirenz with an increased dose.']	Proceed taking efavirenz as normal. There is no recommendation.	For individuals who are rapid metabolizers for the CYP2B6 enzyme, clinicians may consider prescribing efavirenz with caution. Rapid metabolizers can process the drug more quickly, potentially reducing its efficacy due to lower drug levels in the bloodstream. Therapeutic drug monitoring or alternative antiretroviral medications might be recommended to ensure optimal viral suppression and avoid subtherapeutic concentrations.	0.6538297166983473	0.7058875282266428	0.7464471255757467	0.610046479220806	0.6542558	0.68188524	0.71472186	0.52189445	0.686429	0.830931	0.7367101	0.61639404	0.6614028	0.73547643	0.7257293	0.5944356	0.5573445	0.64531857	0.6786317	0.5928695	0
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 with regards to taking efavirenz? Give a 2-3 sentence summary.	No recommendation	['Avoid efavirenz. Take an alternate therapy.', 'Take efavirenz with a reduced dose.', 'Take efavirenz with an increased dose.']	Proceed taking efavirenz as normal. There is no recommendation.	For an individual who is indeterminate for CYP2B6, standard clinical guidelines would generally suggest monitoring rather than immediate dosage adjustment when prescribing efavirenz. Patients should be closely observed for any potential side effects or toxicity, as efavirenz metabolism might be impaired, leading to increased drug levels. Regular follow-ups and possibly plasma level testing can help in making informed decisions about any necessary dosage modifications.	0.24027853784711456	0.45685375366539044	0.22062750492709662	0.6514225005279765	0.15507904	0.33230817	0.15975548	0.59350383	0.05739886	0.21319598	0.0793226	0.6147227	0.015680343	0.38391614	0.16899538	0.6098456	0.28622538	0.5119993	0.36884865	0.5484497	0
efavirenz	CYP2B6	What would be the clinical guidance for someone who is Normal Metabolizer for CYP2B6 with regards to taking efavirenz? Give a 2-3 sentence summary.	Initiate efavirenz with standard dosing (600 mg/day)	['Avoid efavirenz. Take an alternate therapy.', 'Take efavirenz with a reduced dose.', 'Take efavirenz with an increased dose.']	Proceed taking efavirenz as normal. There is no recommendation.	For individuals identified as Normal Metabolizers of CYP2B6, standard dosing of efavirenz is typically appropriate, as they are expected to metabolize the drug at a normal rate. This reduces the likelihood of experiencing either sub-therapeutic effects or heightened adverse reactions associated with the medication. Clinical monitoring for efficacy and tolerability should continue as per usual protocol, but no specific dose adjustments are generally needed based on CYP2B6 metabolizer status alone.	0.6622884677637906	0.7058875282266428	0.7464471255757467	0.6437886754840637	0.66406894	0.68188524	0.71472186	0.499274	0.7291062	0.830931	0.7367101	0.6696123	0.74121046	0.73547643	0.7257293	0.6121486	0.72029114	0.64531857	0.6786317	0.64277095	1
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking enflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking enflurane as normal. There is no recommendation.', 'Take enflurane with a reduced dose.', 'Take enflurane with an increased dose.']	Avoid enflurane. Take an alternate therapy.	For individuals with Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S, the use of enflurane is contraindicated. Enflurane is a trigger for malignant hyperthermia, a life-threatening condition, and alternative anesthetic agents should be considered to prevent potential adverse reactions. It is crucial for such patients to inform their healthcare providers of their genetic susceptibilities to ensure safe medical care.	0.6489872222682206	0.4604239865406462	0.3783731756147286	0.5821595111267365	0.8103119	0.5455181	0.4416665	0.6710251	0.68084234	0.41125908	0.35429028	0.5817037	0.6946101	0.47659147	0.4368042	0.55238795	0.6830398	0.53460175	0.5189058	0.53900844	0
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking enflurane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking enflurane as normal. There is no recommendation.', 'Take enflurane with a reduced dose.', 'Take enflurane with an increased dose.']	Avoid enflurane. Take an alternate therapy.	For an individual with no result for the RYR1 gene but found to have malignant hyperthermia susceptibility related to the CACNA1S gene, strong clinical guidance would recommend avoiding enflurane. This inhalational anesthetic can trigger malignant hyperthermia, a potentially life-threatening condition. Alternative anesthetic agents that do not pose this risk should be considered, and the medical team should be informed of the genetic predisposition.	0.6854077021212185	0.4670926209929809	0.3877821772459262	0.5137237021719139	0.7736841	0.5281073	0.42393398	0.60544133	0.708018	0.39498076	0.3310984	0.55453664	0.7609511	0.46267104	0.41838273	0.52759206	0.68567514	0.5239515	0.5131781	0.5358564	1
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking enflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking enflurane as normal. There is no recommendation.', 'Take enflurane with a reduced dose.', 'Take enflurane with an increased dose.']	Avoid enflurane. Take an alternate therapy.	For a patient with Malignant Hyperthermia Susceptibility (MHS) due to RYR1 gene variants and Uncertain Susceptibility for CACNA1S variants, the clinical guidance would typically involve avoiding the use of enflurane. Enflurane is a known trigger for malignant hyperthermia, a potentially life-threatening condition, and alternative anesthesia methods should be considered to ensure patient safety.	0.7086421013433924	0.4604239865406462	0.3783731756147286	0.5280808489662305	0.7204013	0.5455181	0.4416665	0.5699484	0.77352875	0.41125908	0.35429028	0.53712666	0.773917	0.47659147	0.4368042	0.5398204	0.63935626	0.53460175	0.5189058	0.5106062	0
enflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking enflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid enflurane. Take an alternate therapy.', 'Take enflurane with a reduced dose.', 'Take enflurane with an increased dose.']	Proceed taking enflurane as normal. There is no recommendation.	"Clinical guidance for someone with ""No Result"" for RYR1 and ""Uncertain Susceptibility"" for CACNA1S regarding the use of enflurane would recommend exercising caution. Although the presence of genetic variants related to malignant hyperthermia susceptibility isn't confirmed in such a case, the uncertainty warrants careful monitoring and preparedness for potential complications. Consulting with a specialist in genetic pharmacology or an anesthesiologist is advised."	0.733403258152574	0.41470952525458543	0.3582022796786344	0.5591383142849067	0.67701054	0.47012538	0.30272052	0.49727035	0.6949146	0.32209703	0.30513772	0.50514466	0.5700023	0.3831002	0.33377448	0.47278905	0.7609847	0.429239	0.37656677	0.5179887	0
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking escitalopram? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. If patient does not adequately respond to recommended maintenance dosing, consider titrating to a higher maintenance dose or switching to a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19.	['Avoid escitalopram. Take an alternate therapy.', 'Take escitalopram with a reduced dose.', 'Take escitalopram with an increased dose.']	Proceed taking escitalopram as normal. There is no recommendation.	For a patient identified as a CYP2C19 rapid metabolizer, clinical guidance suggests that escitalopram may be less effective due to increased metabolism of the drug, potentially leading to lower plasma concentrations and reduced therapeutic efficacy. It may be advisable to consider an alternative antidepressant that is not significantly metabolized by CYP2C19 or to adjust the dose of escitalopram while monitoring the patient closely for therapeutic response and side effects.	0.6381857091197329	0.5074998077914457	0.5582139161146665	0.5738254397844588	0.72297597	0.50947756	0.4746803	0.5465799	0.7634344	0.49818575	0.32803977	0.5745328	0.66064125	0.5671486	0.55435556	0.5849599	0.69364977	0.57716674	0.5763718	0.62529784	0
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking escitalopram? Give a 2-3 sentence summary.	Consider a clinically appropriate antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, consider a lower starting dose, slower titration schedule and 50% reduction of the standard maintenance dose as compared to normal metabolizers.	['Proceed taking escitalopram as normal. There is no recommendation.', 'Take escitalopram with a reduced dose.', 'Take escitalopram with an increased dose.']	Avoid escitalopram. Take an alternate therapy.	For individuals identified as Likely Poor Metabolizers (PMs) of CYP2C19, clinical guidelines recommend considering a lower starting dose of escitalopram and careful titration. This is because poor metabolizers may have higher plasma concentrations of the drug, increasing the risk of adverse effects. Monitoring for efficacy and side effects is advisable to ensure safe and effective treatment.	0.7941571424317903	0.6059399016066459	0.6188745292861662	0.6116128179197916	0.7558322	0.5525946	0.4617108	0.48815143	0.7691471	0.50769204	0.3985671	0.5531112	0.79397154	0.654592	0.5856944	0.5815616	0.8006483	0.6138301	0.5987987	0.6522924	0
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking escitalopram? Give a 2-3 sentence summary.	Consider a clinically appropriate alternative antidepressant not predominantly metabolized by CYP2C19. If citalopram or escitalopram are clinically appropriate, and adequate efficacy is not achieved at standard maintenance dosing, consider titrating to a higher maintenance dose.	['Proceed taking escitalopram as normal. There is no recommendation.', 'Take escitalopram with a reduced dose.', 'Take escitalopram with an increased dose.']	Avoid escitalopram. Take an alternate therapy.	Individuals who are Ultrarapid Metabolizers (UMs) for CYP2C19 may experience reduced plasma concentrations of escitalopram due to faster drug metabolism. Clinical guidance generally suggests considering an alternative medication or careful monitoring, as these patients might have a diminished therapeutic response and an increased risk of treatment failure with standard doses of escitalopram. If escitalopram is used, a higher dose than typically prescribed may be considered, but this should be done with caution and under close supervision.	0.7066791275686436	0.6514970657778725	0.6105232442163292	0.6432527405980596	0.67750674	0.5864076	0.47000763	0.55694747	0.7079703	0.5044614	0.4065702	0.58813334	0.7076586	0.67709786	0.61274743	0.5981461	0.75051653	0.66057587	0.61762315	0.65287954	1
escitalopram	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking escitalopram? Give a 2-3 sentence summary.	No recommendation	['Avoid escitalopram. Take an alternate therapy.', 'Take escitalopram with a reduced dose.', 'Take escitalopram with an increased dose.']	Proceed taking escitalopram as normal. There is no recommendation.	If an individual is indeterminate for CYP2C19 metabolization, it generally means their metabolic capacity remains uncertain based on the genetic test. For escitalopram, clinical guidelines typically suggest starting with the standard dose and closely monitoring for efficacy and adverse effects, making dose adjustments based on clinical response rather than genetic result alone. Regular follow-ups are advised to ensure the medication is effective and well-tolerated.	0.2279332542565827	0.450057842775378	0.20839189852612894	0.5806531979388208	0.08162115	0.3081906	0.13594498	0.4697321	0.050940134	0.16049255	0.043031305	0.5566777	-0.044816863	0.29398796	0.07406002	0.46699038	0.28127155	0.533468	0.42430457	0.6349922	0
fluorouracil	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for DPYD with regards to taking fluorouracil? Give a 2-3 sentence summary.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).	['Proceed taking fluorouracil as normal. There is no recommendation.', 'Avoid fluorouracil. Take an alternate therapy.']	Take fluorouracil with an altered dose.	For a patient identified as an Intermediate Metabolizer with a DPYD activity score of 1.5, clinical guidelines suggest a dose reduction when prescribing fluorouracil. Typically, an initial dose reduction of 25-50% is recommended, followed by close monitoring for toxicity and efficacy. Adjustments should be made based on the patient's tolerance and response to the treatment.	0.5566385754762195	0.47097179473104	0.40865421321350237	0.653720124111915	0.6433908	0.4059437	0.3253124	0.49821937	0.615415	0.36285377	0.34309617	0.4360938	0.58475006	0.45642266	0.34486914	0.58094424	0.58814496	0.5977499	0.43774837	0.6585147	1
fluorouracil	DPYD	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for DPYD with regards to taking fluorouracil? Give a 2-3 sentence summary.	Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.	['Proceed taking fluorouracil as normal. There is no recommendation.', 'Take fluorouracil with a reduced dose.', 'Take fluorouracil with an increased dose.']	Avoid fluorouracil. Take an alternate therapy.	For a patient identified as a Poor Metabolizer with an activity score of 0.0 for the DPYD gene, clinical guidance recommends avoiding fluorouracil due to the high risk of severe and potentially life-threatening toxicity. Alternative chemotherapeutic agents that do not rely on DPD (dihydropyrimidine dehydrogenase) metabolism should be considered to ensure patient safety.	0.555821749376093	0.6363380814956673	0.6013364189980233	0.5745688413937478	0.69329894	0.64294934	0.54376984	0.54657227	0.59321916	0.7841388	0.6695526	0.49738282	0.5577914	0.7166224	0.68770885	0.5682747	0.62474203	0.82438254	0.7336395	0.6645948	1
fluorouracil	DPYD	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for DPYD with regards to taking fluorouracil? Give a 2-3 sentence summary.	Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available). Patients with the c.2846A>T/c.2846A>T genotype may require >50% reduction in starting dose.	['Proceed taking fluorouracil as normal. There is no recommendation.', 'Avoid fluorouracil. Take an alternate therapy.']	Take fluorouracil with an altered dose.	For an individual identified as an Intermediate Metabolizer with an activity score of 1.0 for DPYD, the clinical guidance would typically involve a dose reduction of fluorouracil, generally to 50% of the standard dose. This adjustment is recommended to mitigate the risk of severe toxicity, as these individuals have reduced DPYD enzyme activity, leading to slower metabolism and increased exposure to the drug. Regular monitoring for adverse effects is also advised.	0.5470767150891009	0.4805598972380716	0.42038508222498383	0.5857177747786806	0.74413043	0.43045577	0.38388374	0.43503428	0.6410873	0.36284778	0.38803422	0.40809026	0.5228021	0.4147478	0.32485494	0.5548319	0.4817717	0.4676467	0.36165643	0.6265442	1
fluorouracil	DPYD	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for DPYD with regards to taking fluorouracil? Give a 2-3 sentence summary.	Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.	['Avoid fluorouracil. Take an alternate therapy.', 'Take fluorouracil with a reduced dose.', 'Take fluorouracil with an increased dose.']	Proceed taking fluorouracil as normal. There is no recommendation.	For individuals who are normal metabolizers with an activity score of 2.0 for the DPYD gene, standard dosing regimens of fluorouracil can generally be followed. No dose adjustment is typically necessary as normal metabolizers are expected to have standard drug metabolism and clearance, reducing the risk of severe toxicity. However, ongoing clinical monitoring is recommended to promptly identify and manage any adverse effects.	0.4770157502620083	0.4781095705101041	0.3833030003396744	0.6408346751056173	0.62986135	0.6445159	0.39598313	0.56393754	0.5771305	0.5520112	0.3715272	0.6092576	0.5405698	0.5064173	0.44197297	0.5708537	0.53433084	0.61629355	0.4629692	0.6660305	1
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking flurbiprofen? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid flurbiprofen. Take an alternate therapy.', 'Take flurbiprofen with a reduced dose.', 'Take flurbiprofen with an increased dose.']	Proceed taking flurbiprofen as normal. There is no recommendation.	For an individual who is a normal metabolizer with an activity score of 2.0 for CYP2C9, standard dosing of flurbiprofen is generally appropriate. No specific dosage adjustments are necessary since the expected metabolism of the drug should be within the normal range, ensuring both efficacy and safety. However, as with all NSAIDs, monitoring for potential side effects and adjusting dosing based on clinical response and tolerability is recommended.	0.41495853796266213	0.3932689884606633	0.4285416360929572	0.6733242382583938	0.48669872	0.34235176	0.3394964	0.5101595	0.46117783	0.39875066	0.27121523	0.5932444	0.431832	0.36041084	0.3420951	0.6169217	0.4616576	0.47378543	0.46098456	0.64706403	1
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking flurbiprofen? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid flurbiprofen. Take an alternate therapy.', 'Take flurbiprofen with a reduced dose.', 'Take flurbiprofen with an increased dose.']	Proceed taking flurbiprofen as normal. There is no recommendation.	For a patient identified as an intermediate metabolizer with a CYP2C9 activity score of 1.5, caution is advised when prescribing flurbiprofen. Intermediate metabolizers may exhibit reduced enzyme activity, leading to slower drug clearance and potentially increased risk of adverse effects. It is recommended to initiate flurbiprofen at the lowest effective dose and monitor the patient closely for signs of toxicity, adjusting the dosage as necessary based on clinical response and tolerance.	0.43706813809236295	0.3932689884606633	0.4285416360929572	0.6130448626167968	0.40376946	0.34235176	0.3394964	0.5010862	0.44422024	0.39875066	0.27121523	0.51844776	0.41919243	0.36041084	0.3420951	0.56117576	0.47741	0.47378543	0.46098456	0.60163873	0
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking flurbiprofen? Give a 2-3 sentence summary.	No recommendation	['Avoid flurbiprofen. Take an alternate therapy.', 'Take flurbiprofen with a reduced dose.', 'Take flurbiprofen with an increased dose.']	Proceed taking flurbiprofen as normal. There is no recommendation.	For an individual with an indeterminate status for CYP2C9 taking flurbiprofen, close monitoring is advised because the metabolism of flurbiprofen may be unpredictable. Indeterminate status indicates that the CYP2C9 genotype cannot be determined or does not match known variants, potentially leading to variability in drug clearance and increased risk of adverse effects. This patient may require alternative pain management strategies or dose adjustments based on clinical response and tolerance.	0.23640510937405063	0.44440509990330485	0.22527444137880537	0.5671675153111604	0.115823165	0.2772923	0.1422192	0.4183077	0.035563827	0.13851258	0.05173899	0.45194802	-0.006240815	0.2941111	0.100122064	0.52114654	0.302042	0.5312632	0.39120016	0.5898758	0
flurbiprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking flurbiprofen? Give a 2-3 sentence summary.	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	['Avoid flurbiprofen. Take an alternate therapy.', 'Take flurbiprofen with a reduced dose.', 'Take flurbiprofen with an increased dose.']	Proceed taking flurbiprofen as normal. There is no recommendation.	For an individual identified as an intermediate metabolizer with a CYP2C9 activity score of 1.0, caution is advised when prescribing flurbiprofen. These patients may have reduced clearance of the drug, leading to higher plasma concentrations and an increased risk of adverse effects such as gastrointestinal toxicity. Clinical guidelines suggest considering a lower dose or an alternative nonsteroidal anti-inflammatory drug (NSAID) that is less dependent on CYP2C9 metabolism.	0.4210463415458756	0.3797382274224067	0.4325012575671396	0.6306261178034981	0.46588135	0.43295488	0.37236837	0.4907826	0.34149978	0.37317124	0.2394433	0.48788798	0.3298659	0.34830812	0.33611226	0.6042837	0.43339443	0.38620687	0.41235697	0.64290315	0
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin? Give a 2-3 sentence summary.	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 phenotype could not be assigned based on genotyping.	['Avoid fluvastatin. Take an alternate therapy.', 'Take fluvastatin with a reduced dose.', 'Take fluvastatin with an increased dose.']	Proceed taking fluvastatin as normal. There is no recommendation.	For a patient who is indeterminate for CYP2C9 and has a possible decreased function for SLCO1B1, prescribing fluvastatin may require cautious approach. The patient may be at an increased risk for statin-associated side effects such as muscle toxicity. It is advisable to start with the lowest possible dose of fluvastatin and to monitor for adverse effects closely, adjusting the dosage as necessary based on the patient's response and tolerance.    	0.8354434205227753	0.6064374174183249	0.6522115439883961	0.6005920189775621	0.8325704	0.5956503	0.5552284	0.6241796	0.86295056	0.67909634	0.5395389	0.674887	0.77669936	0.5476325	0.5157771	0.569891	0.828137	0.6026437	0.6182136	0.58585536	0
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Indeterminate for SLCO1B1 with regards to taking fluvastatin? Give a 2-3 sentence summary.	n/a	['Avoid fluvastatin. Take an alternate therapy.', 'Take fluvastatin with a reduced dose.', 'Take fluvastatin with an increased dose.']	Proceed taking fluvastatin as normal. There is no recommendation.	For individuals with no genotypic result and activity score for CYP2C9 and an indeterminate result for SLCO1B1, the clinical guidance for fluvastatin would typically default to standard dosing and monitoring protocols. Without specific genetic data, clinicians should monitor the patient's response to the medication and watch for any adverse effects, adjusting the dose as needed based on clinical efficacy and tolerance.	0.13882389405733858	0.2047887250203398	0.10898569540313992	0.6331458997974317	0.21459869	0.123018816	0.092413805	0.5814055	0.06465298	0.038633898	0.042194527	0.59798485	0.004443063	0.016649822	-0.0060947835	0.46122262	0.3640419	0.35597724	0.37700883	0.6657812	0
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 and Decreased Function for SLCO1B1 with regards to taking fluvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day.	['Avoid fluvastatin. Take an alternate therapy.', 'Take fluvastatin with a reduced dose.', 'Take fluvastatin with an increased dose.']	Proceed taking fluvastatin as normal. There is no recommendation.	For a patient who is a Normal Metabolizer (activity score = 2.0) for CYP2C9 and has Decreased Function for SLCO1B1, standard dosing of fluvastatin can generally be used, as no adjustment is needed based on their CYP2C9 genotype. However, due to decreased SLCO1B1 function, there might be a slightly increased risk of statin-associated muscle symptoms, so it would be prudent to monitor for these adverse effects and consider the lowest effective dose.	0.6874885078080268	0.638203655062093	0.6908823729792118	0.6107944595264417	0.5693172	0.50806916	0.53615195	0.63849133	0.64741427	0.65729254	0.4876262	0.6685588	0.53919154	0.5292073	0.51502293	0.5706574	0.65999615	0.5800474	0.6020532	0.595834	0
fluvastatin	CYP2C9;SLCO1B1	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2C9 and Possible Decreased Function for SLCO1B1 with regards to taking fluvastatin? Give a 2-3 sentence summary.	Based on SLCO1B1 status, prescribe desired starting dose and adjust doses of fluvastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >40mg per day. CYP2C9 genotype result is not available.	['Avoid fluvastatin. Take an alternate therapy.', 'Take fluvastatin with a reduced dose.', 'Take fluvastatin with an increased dose.']	Proceed taking fluvastatin as normal. There is no recommendation.	For a patient with an indeterminate CYP2C9 genotype (No Result) and an intermediate functioning SLCO1B1 variant (Possible Decreased Function), the clinical guidance for fluvastatin use would focus on monitoring for potential statin-associated side effects such as myopathy. In this context, it might be prudent to start fluvastatin at a lower dose and carefully monitor the patient for any adverse reactions, adjusting the dosage as necessary based on their clinical response and tolerance.	0.8524925020647101	0.6174447430169545	0.6643161850691812	0.5934064749766019	0.7988571	0.59110075	0.5367722	0.52798265	0.87825274	0.6773422	0.52115065	0.66135186	0.73979354	0.5533287	0.5212448	0.48149687	0.8486124	0.61240405	0.623084	0.60488915	0
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking fluvoxamine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid fluvoxamine. Take an alternate therapy.', 'Take fluvoxamine with a reduced dose.', 'Take fluvoxamine with an increased dose.']	Proceed taking fluvoxamine as normal. There is no recommendation.	For an individual identified as an intermediate metabolizer with a CYP2D6 activity score of 0.5, caution should be advised when prescribing fluvoxamine. Due to the reduced metabolic capacity, there may be an increased risk for adverse effects and higher plasma concentrations of the drug. It may be necessary to consider a lower starting dose and closely monitor the patient for tolerance and effectiveness, with adjustments made as needed.	0.40355466380930005	0.47694865718439633	0.49446253179854155	0.6084051455797777	0.4018665	0.3997225	0.44948137	0.5715127	0.39932743	0.51829517	0.4310933	0.64161146	0.396655	0.48154303	0.48746097	0.54715705	0.5357122	0.51965314	0.57794166	0.61448056	0
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 4.0 for CYP2D6 with regards to taking fluvoxamine? Give a 2-3 sentence summary.	No recommendation due to lack of evidence	['Avoid fluvoxamine. Take an alternate therapy.', 'Take fluvoxamine with a reduced dose.', 'Take fluvoxamine with an increased dose.']	Proceed taking fluvoxamine as normal. There is no recommendation.	Individuals who are ultrarapid metabolizers (UMs) with an activity score of 4.0 for CYP2D6 are likely to metabolize fluvoxamine more quickly than average. However, fluvoxamine is primarily metabolized by CYP1A2, not CYP2D6, meaning standard dosing is usually appropriate as CYP2D6 UM status does not significantly affect fluvoxamine metabolism. Close monitoring is always recommended to adjust doses based on therapeutic response and side effects.	0.20992675514554623	0.42185352414488986	0.27533023855868044	0.5691460265936287	0.14729059	0.3657315	0.21147175	0.46593326	0.15493882	0.32147396	0.16616674	0.5761268	0.018693231	0.26190126	0.08319647	0.4594672	0.22218874	0.53878886	0.3666176	0.59487706	0
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking fluvoxamine? Give a 2-3 sentence summary.	No recommendation due to lack of evidence	['Avoid fluvoxamine. Take an alternate therapy.', 'Take fluvoxamine with a reduced dose.', 'Take fluvoxamine with an increased dose.']	Proceed taking fluvoxamine as normal. There is no recommendation.	For an individual who is an Ultrarapid Metabolizer (UM) with a CYP2D6 activity score ≥ 3.75, specific clinical guidance for taking fluvoxamine may not be well-defined, as fluvoxamine is primarily metabolized by CYP1A2 and CYP2C19 rather than CYP2D6. However, given the extensive metabolism through CYP2D6, the prescriber should be cautious with substrate drugs that are significantly metabolized by CYP2D6 and should closely monitor for potential adverse effects or therapeutic inefficacy, adjusting the dosage as necessary.	0.2385384960203188	0.42185352414488986	0.27533023855868044	0.6086154440119653	0.35784993	0.3657315	0.21147175	0.5607864	0.21589777	0.32147396	0.16616674	0.5906846	0.029439453	0.26190126	0.08319647	0.44776055	0.26078972	0.53878886	0.3666176	0.59500456	0
fluvoxamine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 with regards to taking fluvoxamine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid fluvoxamine. Take an alternate therapy.', 'Take fluvoxamine with a reduced dose.', 'Take fluvoxamine with an increased dose.']	Proceed taking fluvoxamine as normal. There is no recommendation.	For an individual who is an Intermediate Metabolizer with an activity score of 0.25 for CYP2D6, taking fluvoxamine, caution is advised due to the potential for increased drug levels and reduced clearance of medications metabolized by CYP2D6. Alternative medications that do not heavily rely on CYP2D6 metabolism should be considered, or a lower starting dose of fluvoxamine might be appropriate, with close monitoring for side effects and therapeutic response. Consulting with a healthcare provider to tailor the treatment based on genetic testing results is recommended.	0.40147900091767447	0.47694865718439633	0.49446253179854155	0.6413943124575998	0.3987061	0.3997225	0.44948137	0.6098513	0.40054882	0.51829517	0.4310933	0.6206621	0.44577032	0.48154303	0.48746097	0.55093765	0.39117151	0.51965314	0.57794166	0.6118188	0
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin? Give a 2-3 sentence summary.	If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.	['Proceed taking fosphenytoin as normal. There is no recommendation.', 'Take fosphenytoin with a reduced dose.', 'Take fosphenytoin with an increased dose.']	Avoid fosphenytoin. Take an alternate therapy.	HLA-B*15:02 positive individuals should avoid the use of fosphenytoin due to the increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis. It is recommended to choose an alternative medication that does not carry this risk for patients with the HLA-B*15:02 allele.	0.5460817443929402	0.6702188563061829	0.6103615953648364	0.6210421680156599	0.6352114	0.59464514	0.49828228	0.66709316	0.57576776	0.573919	0.5386758	0.6289503	0.56903106	0.72902924	0.6978836	0.64252734	0.59570605	0.66946775	0.5832608	0.6325142	1
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin? Give a 2-3 sentence summary.	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	['Proceed taking fosphenytoin as normal. There is no recommendation.', 'Avoid fosphenytoin. Take an alternate therapy.']	Take fosphenytoin with an altered dose.	For individuals without an HLA-B result, fosphenytoin can still be prescribed, but clinicians should monitor for signs of adverse reactions, including potentially severe cutaneous adverse reactions (SCARs) such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). While the absence of an HLA-B*15:02 allele test may not provide specific risk information, cautious use and patient education on recognizing early symptoms of hypersensitivity reactions remain critical.	0.6695892062883466	0.5011246329360844	0.5278988994742868	0.5611190210075442	0.5330053	0.5278582	0.52631456	0.42167133	0.54317814	0.4648302	0.4938583	0.42768076	0.6127522	0.49366376	0.4657582	0.44498974	0.6385015	0.53713393	0.49919704	0.5545158	0
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking fosphenytoin? Give a 2-3 sentence summary.	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	['Proceed taking fosphenytoin as normal. There is no recommendation.', 'Avoid fosphenytoin. Take an alternate therapy.']	Take fosphenytoin with an altered dose.	For a patient with no available HLA-B result, caution is warranted when prescribing fosphenytoin due to the potential risk of severe cutaneous adverse reactions, such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN), particularly in individuals of Asian descent who may carry the HLA-B*15:02 allele. Clinical monitoring for signs of dermatologic reactions is essential, and alternative treatments may be considered if the risk is deemed significant.	0.6506480568040485	0.5011246329360844	0.5278988994742868	0.5657212062661775	0.5732626	0.5278582	0.52631456	0.43037322	0.5539118	0.4648302	0.4938583	0.43157545	0.5965394	0.49366376	0.4657582	0.48716524	0.644702	0.53713393	0.49919704	0.5693256	0
fosphenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking fosphenytoin? Give a 2-3 sentence summary.	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	['Avoid fosphenytoin. Take an alternate therapy.', 'Take fosphenytoin with a reduced dose.', 'Take fosphenytoin with an increased dose.']	Proceed taking fosphenytoin as normal. There is no recommendation.	HLA-B*15:02 positive individuals should avoid the use of fosphenytoin due to the increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis. It is recommended to choose an alternative medication that does not carry this risk for patients with the HLA-B*15:02 allele.	0.5403513408377286	0.4882418935803664	0.47287796595008064	0.5518493076356894	0.48808658	0.50990474	0.45730582	0.65998214	0.45601225	0.4668076	0.40350342	0.61878586	0.40309042	0.45731205	0.45889655	0.5912916	0.3986555	0.4513046	0.46494868	0.58869755	0
furazolidone	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking furazolidone? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid furazolidone. Take an alternate therapy.', 'Take furazolidone with a reduced dose.', 'Take furazolidone with an increased dose.']	Proceed taking furazolidone as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), use of furazolidone is generally contraindicated due to the elevated risk of hemolysis. G6PD deficiency can lead to oxidative stress in red blood cells when exposed to certain drugs, and furazolidone is one of these oxidative agents that can trigger hemolytic anemia. Therefore, it is crucial for healthcare providers to avoid prescribing furazolidone to G6PD-deficient patients and consider alternative treatments.	0.5784450337220267	0.4791747284528	0.3526706551026228	0.5482569230068748	0.54379916	0.48758885	0.258895	0.57640386	0.5408809	0.37915996	0.1656151	0.55544955	0.49142146	0.3970477	0.26155627	0.5250657	0.6026161	0.54091483	0.41668692	0.5985475	0
furazolidone	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking furazolidone? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid furazolidone. Take an alternate therapy.', 'Take furazolidone with a reduced dose.', 'Take furazolidone with an increased dose.']	Proceed taking furazolidone as normal. There is no recommendation.	For individuals with an indeterminate status for G6PD deficiency, caution is advised when prescribing furazolidone, as the drug can precipitate hemolysis in G6PD-deficient patients. It may be prudent to perform G6PD testing to confirm the patient's status before initiating treatment to avoid potential hemolytic risks. Alternative medications with a safer profile for suspected G6PD deficiency should be considered if testing is not feasible.	0.6425428623622622	0.3772870511025526	0.3073498474644629	0.5694154789757448	0.5987736	0.21883877	0.2292629	0.55510014	0.6557386	0.25067362	0.14510415	0.5913518	0.6466313	0.21878566	0.16820502	0.5101056	0.5953425	0.46202558	0.42795387	0.55608743	0
furazolidone	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking furazolidone? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid furazolidone. Take an alternate therapy.', 'Take furazolidone with a reduced dose.', 'Take furazolidone with an increased dose.']	Proceed taking furazolidone as normal. There is no recommendation.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, specifically those with congenital non-spherocytic hemolytic anemia (CNSHA), the use of furazolidone poses a significant risk of hemolysis. Clinical guidance suggests avoiding furazolidone in these patients due to the potential for severe oxidative stress and subsequent hemolytic anemia. Alternative therapies that do not pose a risk of hemolysis should be considered.	0.4428061360069901	0.35917969285934237	0.37003989317204083	0.5388212205991056	0.568574	0.47450686	0.42660522	0.577266	0.5527361	0.45595145	0.34154227	0.5239459	0.52611023	0.42122033	0.3597677	0.49257737	0.5462169	0.41092566	0.46192658	0.5508481	0
furazolidone	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking furazolidone? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid furazolidone. Take an alternate therapy.', 'Take furazolidone with a reduced dose.', 'Take furazolidone with an increased dose.']	Proceed taking furazolidone as normal. There is no recommendation.	Individuals with normal glucose-6-phosphate dehydrogenase (G6PD) enzyme levels typically have no contraindications specific to taking furazolidone related to G6PD deficiency. However, as with any medication, monitoring for possible side effects and interactions is advised, and it is always best to follow a healthcare provider's guidance regarding its use.	0.6159437903923695	0.40578370058217755	0.27566315242489914	0.6111525627018848	0.5053249	0.37016988	0.14049475	0.6407223	0.4576554	0.2350072	0.060228232	0.66176355	0.35971016	0.14649555	0.05922235	0.55972075	0.53656125	0.44692647	0.3262125	0.6303343	1
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking gentamicin as normal. There is no recommendation.', 'Take gentamicin with a reduced dose.', 'Take gentamicin with an increased dose.']	Avoid gentamicin. Take an alternate therapy.	For patients with a genetic variant in MT-RNR1, there is an increased risk of aminoglycoside-induced hearing loss, such as from taking gentamicin. Clinical guidance recommends avoiding the use of aminoglycosides in these individuals when possible, opting for alternative antibiotics to mitigate the risk of ototoxicity. If aminoglycosides must be used, monitoring for hearing loss is crucial, and the lowest effective dose should be administered.	0.728624874367907	0.5726659889332882	0.5020238129819993	0.5495665209873186	0.72481877	0.5789479	0.47764573	0.5538509	0.7495525	0.5039189	0.48770857	0.54579675	0.7730625	0.46210888	0.43198904	0.49484855	0.6716373	0.64363265	0.56155294	0.6281588	1
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid gentamicin. Take an alternate therapy.', 'Take gentamicin with a reduced dose.', 'Take gentamicin with an increased dose.']	Proceed taking gentamicin as normal. There is no recommendation.	For individuals identified as being at normal risk for aminoglycoside-induced hearing loss based on the MT-RNR1 genetic test, the clinical guidance typically would not contraindicate the use of gentamicin when it is clinically indicated. Standard precautions should still be observed, such as monitoring renal function and auditory function, and adjusting dosing appropriately to minimize potential toxicity.	0.6639057642453089	0.49346778233169275	0.5105623874368649	0.624504638197771	0.6783337	0.51108366	0.50961566	0.55348575	0.6966441	0.5786555	0.5471874	0.58622247	0.67686146	0.4842328	0.48317716	0.5680621	0.6466078	0.5789062	0.61058813	0.63296694	1
gentamicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking gentamicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid gentamicin. Take an alternate therapy.', 'Take gentamicin with a reduced dose.', 'Take gentamicin with an increased dose.']	Proceed taking gentamicin as normal. There is no recommendation.	For individuals with uncertain risk of aminoglycoside-induced hearing loss related to MT-RNR1 variants, caution is advised when prescribing gentamicin due to its potential to cause significant ototoxicity, even at standard therapeutic doses. Alternative antibiotics should be considered where possible, and if gentamicin use is essential, close monitoring for early signs of hearing loss and regular audiological assessments are recommended.	0.6683821301345938	0.49346778233169275	0.5105623874368649	0.5779516699839969	0.570538	0.51108366	0.50961566	0.5666405	0.7029712	0.5786555	0.5471874	0.58051807	0.7299596	0.4842328	0.48317716	0.5542588	0.6436858	0.5789062	0.61058813	0.5806911	0
glyburide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking glyburide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid glyburide. Take an alternate therapy.', 'Take glyburide with a reduced dose.', 'Take glyburide with an increased dose.']	Proceed taking glyburide as normal. There is no recommendation.	Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency should use caution when taking glyburide due to an increased risk of hemolytic anemia. It is recommended to monitor these patients closely for signs of hemolysis and consider alternative antidiabetic medications to mitigate this risk. Clinical decisions should be personalized, weighing the benefits and risks for each patient.	0.6296974164779664	0.5060629060399261	0.38439035596473015	0.5273074649754412	0.6122018	0.63096595	0.449918	0.58097684	0.6357073	0.58356655	0.41665676	0.6440099	0.6456338	0.5568763	0.45458224	0.60591215	0.5724459	0.56947976	0.44801283	0.5360235	0
glyburide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking glyburide? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid glyburide. Take an alternate therapy.', 'Take glyburide with a reduced dose.', 'Take glyburide with an increased dose.']	Proceed taking glyburide as normal. There is no recommendation.	For individuals with an indeterminate G6PD (glucose-6-phosphate dehydrogenase) status, caution is advised when prescribing glyburide due to the risk of hemolysis in G6PD-deficient patients. Close monitoring for signs of hemolysis and considering alternative hypoglycemic agents may be appropriate to ensure patient safety. It is important to evaluate the benefits and risks on a case-by-case basis.	0.6314943082882978	0.3997814223439668	0.33703384042885354	0.560232742154025	0.5705976	0.33047712	0.33726552	0.599266	0.6370227	0.4088208	0.3365036	0.62785625	0.60950965	0.37284452	0.34635338	0.61369395	0.62454426	0.46678165	0.45682275	0.531176	0
glyburide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking glyburide? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid glyburide. Take an alternate therapy.', 'Take glyburide with a reduced dose.', 'Take glyburide with an increased dose.']	Proceed taking glyburide as normal. There is no recommendation.	For a patient with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly Chronic Non-Spherocytic Hemolytic Anemia (CNSHA), the use of glyburide (a sulfonylurea) may pose a risk of precipitating hemolytic anemia. It is advisable to consider alternative antidiabetic medications that do not pose the same risk. Consulting with a healthcare professional for personalized advice is essential to ensure safe and effective diabetes management.	0.4356245154963047	0.3674729473136461	0.39810511701391965	0.5173829136732534	0.54096663	0.48771554	0.48725367	0.6018948	0.50340474	0.432418	0.42766428	0.6150289	0.4666478	0.42212632	0.39028057	0.57403743	0.58571994	0.38036683	0.46689296	0.5175256	0
glyburide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking glyburide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid glyburide. Take an alternate therapy.', 'Take glyburide with a reduced dose.', 'Take glyburide with an increased dose.']	Proceed taking glyburide as normal. There is no recommendation.	For individuals with normal glucose-6-phosphate dehydrogenase (G6PD) enzyme activity, there are no specific pharmacogenomic contraindications or precautions for taking glyburide. Glyburide can be prescribed and used as per standard clinical guidelines for managing type 2 diabetes, focusing on dosages and monitoring as recommended for the general population without G6PD deficiency concerns.	0.6163188703131068	0.4476245481047508	0.3202341466305468	0.6339882005530705	0.51446956	0.45541748	0.2555866	0.6717918	0.50247896	0.3578019	0.21604626	0.677173	0.40997878	0.2883241	0.21600159	0.5939572	0.595902	0.49520376	0.36960807	0.5661393	1
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking halothane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking halothane as normal. There is no recommendation.', 'Take halothane with a reduced dose.', 'Take halothane with an increased dose.']	Avoid halothane. Take an alternate therapy.	For an individual with Malignant Hyperthermia Susceptibility due to an RYR1 genetic variant and Uncertain Susceptibility related to CACNA1S, clinical guidelines strongly advise against the use of halothane. Halothane is a known trigger for malignant hyperthermia and could lead to a life-threatening reaction in susceptible individuals. Alternative anesthetic agents that do not trigger malignant hyperthermia should be used instead.	0.7488885320345128	0.5125164503275788	0.4363443144668568	0.5885579601760484	0.75128645	0.64343655	0.54182506	0.59103566	0.8152662	0.5877566	0.49858084	0.6319318	0.77641755	0.47715393	0.41892657	0.58823663	0.6579415	0.593848	0.5662722	0.5389209	1
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking halothane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking halothane as normal. There is no recommendation.', 'Take halothane with a reduced dose.', 'Take halothane with an increased dose.']	Avoid halothane. Take an alternate therapy.	Individuals with Malignant Hyperthermia Susceptibility (MHS) associated with RYR1 or CACNA1S mutations are at high risk for developing a life-threatening reaction if exposed to halothane. Clinical guidance strongly recommends avoiding the use of halothane and other triggering agents like succinylcholine, opting instead for safe alternatives such as non-triggering anesthetics and vigilant perioperative monitoring to manage and mitigate risks.	0.7582143174855075	0.5125164503275788	0.4363443144668568	0.532280760786492	0.7774129	0.64343655	0.54182506	0.6239268	0.8148889	0.5877566	0.49858084	0.6088444	0.78865653	0.47715393	0.41892657	0.5939225	0.74442965	0.593848	0.5662722	0.6262587	1
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking halothane? Give a 2-3 sentence summary.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid halothane. Take an alternate therapy.', 'Take halothane with a reduced dose.', 'Take halothane with an increased dose.']	Proceed taking halothane as normal. There is no recommendation.	For a patient with uncertain susceptibility for RYR1 and no result for CACNA1S, caution is advised when considering the use of halothane due to the potential risk of malignant hyperthermia (MH). It would be prudent to either conduct further genetic testing if clinically appropriate or opt for alternative anesthetic agents that do not trigger MH in susceptible individuals. Consulting a specialist in anesthesiology or pharmacogenomics for personalized guidance is recommended.	0.7356219658773487	0.43097134698913875	0.3723399952249588	0.5641526819271342	0.7471922	0.5207518	0.37978885	0.5632074	0.7802844	0.39891067	0.40849733	0.54817283	0.56183857	0.37230834	0.32514367	0.4721601	0.74501544	0.4512372	0.41108954	0.58363974	1
halothane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking halothane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking halothane as normal. There is no recommendation.', 'Take halothane with a reduced dose.', 'Take halothane with an increased dose.']	Avoid halothane. Take an alternate therapy.	If an individual has no results for RYR1 but is positive for malignant hyperthermia susceptibility (MHS) due to a CACNA1S variant, the clinical guidance would typically advise against the use of halothane. Halothane is a known trigger for malignant hyperthermia, and the presence of MHS due to CACNA1S indicates a heightened risk for this life-threatening reaction. Alternative anesthesia options that do not trigger MH should be considered.	0.7381176723450561	0.5190654127979403	0.4445307876632816	0.5310535631329456	0.79712147	0.6295587	0.53317	0.582292	0.83089757	0.561159	0.46712598	0.6111634	0.7816071	0.45054668	0.39339375	0.53671616	0.7399892	0.57862145	0.5561028	0.5009419	1
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking hydrocodone? Give a 2-3 sentence summary.	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	['Avoid hydrocodone. Take an alternate therapy.', 'Take hydrocodone with a reduced dose.', 'Take hydrocodone with an increased dose.']	Proceed taking hydrocodone as normal. There is no recommendation.	For an individual who is an ultrarapid metabolizer with a CYP2D6 activity score of ≥5.0, taking hydrocodone may result in rapid and extensive conversion to hydromorphone, leading to potentially increased opioid effects and a higher risk of side effects or toxicity. Clinicians are advised to consider alternative analgesics, not primarily metabolized by CYP2D6, or to closely monitor the patient for signs of opioid toxicity if hydrocodone use is necessary.	0.5267594501698843	0.6160805783810074	0.5685853348620573	0.5284554269749174	0.40437743	0.5862034	0.42646357	0.5511256	0.62531734	0.7300503	0.6321302	0.5987414	0.61791915	0.7018527	0.60289425	0.58273053	0.5389522	0.79865915	0.6221513	0.57566917	0
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking hydrocodone? Give a 2-3 sentence summary.	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	['Avoid hydrocodone. Take an alternate therapy.', 'Take hydrocodone with a reduced dose.', 'Take hydrocodone with an increased dose.']	Proceed taking hydrocodone as normal. There is no recommendation.	For a person identified as a CYP2D6 ultrarapid metabolizer with an activity score of 2.5, clinical guidance typically recommends caution when prescribing hydrocodone. Due to the increased metabolic activity, there is a risk of accelerated conversion of hydrocodone to its active metabolite, hydromorphone, which can enhance both therapeutic and adverse effects, such as respiratory depression. Alternative pain management strategies or medications that are not significantly metabolized by CYP2D6 should be considered.	0.5649288175382094	0.6160805783810074	0.5685853348620573	0.5738572538866981	0.37485492	0.5862034	0.42646357	0.51865256	0.6366444	0.7300503	0.6321302	0.5638945	0.6222638	0.7018527	0.60289425	0.59554136	0.54930377	0.79865915	0.6221513	0.57257515	0
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 with regards to taking hydrocodone? Give a 2-3 sentence summary.	Use hydrocodone label recommended age- or weight-specific dosing.	['Avoid hydrocodone. Take an alternate therapy.', 'Take hydrocodone with a reduced dose.', 'Take hydrocodone with an increased dose.']	Proceed taking hydrocodone as normal. There is no recommendation.	For an individual who is a normal metabolizer with a CYP2D6 activity score of 1.5, no specific adjustments are usually needed for hydrocodone dosing. Clinicians generally prescribe the standard dose, as normal metabolizers have typical enzyme activity that should adequately convert hydrocodone into its active form, hydromorphone. However, as always, clinical monitoring for efficacy and side effects is recommended.	0.5732839949298298	0.6089938886628808	0.6434182018202387	0.5931069267529878	0.5357429	0.4760395	0.5420722	0.49972028	0.5813509	0.6623268	0.6348389	0.55149436	0.5997652	0.7024994	0.5987571	0.5698593	0.5628991	0.67024654	0.68248653	0.5864111	1
hydrocodone	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking hydrocodone? Give a 2-3 sentence summary.	No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.	['Avoid hydrocodone. Take an alternate therapy.', 'Take hydrocodone with a reduced dose.', 'Take hydrocodone with an increased dose.']	Proceed taking hydrocodone as normal. There is no recommendation.	For individuals who are ultrarapid metabolizers (UMs) with a CYP2D6 activity score of ≥6.0, it is generally recommended to avoid the use of hydrocodone due to the risk of increased formation of hydromorphone, which may lead to enhanced effects and potential opioid toxicity. Alternative analgesics that are not metabolized by CYP2D6 should be considered to mitigate these risks.	0.5528825330737033	0.6160805783810074	0.5685853348620573	0.5313667783372585	0.5584388	0.5862034	0.42646357	0.62271285	0.6681478	0.7300503	0.6321302	0.6091962	0.6180541	0.7018527	0.60289425	0.59709555	0.59988683	0.79865915	0.6221513	0.6080239	0
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking hydroxychloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid hydroxychloroquine. Take an alternate therapy.', 'Take hydroxychloroquine with a reduced dose.', 'Take hydroxychloroquine with an increased dose.']	Proceed taking hydroxychloroquine as normal. There is no recommendation.	For individuals with variable G6PD (glucose-6-phosphate dehydrogenase) activity, caution should be exercised when considering hydroxychloroquine, as this medication can induce hemolysis in G6PD-deficient individuals. Clinical guidance typically advises close monitoring for symptoms of hemolysis, and alternative treatments may be recommended for those with significant deficiency. Consultation with a healthcare professional for personalized advice is crucial.	0.618357093047157	0.4521178454584941	0.33292752489512883	0.5225186240443053	0.5744507	0.53098786	0.31695512	0.57310027	0.5838785	0.4210606	0.23939109	0.5759514	0.5824559	0.3804098	0.2339322	0.53958786	0.54361564	0.52370197	0.38278016	0.5064851	0
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking hydroxychloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid hydroxychloroquine. Take an alternate therapy.', 'Take hydroxychloroquine with a reduced dose.', 'Take hydroxychloroquine with an increased dose.']	Proceed taking hydroxychloroquine as normal. There is no recommendation.	For an individual with a normal glucose-6-phosphate dehydrogenase (G6PD) enzyme level, there is no increased risk of hemolysis when taking hydroxychloroquine. As such, standard dosing guidelines for hydroxychloroquine can be followed without the need for additional precautions related to G6PD deficiency. However, as with all medications, monitoring for possible side effects and adherence to prescribing physician guidance is important.	0.601205362474877	0.3887935215403734	0.2590051270433919	0.5863187083889146	0.48334828	0.39236602	0.19392097	0.64446765	0.44336915	0.2570259	0.12544473	0.6711625	0.32994545	0.14874986	0.058984935	0.62711966	0.56545585	0.46030134	0.32393628	0.58577	1
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking hydroxychloroquine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid hydroxychloroquine. Take an alternate therapy.', 'Take hydroxychloroquine with a reduced dose.', 'Take hydroxychloroquine with an increased dose.']	Proceed taking hydroxychloroquine as normal. There is no recommendation.	Clinical guidance for an individual with an indeterminate G6PD status regarding hydroxychloroquine use would generally advise caution. Although an indeterminate result means the G6PD enzyme activity level is uncertain, it is prudent to avoid starting hydroxychloroquine until G6PD deficiency is ruled out, due to the risk of hemolytic anemia. Additional G6PD testing may be recommended to clarify the individual's status before initiating treatment.	0.6889365240747092	0.3572031880639572	0.2951994512519092	0.5227178521733513	0.5325996	0.2443593	0.2666361	0.60937595	0.6312482	0.27711585	0.2106483	0.5838174	0.6301276	0.20778726	0.14779186	0.5638541	0.5769457	0.45534867	0.41669607	0.44853964	0
hydroxychloroquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking hydroxychloroquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid hydroxychloroquine. Take an alternate therapy.', 'Take hydroxychloroquine with a reduced dose.', 'Take hydroxychloroquine with an increased dose.']	Proceed taking hydroxychloroquine as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), hydroxychloroquine should be used with caution due to the increased risk of hemolytic anemia. Clinical guidance typically suggests close monitoring of these patients if hydroxychloroquine use is necessary, or considering alternative treatments to avoid potential adverse effects.	0.590028288180449	0.4521178454584941	0.33292752489512883	0.5258496927682105	0.58602494	0.53098786	0.31695512	0.5892223	0.57531136	0.4210606	0.23939109	0.6511454	0.54924035	0.3804098	0.2339322	0.5995653	0.51832294	0.52370197	0.38278016	0.53855234	0
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking ibuprofen? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid ibuprofen. Take an alternate therapy.', 'Take ibuprofen with a reduced dose.', 'Take ibuprofen with an increased dose.']	Proceed taking ibuprofen as normal. There is no recommendation.	For a patient who is identified as a normal metabolizer with an activity score of 2.0 for the CYP2C9 enzyme, standard dosing of ibuprofen is generally recommended. This genetic profile indicates that the patient has typical enzyme activity, which should result in normal metabolism and clearance of the drug, minimizing the risk of adverse effects and ensuring therapeutic efficacy. However, all standard considerations for ibuprofen use, such as monitoring for gastrointestinal side effects, should still be adhered to.	0.4078671309274461	0.40066570755651604	0.43972643301287434	0.5520072360776939	0.40435296	0.32480752	0.31108814	0.45039052	0.36561185	0.35875928	0.24688192	0.4498963	0.3303809	0.33359307	0.30585036	0.4541142	0.42185825	0.4845923	0.44641063	0.6064029	1
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking ibuprofen? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid ibuprofen. Take an alternate therapy.', 'Take ibuprofen with a reduced dose.', 'Take ibuprofen with an increased dose.']	Proceed taking ibuprofen as normal. There is no recommendation.	For a patient identified as an intermediate metabolizer with a CYP2C9 activity score of 1.5, it is generally advisable to use caution with ibuprofen dosing due to potentially reduced clearance of the drug. The patient may be at an increased risk for adverse effects, and thus starting with a lower dose and monitoring for efficacy and toxicity is recommended. If available, considering alternative analgesics that are not metabolized by CYP2C9 could also be a prudent approach.	0.47808948295539994	0.40066570755651604	0.43972643301287434	0.515394636913981	0.43332773	0.32480752	0.31108814	0.49062958	0.35414696	0.35875928	0.24688192	0.5285416	0.3698224	0.33359307	0.30585036	0.5730749	0.44937488	0.4845923	0.44641063	0.5520169	0
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking ibuprofen? Give a 2-3 sentence summary.	No recommendation	['Avoid ibuprofen. Take an alternate therapy.', 'Take ibuprofen with a reduced dose.', 'Take ibuprofen with an increased dose.']	Proceed taking ibuprofen as normal. There is no recommendation.	For individuals with an indeterminate CYP2C9 genotype, the clinical guidance for ibuprofen use would involve careful monitoring for signs of adverse effects, as the variability in drug metabolism could lead to altered efficacy and increased risk of toxicity. Physicians may consider starting with the lowest effective dose and use the medication for the shortest duration necessary to minimize potential risk. Regular follow-ups to assess therapeutic outcomes and side effects are recommended.	0.26078540108546633	0.48597187627325455	0.21826482271593176	0.5283041961641184	0.13486585	0.2338539	0.100331865	0.4746404	0.046553086	0.09324742	0.01574631	0.47346014	-0.033476934	0.27112198	0.069338	0.47433653	0.29140717	0.5637174	0.4093674	0.5671046	0
ibuprofen	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking ibuprofen? Give a 2-3 sentence summary.	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	['Avoid ibuprofen. Take an alternate therapy.', 'Take ibuprofen with a reduced dose.', 'Take ibuprofen with an increased dose.']	Proceed taking ibuprofen as normal. There is no recommendation.	For individuals identified as Intermediate Metabolizers (activity score = 1.0) for CYP2C9, the metabolism of ibuprofen may be slower compared to normal metabolizers. Clinical guidance typically suggests starting with the lowest effective dose of ibuprofen and monitoring for increased effectiveness or adverse effects, such as gastrointestinal discomfort or renal impairment, as these individuals may have higher plasma levels of the drug. Adjustments in dosage or switching to an alternative nonsteroidal anti-inflammatory drug (NSAID) with less dependency on CYP2C9 metabolism may be considered based on the patient's response.	0.5058631351432076	0.3927633692080907	0.4441805040899353	0.5383337116533766	0.47483176	0.4101102	0.34259138	0.42204493	0.3717031	0.340576	0.222553	0.46514267	0.441251	0.32714763	0.30738142	0.51153076	0.45721936	0.3936428	0.39321002	0.55016774	0
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine? Give a 2-3 sentence summary.	Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking imipramine as normal. There is no recommendation.', 'Take imipramine with a reduced dose.', 'Take imipramine with an increased dose.']	Avoid imipramine. Take an alternate therapy.	For a patient who is an Ultrarapid Metabolizer (UM) with an activity score of ≥3.25 for CYP2D6 and an Intermediate Metabolizer for CYP2C19, utilization of imipramine may require caution due to the risk of subtherapeutic levels and reduced efficacy, given the accelerated metabolism via CYP2D6. Alternative treatments or careful dosing adjustments, along with close monitoring for therapeutic effectiveness and side effects, are recommended to ensure optimal treatment outcomes.	0.7450370714766461	0.7450542603816563	0.7134292098918689	0.6485579124092142	0.634283	0.649646	0.55292267	0.54463476	0.6311466	0.65750116	0.5660723	0.60433865	0.51528984	0.56931394	0.53625494	0.547833	0.6049854	0.6534099	0.56885785	0.60897887	0
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 and Intermediate Metabolizer for CYP2C19 with regards to taking imipramine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid imipramine. Take an alternate therapy.', 'Take imipramine with a reduced dose.', 'Take imipramine with an increased dose.']	Proceed taking imipramine as normal. There is no recommendation.	For a patient identified as a Normal Metabolizer with an activity score of 2.25 for CYP2D6 and an Intermediate Metabolizer for CYP2C19, it is generally safe to initiate imipramine at standard starting doses. Close monitoring for adverse effects or therapeutic efficacy may be considered, as the intermediate metabolism via CYP2C19 might slightly alter drug levels, though significant deviations from expected outcomes are unlikely. Adjustments can be made based on clinical response.	0.49610637764661725	0.49091623309996707	0.512320012403109	0.6516311897631872	0.5329772	0.3806608	0.41784343	0.59050566	0.44045302	0.50194806	0.39618644	0.7120378	0.40647358	0.4548647	0.47493827	0.6167335	0.5088822	0.5462583	0.59047675	0.6272292	1
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 and No Result for CYP2C19 with regards to taking imipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	['Proceed taking imipramine as normal. There is no recommendation.', 'Take imipramine with a reduced dose.', 'Take imipramine with an increased dose.']	Avoid imipramine. Take an alternate therapy.	For a patient who is an ultrarapid metabolizer (activity score ≥4.0) of CYP2D6 and has no result for CYP2C19 genotype, the clinical guidance would suggest avoiding imipramine due to the increased risk of subtherapeutic drug levels and lack of efficacy. Alternative treatments that are less affected by CYP2D6 metabolism should be considered, or if imipramine is needed, careful and possibly higher dosing with close monitoring could be considered.	0.6629111300418892	0.5577067091234655	0.5191844915467912	0.6763106119456372	0.6533572	0.44053558	0.40628043	0.6156792	0.70211774	0.3261351	0.32180753	0.5727081	0.6353123	0.40993166	0.41416636	0.5784886	0.6052709	0.47192645	0.41823354	0.6421429	1
imipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 3.0 for CYP2D6 and Indeterminate for CYP2C19 with regards to taking imipramine? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.	['Proceed taking imipramine as normal. There is no recommendation.', 'Take imipramine with a reduced dose.', 'Take imipramine with an increased dose.']	Avoid imipramine. Take an alternate therapy.	For an individual who is an ultrarapid metabolizer (UM) with an activity score of 3.0 for CYP2D6 and has an indeterminate status for CYP2C19, the clinical guidance would be to consider alternative medications to imipramine due to the increased risk of subtherapeutic levels and reduced efficacy. If imipramine is prescribed, monitoring plasma concentrations closely and considering dose adjustments to achieve therapeutic levels may be necessary.	0.6141157587855542	0.5577067091234655	0.5191844915467912	0.6316849349591588	0.7187534	0.44053558	0.40628043	0.523175	0.67885613	0.3261351	0.32180753	0.5421753	0.58424264	0.40993166	0.41416636	0.6103887	0.62057734	0.47192645	0.41823354	0.6285152	1
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking isoflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking isoflurane as normal. There is no recommendation.', 'Take isoflurane with a reduced dose.', 'Take isoflurane with an increased dose.']	Avoid isoflurane. Take an alternate therapy.	Individuals with an Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S should avoid the use of isoflurane, as it can trigger malignant hyperthermia, a potentially life-threatening reaction. It is crucial for healthcare providers to consider alternative anesthesia options and to take appropriate preventive measures if isoflurane use is unavoidable.	0.6447695435715808	0.44946276323134104	0.36163624250608833	0.5518156425853242	0.7872602	0.5382512	0.44272187	0.6759561	0.73052317	0.4140642	0.3637462	0.6262547	0.63983756	0.3757719	0.38502988	0.54993206	0.61522317	0.54628694	0.524697	0.60344833	0
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking isoflurane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking isoflurane as normal. There is no recommendation.', 'Take isoflurane with a reduced dose.', 'Take isoflurane with an increased dose.']	Avoid isoflurane. Take an alternate therapy.	"For a patient with ""No Result"" for the RYR1 gene and ""Malignant Hyperthermia Susceptibility"" (MHS) associated with the CACNA1S gene, clinical guidance would typically advise avoiding isoflurane. Isoflurane is a known trigger for malignant hyperthermia, a potentially life-threatening reaction. Anesthesiologists should choose alternative, non-triggering anesthetics and take precautions to manage and prevent malignant hyperthermia events."	0.7106050580734012	0.455976507206211	0.3702166731773702	0.5585930031519895	0.7262705	0.5214989	0.43131423	0.5742143	0.76319164	0.3956144	0.33795962	0.56246585	0.69823724	0.35871986	0.3619164	0.5683148	0.6888133	0.5345821	0.5182881	0.5781672	1
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking isoflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking isoflurane as normal. There is no recommendation.', 'Take isoflurane with a reduced dose.', 'Take isoflurane with an increased dose.']	Avoid isoflurane. Take an alternate therapy.	For individuals with Malignant Hyperthermia Susceptibility (MHS) associated with the RYR1 gene, it is advised to avoid the use of isoflurane due to the risk of triggering a potentially life-threatening hypermetabolic reaction. For those with uncertain susceptibility related to the CACNA1S gene, there remains a cautionary stance, and alternative anesthetics that do not pose a risk for malignant hyperthermia should be considered to ensure patient safety.	0.730110272715262	0.44946276323134104	0.36163624250608833	0.5165917063715977	0.7145561	0.5382512	0.44272187	0.5747299	0.7775371	0.4140642	0.3637462	0.5387885	0.6881333	0.3757719	0.38502988	0.5168054	0.65160316	0.54628694	0.524697	0.57372856	1
isoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking isoflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid isoflurane. Take an alternate therapy.', 'Take isoflurane with a reduced dose.', 'Take isoflurane with an increased dose.']	Proceed taking isoflurane as normal. There is no recommendation.	For an individual with no result for RYR1 and uncertain susceptibility for CACNA1S, it would be important to proceed with caution regarding the use of isoflurane due to the potential risk of malignant hyperthermia (MH). Consultation with a specialist in malignant hyperthermia and consideration of alternative anesthesia options might be warranted to ensure patient safety.	0.7051285339085688	0.4088964953087903	0.35927820990626663	0.5599183284032544	0.6401394	0.4716219	0.31851384	0.5853578	0.6196045	0.30084202	0.3122631	0.57388216	0.5408605	0.38888186	0.34076652	0.5549223	0.69334483	0.44305614	0.40123066	0.55931187	0
ivacaftor	CFTR	What would be the clinical guidance for someone who is ivacaftor responsive in CF patients for CFTR with regards to taking ivacaftor? Give a 2-3 sentence summary.	Use ivacaftor according to the product label	['Avoid ivacaftor. Take an alternate therapy.', 'Take ivacaftor with a reduced dose.', 'Take ivacaftor with an increased dose.']	Proceed taking ivacaftor as normal. There is no recommendation.	For patients with cystic fibrosis who have CFTR mutations that are responsive to ivacaftor, such as the G551D mutation, clinical guidance typically recommends initiating ivacaftor therapy. Ivacaftor targets the defective CFTR protein, enhancing chloride transport and improving lung function and overall health outcomes. Dosage and administration should follow specific guidelines provided by healthcare providers, taking into consideration the individual's age, weight, and specific CFTR mutation.	0.6473547620207272	0.7318446571841951	0.7403326137322366	0.5940085851547352	0.5372249	0.66270757	0.6826219	0.46422303	0.51973283	0.77529657	0.74275035	0.5794303	0.33136722	0.48500445	0.42284772	0.50046104	0.61965406	0.60623586	0.7029137	0.44017807	0
ivacaftor	CFTR	What would be the clinical guidance for someone who is ivacaftor non-responsive in CF patients for CFTR with regards to taking ivacaftor? Give a 2-3 sentence summary.	Ivacaftor is not recommended	['Proceed taking ivacaftor as normal. There is no recommendation.', 'Take ivacaftor with a reduced dose.', 'Take ivacaftor with an increased dose.']	Avoid ivacaftor. Take an alternate therapy.	If a cystic fibrosis (CF) patient with CFTR mutations is non-responsive to ivacaftor, clinical guidance typically recommends discontinuing the use of ivacaftor. Instead, alternative treatments should be considered based on the specific CFTR mutation, including other CFTR modulators or symptomatic therapies tailored to the patient's needs. Genetic testing and consultation with a CF specialist would be crucial for optimizing the individual's treatment plan.	0.5971237749247291	0.6983151628267369	0.7287627901154536	0.6034810912611008	0.5493758	0.72865677	0.6260348	0.6093808	0.49165508	0.7701303	0.6478148	0.5278903	0.3879447	0.57497907	0.5446182	0.5155769	0.5847314	0.88494927	0.6666562	0.61125296	0
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking kanamycin as normal. There is no recommendation.', 'Take kanamycin with a reduced dose.', 'Take kanamycin with an increased dose.']	Avoid kanamycin. Take an alternate therapy.	Individuals with genetic variants in the MT-RNR1 gene, which increase their risk of aminoglycoside-induced hearing loss, should avoid the use of aminoglycosides such as kanamycin. Clinical guidance would typically recommend the use of alternative antibiotics that do not pose a similar risk to prevent potential irreversible hearing damage. Genetic testing for MT-RNR1 variants can help inform this clinical decision.	0.6884611557767756	0.4941266512455509	0.4266292330735922	0.5120929958841188	0.76307046	0.60887337	0.48264706	0.61962193	0.7124689	0.51080865	0.4708965	0.53938943	0.72959304	0.4277275	0.41820824	0.45447242	0.61651367	0.6533365	0.54472524	0.6281983	1
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid kanamycin. Take an alternate therapy.', 'Take kanamycin with a reduced dose.', 'Take kanamycin with an increased dose.']	Proceed taking kanamycin as normal. There is no recommendation.	For individuals who are at normal risk of aminoglycoside-induced hearing loss based on their MT-RNR1 genetic profile, clinical guidance typically does not necessitate alterations in standard kanamycin usage protocols. These individuals can generally be administered kanamycin according to established dosing guidelines, while monitoring for common side effects as per usual clinical practice. However, it is important to stay vigilant for any symptoms of ototoxicity and manage them promptly if they arise.	0.6451395653290631	0.44425502585555465	0.4246155809599647	0.6206297270188597	0.6542991	0.4515293	0.4905009	0.61687	0.7069596	0.5106668	0.52820116	0.6798508	0.7401467	0.46866766	0.48679957	0.49564785	0.60348654	0.5193926	0.5740321	0.6077586	1
kanamycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking kanamycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid kanamycin. Take an alternate therapy.', 'Take kanamycin with a reduced dose.', 'Take kanamycin with an increased dose.']	Proceed taking kanamycin as normal. There is no recommendation.	For individuals with an uncertain risk of aminoglycoside-induced hearing loss due to variations in the MT-RNR1 gene, it is advised to consider alternative antibiotics to avoid potential ototoxicity associated with kanamycin unless absolutely necessary. Genetic testing for MT-RNR1 variants can provide more definitive risk assessment, and guidance should be tailored based on the results of such testing.	0.5826446334218307	0.44425502585555465	0.4246155809599647	0.5124251620475699	0.54624337	0.4515293	0.4905009	0.49533665	0.6499049	0.5106668	0.52820116	0.56671816	0.6609653	0.46866766	0.48679957	0.41479498	0.5596146	0.5193926	0.5740321	0.5550685	0
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2C19 with regards to taking lansoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.Monitor for efficacy.	['Proceed taking lansoprazole as normal. There is no recommendation.', 'Avoid lansoprazole. Take an alternate therapy.']	Take lansoprazole with an altered dose.	For individuals who are rapid metabolizers of CYP2C19, the efficacy of lansoprazole, a proton pump inhibitor, may be reduced due to increased drug metabolism. Clinical guidelines often recommend considering an alternative proton pump inhibitor that is less dependent on CYP2C19 for metabolism, such as rabeprazole or esomeprazole, to ensure effective acid suppression.	0.41831068803686444	0.46182673951521525	0.43395550954207296	0.6500257601190134	0.39072496	0.5101035	0.40146238	0.59263384	0.3598095	0.43865702	0.42940694	0.5568161	0.28114855	0.39795917	0.3685161	0.5167017	0.34498897	0.5292413	0.40537286	0.64761084	0
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking lansoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking lansoprazole as normal. There is no recommendation.', 'Avoid lansoprazole. Take an alternate therapy.']	Take lansoprazole with an altered dose.	For a patient who is a likely poor metabolizer of CYP2C19, clinical guidance suggests that standard dosing of lansoprazole may result in higher plasma concentrations and an increased pharmacodynamic effect. No specific dose adjustments are generally necessary; however, monitoring the patient for any adverse effects and efficacy can be a prudent approach. It is important to consider other medications metabolized by CYP2C19 to avoid potential interactions.	0.4140306250277892	0.4415783715532123	0.41776876235020943	0.6877778460488911	0.40746003	0.4223595	0.40915698	0.6382857	0.40951294	0.38802177	0.42315465	0.5979036	0.33881888	0.3922677	0.41773146	0.51892805	0.4844831	0.49732292	0.37711358	0.67224085	0
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking lansoprazole? Give a 2-3 sentence summary.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	['Proceed taking lansoprazole as normal. There is no recommendation.', 'Avoid lansoprazole. Take an alternate therapy.']	Take lansoprazole with an altered dose.	Individuals identified as Ultrarapid Metabolizers (UMs) for CYP2C19 may exhibit reduced plasma concentrations of lansoprazole due to increased metabolic activity. Clinical guidance generally recommends considering an alternative proton pump inhibitor (PPI) not significantly metabolized by CYP2C19, such as rabeprazole, to ensure adequate therapeutic effect. If lansoprazole must be used, a dose increase could be considered, but this should be carefully monitored.	0.3570925873301611	0.4569807488285123	0.3816847553985631	0.6548885251264689	0.37744683	0.63462967	0.48931375	0.5538741	0.36125168	0.6092482	0.5184678	0.5427891	0.30243072	0.5226104	0.4483412	0.45952976	0.35792276	0.5466818	0.34637892	0.6500529	0
lansoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking lansoprazole? Give a 2-3 sentence summary.	No recommendation	['Avoid lansoprazole. Take an alternate therapy.', 'Take lansoprazole with a reduced dose.', 'Take lansoprazole with an increased dose.']	Proceed taking lansoprazole as normal. There is no recommendation.	For patients with an indeterminate CYP2C19 genotype, the clinical guidance for taking lansoprazole would typically involve following standard dosing recommendations due to a lack of specific information on their metabolizer status. However, clinicians should remain vigilant for signs of excessive drug effect or adverse reactions, as this genotype does not clarify whether the patient may potentially have an altered metabolism of the drug. Pharmacy professionals may also consider alternative proton pump inhibitors that are less affected by CYP2C19 variability.	0.26087242507404235	0.467878155039715	0.237100401426758	0.6346905416656278	0.16772978	0.31533885	0.15860726	0.5869927	0.096863925	0.19615881	0.08397599	0.6359597	-0.010392704	0.2997135	0.087713726	0.59169894	0.347013	0.532819	0.39466333	0.6152596	0
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking lornoxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid lornoxicam. Take an alternate therapy.', 'Take lornoxicam with a reduced dose.', 'Take lornoxicam with an increased dose.']	Proceed taking lornoxicam as normal. There is no recommendation.	For a patient identified as a normal metabolizer with an activity score of 2.0 for CYP2C9, the clinical guidance for taking lornoxicam would generally not require any dosage adjustment. This is because normal metabolizers typically process lornoxicam efficiently and are not at increased risk for adverse effects related to altered drug metabolism. Monitoring for standard therapeutic effects and side effects as per usual clinical practice remains appropriate.	0.39064480750953956	0.4127225545628497	0.4277311966204298	0.6955622741556392	0.4683596	0.3884604	0.34619507	0.62237	0.46355316	0.47035354	0.31686807	0.67347205	0.3739209	0.3714914	0.39143804	0.5708103	0.42335832	0.44307697	0.4528331	0.66284215	1
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking lornoxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid lornoxicam. Take an alternate therapy.', 'Take lornoxicam with a reduced dose.', 'Take lornoxicam with an increased dose.']	Proceed taking lornoxicam as normal. There is no recommendation.	For an individual who is an intermediate metabolizer (activity score = 1.5) for CYP2C9, the clinical guidance regarding lornoxicam would likely recommend caution due to the potential for slower drug metabolism, which could increase the risk of adverse effects. Dose adjustments or more careful monitoring may be needed to balance efficacy and safety. Always consult with a healthcare provider for personalized advice.	0.40409839939585845	0.4127225545628497	0.4277311966204298	0.6454364869898265	0.44843268	0.3884604	0.34619507	0.6117851	0.4404348	0.47035354	0.31686807	0.7218005	0.38297778	0.3714914	0.39143804	0.59720105	0.45726603	0.44307697	0.4528331	0.6390181	0
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking lornoxicam? Give a 2-3 sentence summary.	No recommendation	['Avoid lornoxicam. Take an alternate therapy.', 'Take lornoxicam with a reduced dose.', 'Take lornoxicam with an increased dose.']	Proceed taking lornoxicam as normal. There is no recommendation.	For individuals with an indeterminate CYP2C9 genotype, the clinical recommendation for lornoxicam usage would generally proceed with caution. Indeterminate status indicates uncertain enzyme activity, so close monitoring for efficacy and adverse effects is advisable. Dose adjustments may be necessary based on clinical response and tolerability.	0.3164629832390718	0.4701374825992941	0.2403836044126967	0.6493933751043685	0.18772687	0.3987904	0.25833634	0.59357727	0.14538877	0.299285	0.20445186	0.65239906	0.011964492	0.3430518	0.12544464	0.5498554	0.33496004	0.4946224	0.3532697	0.6118077	0
lornoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking lornoxicam? Give a 2-3 sentence summary.	Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.	['Avoid lornoxicam. Take an alternate therapy.', 'Take lornoxicam with a reduced dose.', 'Take lornoxicam with an increased dose.']	Proceed taking lornoxicam as normal. There is no recommendation.	For individuals who are intermediate metabolizers (activity score = 1.0) of CYP2C9 taking lornoxicam, clinical guidance generally suggests a cautious approach due to the potential for reduced drug clearance and increased risk of adverse effects. It may be recommended to start with a lower dose and monitor the patient closely for signs of toxicity. Adjustments should be made based on clinical response and tolerability.	0.5011728220647179	0.4075297501650019	0.442191544531386	0.6636870607182687	0.6641223	0.52421033	0.45007885	0.6377832	0.53927624	0.5286274	0.36907008	0.7175097	0.45956126	0.36361733	0.3853556	0.57338774	0.49596018	0.35874158	0.42705807	0.6405375	1
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking lovastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid lovastatin. Take an alternate therapy.', 'Take lovastatin with a reduced dose.', 'Take lovastatin with an increased dose.']	Proceed taking lovastatin as normal. There is no recommendation.	Individuals with a Normal Function allele for SLCO1B1 can generally initiate and maintain standard dosing of lovastatin without requiring adjustments. Normal Function in SLCO1B1 suggests a typical transport and clearance of the drug, which reduces the risk of statin-induced side effects like myopathy. As always, clinical decisions should also consider other patient-specific factors and monitoring.	0.3481434641367133	0.3676762733644924	0.34416993386449873	0.5688623142285317	0.39961782	0.28405106	0.3851215	0.5539764	0.3706187	0.46173462	0.34138265	0.62448096	0.26652843	0.30372792	0.2644547	0.4518224	0.3734338	0.5272063	0.58332014	0.5776952	1
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking lovastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid lovastatin. Take an alternate therapy.', 'Take lovastatin with a reduced dose.', 'Take lovastatin with an increased dose.']	Proceed taking lovastatin as normal. There is no recommendation.	Individuals with Increased Function of the SLCO1B1 gene generally transport statins more efficiently into the liver. For lovastatin, this could lead to lower systemic drug levels and potentially decreased efficacy in lowering LDL cholesterol. Clinical guidance would include potentially using higher doses of lovastatin or considering alternative statins to achieve desired lipid-lowering effects, but always under clinical supervision to balance efficacy and safety.	0.3304343588251543	0.3676762733644924	0.34416993386449873	0.5477098607332571	0.37652987	0.28405106	0.3851215	0.458938	0.34423447	0.46173462	0.34138265	0.5956486	0.20452741	0.30372792	0.2644547	0.56665033	0.47349885	0.5272063	0.58332014	0.5500809	0
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking lovastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid lovastatin. Take an alternate therapy.', 'Take lovastatin with a reduced dose.', 'Take lovastatin with an increased dose.']	Proceed taking lovastatin as normal. There is no recommendation.	For a patient with an indeterminate genotype for SLCO1B1 taking lovastatin, standard clinical practice generally applies as specific genetic guidance isn't available. This means that regular monitoring for efficacy and potential side effects, particularly myopathy, should be followed as per usual clinical guidelines for statin therapy. If adverse effects occur, alternative lipid-lowering therapies or dosing adjustments can be considered.	0.2168101831475937	0.4504989115869961	0.2003953449673671	0.6292423672473755	0.21260855	0.3070172	0.15846999	0.59932035	0.10300686	0.21312563	0.09796446	0.638875	-0.012742642	0.3272291	0.11403365	0.52031094	0.26906958	0.5263305	0.41636434	0.6175226	0
lovastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking lovastatin? Give a 2-3 sentence summary.	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If lovastatin therapy is warranted, limit dose to ≤20mg/day.	['Proceed taking lovastatin as normal. There is no recommendation.', 'Take lovastatin with a reduced dose.', 'Take lovastatin with an increased dose.']	Avoid lovastatin. Take an alternate therapy.	For individuals identified as having Possible Decreased Function of the SLCO1B1 gene, there may be an increased risk of statin-related myopathy when taking lovastatin. Clinical guidance typically suggests considering a lower starting dose of lovastatin or choosing an alternative statin that is less dependent on SLCO1B1 for hepatic uptake, such as pravastatin or rosuvastatin. It is also recommended to monitor for signs and symptoms of muscle toxicity closely.	0.6913830693697303	0.7214514905672156	0.6558591206905496	0.6326708126487368	0.68499994	0.71675396	0.6497324	0.6309003	0.6962313	0.7942625	0.76160735	0.68022233	0.6264635	0.5678524	0.5901709	0.5923329	0.5664329	0.6932386	0.6043498	0.62338156	0
mafenide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking mafenide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid mafenide. Take an alternate therapy.', 'Take mafenide with a reduced dose.', 'Take mafenide with an increased dose.']	Proceed taking mafenide as normal. There is no recommendation.	For individuals deficient in glucose-6-phosphate dehydrogenase (G6PD), the use of mafenide is generally contraindicated due to the risk of hemolytic anemia. Mafenide can cause oxidative stress in red blood cells, which people with G6PD deficiency cannot adequately manage, leading to significant hemolysis. Therefore, alternative treatments should be considered to avoid serious complications.	0.5683959987584397	0.4873531784265248	0.37763285453946355	0.5523686393659575	0.57898057	0.5759996	0.37785313	0.58098996	0.5994303	0.4797832	0.26543137	0.6165627	0.51688975	0.46378395	0.34015134	0.55726725	0.57472944	0.48334712	0.39555946	0.49355015	0
mafenide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking mafenide? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid mafenide. Take an alternate therapy.', 'Take mafenide with a reduced dose.', 'Take mafenide with an increased dose.']	Proceed taking mafenide as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, caution is advised when prescribing mafenide. This is because mafenide can precipitate hemolysis in patients who have G6PD deficiency. It is suggested to either confirm the G6PD status through further testing or consider alternative treatments that do not pose a risk of hemolysis.	0.6081397866731666	0.38021289394021557	0.3145788792464871	0.5742062675974026	0.531342	0.21448569	0.22117795	0.61948127	0.5575379	0.24836837	0.12441173	0.63571775	0.54367334	0.24246386	0.1924833	0.62385744	0.48894036	0.38702697	0.3968198	0.40125886	0
mafenide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking mafenide? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid mafenide. Take an alternate therapy.', 'Take mafenide with a reduced dose.', 'Take mafenide with an increased dose.']	Proceed taking mafenide as normal. There is no recommendation.	Clinical guidance for individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, particularly those with Chronic Non-Spherocytic Hemolytic Anemia (CNSHA), advises against the use of mafenide. Mafenide is known to potentially cause hemolysis in patients with G6PD deficiency, and its use should be avoided to prevent hemolytic episodes. Alternative treatments that do not pose a risk for hemolysis should be considered.	0.4519549121983186	0.36991653165471183	0.41214908196301264	0.5396545864965954	0.49978215	0.49657178	0.5036513	0.6245592	0.5763272	0.48547995	0.40020898	0.6060379	0.47257832	0.39984727	0.3476522	0.57566166	0.47501057	0.30615038	0.4076803	0.43858412	0
mafenide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking mafenide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid mafenide. Take an alternate therapy.', 'Take mafenide with a reduced dose.', 'Take mafenide with an increased dose.']	Proceed taking mafenide as normal. There is no recommendation.	For individuals with normal G6PD (glucose-6-phosphate dehydrogenase) activity, standard clinical guidelines indicate that mafenide can be used without additional precautions specifically related to G6PD deficiency. However, it is still essential to monitor for possible side effects associated with mafenide itself, such as allergic reactions or metabolic acidosis, as these are concerns unrelated to G6PD status.	0.6637719336982738	0.4319105797940957	0.2997540743286297	0.6140316669971411	0.56673086	0.44815361	0.23981698	0.6746065	0.53353405	0.34508473	0.16066022	0.66686404	0.44295335	0.20597127	0.12792926	0.61213255	0.598785	0.40791824	0.30661857	0.4817733	1
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking meloxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid meloxicam. Take an alternate therapy.', 'Take meloxicam with a reduced dose.', 'Take meloxicam with an increased dose.']	Proceed taking meloxicam as normal. There is no recommendation.	For an individual who is a normal metabolizer (activity score = 2.0) for the CYP2C9 enzyme, standard dosing of meloxicam is typically appropriate. This is because their ability to metabolize the drug is expected to be normal, leading to predictable therapeutic effects and risk of side effects. Always consult with a healthcare provider for personalized recommendations and monitoring.	0.39014178379666276	0.4093075144800352	0.40238962159191205	0.6304729504645367	0.43611196	0.3629332	0.34451768	0.49251553	0.4234537	0.4411724	0.29360867	0.6085883	0.40183327	0.36278898	0.37953627	0.63989276	0.44069105	0.47265476	0.45383406	0.6626067	1
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking meloxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid meloxicam. Take an alternate therapy.', 'Take meloxicam with a reduced dose.', 'Take meloxicam with an increased dose.']	Proceed taking meloxicam as normal. There is no recommendation.	For an individual identified as an Intermediate Metabolizer with an activity score of 1.5 for CYP2C9, when considering meloxicam, clinical guidelines generally suggest using caution. It may be appropriate to initiate meloxicam at a reduced dose and closely monitor for signs of toxicity or adverse effects, given the potential for slower metabolism and increased drug exposure compared to normal metabolizers. Clinical judgment should be used to adjust dosing as needed based on the patient's response and tolerability.	0.7265146521293014	0.6239895276065872	0.6761344435330586	0.6150940443323186	0.6104678	0.4756467	0.45348	0.5710066	0.6405786	0.637522	0.47306225	0.6252116	0.6593516	0.6126197	0.6238072	0.6124986	0.6712971	0.6139773	0.5632675	0.6146823	0
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking meloxicam? Give a 2-3 sentence summary.	No recommendation	['Avoid meloxicam. Take an alternate therapy.', 'Take meloxicam with a reduced dose.', 'Take meloxicam with an increased dose.']	Proceed taking meloxicam as normal. There is no recommendation.	For individuals who are indeterminate for CYP2C9, it is recommended to exercise caution when prescribing meloxicam due to potential variability in drug metabolism. Clinicians may consider alternative nonsteroidal anti-inflammatory drugs (NSAIDs) or closely monitor for efficacy and adverse effects if meloxicam is used. Dose adjustments may be necessary based on individual response and tolerability.	0.2758964757349061	0.45387754583262213	0.21927903735218893	0.6045355611130299	0.14607237	0.27544245	0.12379992	0.5744499	0.08939026	0.15118876	0.061338603	0.6171933	0.07008854	0.36191893	0.1392984	0.6356787	0.37120312	0.5366868	0.42050436	0.6768914	0
meloxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking meloxicam? Give a 2-3 sentence summary.	Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	['Proceed taking meloxicam as normal. There is no recommendation.', 'Avoid meloxicam. Take an alternate therapy.']	Take meloxicam with an altered dose.	For an individual with an intermediate metabolizer status and an activity score of 1.0 for the CYP2C9 enzyme, clinical guidance would suggest using caution when prescribing meloxicam. Due to reduced enzyme activity, the patient may have higher plasma concentrations of the drug, increasing the risk of adverse effects. Consideration should be given to starting at the lowest recommended dose or using an alternative NSAID that is less affected by CYP2C9 variations.	0.8017322802855573	0.6421007828968138	0.6437800754034764	0.6648801316915308	0.6374529	0.5590074	0.53591466	0.5024251	0.79524654	0.5396923	0.62097377	0.47016993	0.73122674	0.5727232	0.5665211	0.6059402	0.7330605	0.6676765	0.57324535	0.6548511	0
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine? Give a 2-3 sentence summary.	For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	['Proceed taking mercaptopurine as normal. There is no recommendation.', 'Avoid mercaptopurine. Take an alternate therapy.']	Take mercaptopurine with an altered dose.	For individuals who are normal metabolizers for TPMT but poor metabolizers for NUDT15, clinical guidance suggests initiating mercaptopurine at a reduced dose to mitigate the risk of toxicity. Specifically, starting at a dose of 30-50% of the standard dosage and adjusting based on tolerance and therapeutic response is recommended. Frequent monitoring of blood counts is essential to manage potential myelosuppression.	0.7478707253904194	0.6560735786374879	0.6531190325251919	0.6534608087420386	0.66549706	0.54011464	0.50656915	0.58035725	0.6865314	0.54434955	0.61700004	0.49223304	0.673016	0.5340058	0.49136612	0.5950343	0.6654688	0.64090717	0.50744545	0.6983212	0
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking mercaptopurine? Give a 2-3 sentence summary.	Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is ≥ 75 mg/m2/day or ≥ 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.	['Proceed taking mercaptopurine as normal. There is no recommendation.', 'Avoid mercaptopurine. Take an alternate therapy.']	Take mercaptopurine with an altered dose.	For individuals who are intermediate metabolizers of both TPMT (thiopurine S-methyltransferase) and NUDT15, clinical guidelines generally recommend starting mercaptopurine at a reduced dose of 30-80% of the standard dose, with close monitoring of blood counts and for signs of myelosuppression. Subsequent dose adjustments should be based on the patient’s tolerance and therapeutic response.	0.8150885961856776	0.6874865788054583	0.6656296099076705	0.6697629032006538	0.71729374	0.5255367	0.47550336	0.51173854	0.75674826	0.5455121	0.6310688	0.48718816	0.7869848	0.63834167	0.62519175	0.6044812	0.7492912	0.5916299	0.4712168	0.6657711	1
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking mercaptopurine? Give a 2-3 sentence summary.	For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	['Proceed taking mercaptopurine as normal. There is no recommendation.', 'Avoid mercaptopurine. Take an alternate therapy.']	Take mercaptopurine with an altered dose.	For a patient who is a Possible Intermediate Metabolizer for TPMT and a Poor Metabolizer for NUDT15, the clinical guidance typically involves considering a substantial reduction in the starting dose of mercaptopurine to mitigate the risk of severe myelosuppression. Close monitoring of blood counts and adjusting the dose based on tolerance and therapeutic response is essential.	0.7404523673314104	0.6560735786374879	0.6531190325251919	0.6682373548236267	0.62996083	0.54011464	0.50656915	0.4995078	0.6157796	0.54434955	0.61700004	0.44551966	0.626904	0.5340058	0.49136612	0.571263	0.6721994	0.64090717	0.50744545	0.69080323	0
mercaptopurine	TPMT;NUDT15	What would be the clinical guidance for someone who is Poor Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking mercaptopurine? Give a 2-3 sentence summary.	For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).	['Proceed taking mercaptopurine as normal. There is no recommendation.', 'Avoid mercaptopurine. Take an alternate therapy.']	Take mercaptopurine with an altered dose.	For an individual who is a Poor Metabolizer for TPMT (thiopurine S-methyltransferase) and a Normal Metabolizer for NUDT15, it is recommended to consider significantly reducing the dosage of mercaptopurine and closely monitoring for toxicity. TPMT poor metabolizers are at a higher risk for severe myelosuppression due to increased drug levels. Therefore, consultation with a clinical pharmacogenomics specialist or adjusting the dose based on clinical response and tolerance is advised.	0.7216871200742536	0.682473122351887	0.6785191731731895	0.6474508126595921	0.5873474	0.5262177	0.46661657	0.5180791	0.6395407	0.5685097	0.64690125	0.46153668	0.58029026	0.5993989	0.5671046	0.5218431	0.63527006	0.67332494	0.53246915	0.6298249	0
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking methoxyflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking methoxyflurane as normal. There is no recommendation.', 'Take methoxyflurane with a reduced dose.', 'Take methoxyflurane with an increased dose.']	Avoid methoxyflurane. Take an alternate therapy.	For a person with Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S, the clinical guidance would generally recommend avoiding methoxyflurane. Methoxyflurane is a known trigger for malignant hyperthermia, a potentially life-threatening condition. Alternative anesthetic agents should be considered that do not pose a risk for triggering malignant hyperthermia.	0.7042416841654092	0.4832284003373381	0.4436197409981517	0.5988110593525983	0.7673689	0.52831686	0.4143478	0.6766595	0.75882167	0.39927134	0.32240805	0.6324943	0.6868315	0.4576995	0.41020024	0.5715925	0.6338695	0.58519626	0.5607931	0.6038525	0
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking methoxyflurane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking methoxyflurane as normal. There is no recommendation.', 'Take methoxyflurane with a reduced dose.', 'Take methoxyflurane with an increased dose.']	Avoid methoxyflurane. Take an alternate therapy.	Methoxyflurane is a potent inhaled anesthetic that has been associated with triggering malignant hyperthermia (MH) in susceptible individuals. Clinical guidance for a patient with no results for RYR1 and a positive result for CACNA1S suggesting susceptibility to MH would advise against using methoxyflurane due to the increased risk of MH. Alternative anesthetics with a lower risk profile should be considered for such individuals.	0.7010256869093762	0.4837950943624124	0.4439013249702235	0.6330315778859718	0.77969813	0.5184894	0.41190395	0.5894252	0.75334734	0.37468737	0.29270247	0.5746829	0.7852976	0.42452848	0.3807415	0.60119516	0.67424834	0.5696414	0.5502053	0.6290332	0
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking methoxyflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking methoxyflurane as normal. There is no recommendation.', 'Take methoxyflurane with a reduced dose.', 'Take methoxyflurane with an increased dose.']	Avoid methoxyflurane. Take an alternate therapy.	Patients with Malignant Hyperthermia Susceptibility associated with the RYR1 gene mutation should avoid methoxyflurane due to the high risk of triggering a malignant hyperthermia crisis. While the susceptibility related to CACNA1S is uncertain, the contraindication primarily stemming from RYR1 mutation warrants caution and the avoidance of methoxyflurane to mitigate potential life-threatening complications.	0.6473342502519744	0.4832284003373381	0.4436197409981517	0.490700677630994	0.68050534	0.52831686	0.4143478	0.55875236	0.63017803	0.39927134	0.32240805	0.506422	0.62062526	0.4576995	0.41020024	0.48277757	0.6468518	0.58519626	0.5607931	0.6051503	0
methoxyflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking methoxyflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid methoxyflurane. Take an alternate therapy.', 'Take methoxyflurane with a reduced dose.', 'Take methoxyflurane with an increased dose.']	Proceed taking methoxyflurane as normal. There is no recommendation.	"For a patient with ""No Result"" for RYR1 and ""Uncertain Susceptibility"" for CACNA1S, clinical guidance would typically be to exercise caution regarding the use of methoxyflurane. Methoxyflurane is known to be a potential trigger for malignant hyperthermia, a serious reaction linked to variants in RYR1 and CACNA1S genes. Given the incomplete genetic profile and uncertain risk, it is prudent to consult with a specialist in pharmacogenomics or an anesthesiologist for personalized advice and consider alternative anesthetic options."	0.7462835583811244	0.44249060611511004	0.37550003957226236	0.5822790085366625	0.6738483	0.4584452	0.28589624	0.57014406	0.7926682	0.24951355	0.24346183	0.4407415	0.67837924	0.39962566	0.34295967	0.5180716	0.77537245	0.44583097	0.39463887	0.6161383	0
methylene blue	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking methylene blue? Give a 2-3 sentence summary.	Avoid use	['Proceed taking methylene blue as normal. There is no recommendation.', 'Take methylene blue with a reduced dose.', 'Take methylene blue with an increased dose.']	Avoid methylene blue. Take an alternate therapy.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) should avoid taking methylene blue due to the risk of severe hemolysis. In G6PD-deficient patients, methylene blue can trigger oxidative stress that the compromised erythrocytes cannot handle, leading to rapid destruction of red blood cells and potential acute hemolytic anemia. Therefore, alternative treatments should be sought in these patients.	0.2042931023194618	0.2939628178325647	0.2635604156590256	0.6121483080717685	0.34931865	0.40431288	0.33383933	0.65426946	0.1740072	0.21889375	0.2300791	0.6217317	0.16635135	0.18944	0.18988742	0.65465313	0.47823533	0.62678844	0.54241157	0.6848861	1
methylene blue	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking methylene blue? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid methylene blue. Take an alternate therapy.', 'Take methylene blue with a reduced dose.', 'Take methylene blue with an increased dose.']	Proceed taking methylene blue as normal. There is no recommendation.	For individuals with an indeterminate G6PD (glucose-6-phosphate dehydrogenase) status, the clinical guidance typically advises caution when considering methylene blue due to the risk of hemolysis. It would be prudent to either confirm G6PD deficiency status through additional testing or choose an alternative treatment to avoid potential complications.	0.6520615149711761	0.39924587207907747	0.340209733039893	0.6084254671532383	0.54653454	0.25596604	0.27685204	0.6326368	0.56075746	0.2835732	0.24537908	0.68328494	0.5209818	0.19279316	0.19199748	0.66738486	0.6068503	0.4199374	0.4220883	0.6192661	0
methylene blue	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking methylene blue? Give a 2-3 sentence summary.	Avoid use	['Proceed taking methylene blue as normal. There is no recommendation.', 'Take methylene blue with a reduced dose.', 'Take methylene blue with an increased dose.']	Avoid methylene blue. Take an alternate therapy.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) and have Congenital Nonspherocytic Hemolytic Anemia (CNSHA) should avoid taking methylene blue. This is because methylene blue is an oxidative agent that can precipitate severe hemolysis in G6PD-deficient patients, potentially leading to serious complications.	0.2092073905171631	0.2939628178325647	0.2635604156590256	0.5515111361162618	0.3573621	0.40431288	0.33383933	0.6538063	0.19474904	0.21889375	0.2300791	0.61906713	0.17004429	0.18944	0.18988742	0.6507457	0.48845008	0.62678844	0.54241157	0.7051626	1
methylene blue	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking methylene blue? Give a 2-3 sentence summary.	No reason to avoid ased on G6PD status	['Avoid methylene blue. Take an alternate therapy.', 'Take methylene blue with a reduced dose.', 'Take methylene blue with an increased dose.']	Proceed taking methylene blue as normal. There is no recommendation.	Individuals who have a normal G6PD enzyme level are typically not at risk for hemolytic anemia induced by methylene blue. Clinically, methylene blue can be used in these patients without concerns specifically related to G6PD deficiency. However, it’s always important to consider other contraindications and potential drug interactions when prescribing methylene blue.	0.6191579944903796	0.4095845124378705	0.28895703602332495	0.5424548439452707	0.43177107	0.33019605	0.17593656	0.6531968	0.38646153	0.21580131	0.122321464	0.65918213	0.29739788	0.140126	0.09004673	0.64525515	0.49091113	0.3815878	0.30839118	0.60501504	1
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking nalidixic acid? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid nalidixic acid. Take an alternate therapy.', 'Take nalidixic acid with a reduced dose.', 'Take nalidixic acid with an increased dose.']	Proceed taking nalidixic acid as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), nalidixic acid is generally contraindicated due to the heightened risk of hemolytic anemia. It is advisable for healthcare providers to consider alternative antibiotics that do not pose the same risk of hemolysis for these patients. Clinical guidance should prioritize patient safety by avoiding medications that can exacerbate G6PD deficiency.	0.6031685142618064	0.5104626101514396	0.399610488117813	0.593006950986133	0.56618553	0.5367554	0.33543587	0.6106707	0.5656597	0.43464696	0.2505579	0.6310448	0.5431573	0.44526798	0.328848	0.5999048	0.60223174	0.5274702	0.4168521	0.63095903	0
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking nalidixic acid? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid nalidixic acid. Take an alternate therapy.', 'Take nalidixic acid with a reduced dose.', 'Take nalidixic acid with an increased dose.']	Proceed taking nalidixic acid as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, caution is advised when considering nalidixic acid due to the potential risk of hemolytic anemia. It is recommended to evaluate the G6PD enzyme activity more precisely before administering nalidixic acid, and if the enzyme deficiency is confirmed, alternative antibiotics should be considered.	0.635328396771358	0.41034851018285395	0.3413842583945894	0.6082834949901079	0.57962906	0.25943497	0.27332574	0.61485124	0.63162714	0.31100872	0.2369225	0.6585122	0.58958745	0.22788675	0.19734378	0.6379336	0.58139485	0.44425178	0.4279995	0.57465607	0
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking nalidixic acid? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid nalidixic acid. Take an alternate therapy.', 'Take nalidixic acid with a reduced dose.', 'Take nalidixic acid with an increased dose.']	Proceed taking nalidixic acid as normal. There is no recommendation.	For a patient who is G6PD-deficient and has Chronic Non-Spherocytic Hemolytic Anemia (CNSHA), nalidixic acid should generally be avoided. This antibiotic can induce hemolysis in individuals with G6PD deficiency, potentially leading to severe hemolytic anemia. Alternative antibiotics that do not pose this risk should be considered.	0.45189954895588935	0.4195032969399163	0.44911668542281585	0.5340413305675866	0.55794615	0.4938283	0.4958154	0.6694507	0.55456597	0.48200256	0.45384482	0.66675055	0.5021815	0.39614514	0.3658625	0.6034824	0.5161023	0.38244382	0.45668852	0.5694475	0
nalidixic acid	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking nalidixic acid? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid nalidixic acid. Take an alternate therapy.', 'Take nalidixic acid with a reduced dose.', 'Take nalidixic acid with an increased dose.']	Proceed taking nalidixic acid as normal. There is no recommendation.	For individuals with normal G6PD (glucose-6-phosphate dehydrogenase) enzyme activity, there are no specific restrictions against taking nalidixic acid based on their G6PD status alone. These individuals can be prescribed nalidixic acid if indicated, but it’s always important to consider other potential contraindications or interactions based on their overall health and medication profile. Routine monitoring for any adverse effects is still recommended.	0.6667102429159564	0.4500537257261992	0.3202444022550029	0.6406547290882184	0.528871	0.385179	0.19050063	0.6179726	0.49393418	0.25284714	0.12328878	0.6602433	0.42909718	0.16881052	0.08779635	0.6042109	0.6143719	0.4520528	0.34309897	0.6698678	1
neomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking neomycin as normal. There is no recommendation.', 'Take neomycin with a reduced dose.', 'Take neomycin with an increased dose.']	Avoid neomycin. Take an alternate therapy.	Individuals identified with increased risk of aminoglycoside-induced hearing loss due to MT-RNR1 genetic variants are generally advised to avoid aminoglycosides, including neomycin, due to the high risk of ototoxicity. Alternative antibiotics that do not carry the same risk of hearing loss should be considered for these patients.	0.725528554138174	0.5169270402209407	0.43896268821096446	0.5146777888740133	0.7837609	0.6029398	0.48924628	0.59223765	0.77644444	0.5176673	0.5016423	0.57601106	0.7829211	0.47639155	0.44747856	0.5041133	0.67316455	0.61491114	0.5094502	0.61609495	1
neomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid neomycin. Take an alternate therapy.', 'Take neomycin with a reduced dose.', 'Take neomycin with an increased dose.']	Proceed taking neomycin as normal. There is no recommendation.	For individuals at normal risk for aminoglycoside-induced hearing loss based on MT-RNR1 genotyping, there are typically no specific genetic contraindications to using neomycin as guided by their genotypic data. However, standard clinical guidelines should still be followed, which includes monitoring for ototoxicity, especially with prolonged use or high doses, as aminoglycosides are known to have a general risk of causing hearing loss irrespective of genetic predisposition.	0.6227809427822067	0.43679438130177267	0.4586484881758728	0.5583005084629685	0.581447	0.45833433	0.48983467	0.576173	0.64167434	0.52771837	0.55508226	0.52090156	0.68044204	0.5022767	0.50675637	0.4723344	0.5434834	0.49401554	0.5422488	0.5287072	0
neomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking neomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid neomycin. Take an alternate therapy.', 'Take neomycin with a reduced dose.', 'Take neomycin with an increased dose.']	Proceed taking neomycin as normal. There is no recommendation.	For individuals with uncertain risk of aminoglycoside-induced hearing loss related to MT-RNR1 variants, current clinical guidance suggests avoiding aminoglycosides such as neomycin, if possible, due to the potential for irreversible hearing damage, even at low doses. Alternative antibiotics should be considered, and if aminoglycoside therapy is necessary, it should be administered under close medical supervision, with regular hearing assessments to monitor for ototoxicity.	0.6922209046657097	0.43679438130177267	0.4586484881758728	0.5099199418304049	0.54868966	0.45833433	0.48983467	0.58999527	0.7158587	0.52771837	0.55508226	0.5402269	0.7933594	0.5022767	0.50675637	0.46582037	0.6183109	0.49401554	0.5422488	0.5317413	0
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking netilmicin as normal. There is no recommendation.', 'Take netilmicin with a reduced dose.', 'Take netilmicin with an increased dose.']	Avoid netilmicin. Take an alternate therapy.	For patients at increased risk of aminoglycoside-induced hearing loss due to MT-RNR1 genetic variants, it is generally recommended to avoid the use of aminoglycosides like netilmicin whenever possible. Alternative antibiotics should be considered to mitigate the risk of ototoxicity. Genetic testing and careful clinical evaluation should guide the choice of antibiotic therapy in these cases.	0.7263519599444752	0.5081320964099137	0.43528157246933513	0.5503569410637801	0.7896178	0.5710496	0.45728865	0.5945121	0.7826983	0.43058947	0.4166976	0.52633554	0.81024224	0.40535906	0.39526197	0.48788786	0.6810737	0.59560007	0.4809334	0.58942896	1
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid netilmicin. Take an alternate therapy.', 'Take netilmicin with a reduced dose.', 'Take netilmicin with an increased dose.']	Proceed taking netilmicin as normal. There is no recommendation.	For individuals with a normal risk of aminoglycoside-induced hearing loss based on MT-RNR1 genetic testing, standard dosing guidelines for netilmicin can be followed. No specific genetic-related dose adjustments are necessary. Nonetheless, it is important to monitor renal function and auditory function, as recommended for any patient undergoing aminoglycoside therapy.	0.6461827023311814	0.428499687971121	0.4142124893110482	0.592524923314748	0.6628261	0.45805693	0.45130834	0.5570824	0.6561747	0.46308684	0.4700779	0.5911435	0.69612765	0.4688181	0.46443877	0.51470095	0.57198423	0.45471817	0.5047259	0.50893366	1
netilmicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking netilmicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid netilmicin. Take an alternate therapy.', 'Take netilmicin with a reduced dose.', 'Take netilmicin with an increased dose.']	Proceed taking netilmicin as normal. There is no recommendation.	Individuals with variants in the MT-RNR1 gene are at increased risk for aminoglycoside-induced hearing loss, including drugs like netilmicin. Clinical guidance for such patients generally recommends genetic testing to confirm their MT-RNR1 status before administering aminoglycosides. If the patient carries a pathogenic variant, alternative antibiotics that do not carry this risk should be considered.	0.5562775158613826	0.428499687971121	0.4142124893110482	0.4657074610393507	0.5150567	0.45805693	0.45130834	0.41470635	0.6276018	0.46308684	0.4700779	0.47115326	0.63694054	0.4688181	0.46443877	0.37028068	0.57088053	0.45471817	0.5047259	0.47590184	0
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking nitrofurantoin? Give a 2-3 sentence summary.	Use at standard doses with caution and with close monitoring for anemia	['Avoid nitrofurantoin. Take an alternate therapy.', 'Take nitrofurantoin with a reduced dose.', 'Take nitrofurantoin with an increased dose.']	Proceed taking nitrofurantoin as normal. There is no recommendation.	Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at increased risk of hemolytic anemia when taking nitrofurantoin. Clinical guidance generally advises against the use of nitrofurantoin in G6PD-deficient patients to prevent hemolytic episodes. Alternative antibiotics should be considered to avoid potential complications.	0.3689365609053138	0.3871798782826935	0.40617993207924025	0.5855597588956933	0.536167	0.522519	0.46297336	0.6342604	0.5198019	0.52863866	0.40362564	0.6488418	0.4585014	0.40946656	0.30822968	0.5327265	0.48355588	0.4074011	0.44536152	0.59132296	0
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking nitrofurantoin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid nitrofurantoin. Take an alternate therapy.', 'Take nitrofurantoin with a reduced dose.', 'Take nitrofurantoin with an increased dose.']	Proceed taking nitrofurantoin as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, caution is advised when prescribing nitrofurantoin due to the potential risk of hemolytic anemia. Clinical guidelines suggest that alternative antibiotics should be considered to avoid this risk, especially in populations or situations where G6PD deficiency might be more prevalent. Careful monitoring for hemolysis is recommended if nitrofurantoin use is necessary.	0.5572774318136495	0.349165430828482	0.2860188332604536	0.6217948881272368	0.5382148	0.2725553	0.28808874	0.6286361	0.5556397	0.33166835	0.2709732	0.69406575	0.5101806	0.21320395	0.1774652	0.6354869	0.512703	0.40906748	0.38126984	0.5939973	0
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking nitrofurantoin? Give a 2-3 sentence summary.	Avoid	['Proceed taking nitrofurantoin as normal. There is no recommendation.', 'Take nitrofurantoin with a reduced dose.', 'Take nitrofurantoin with an increased dose.']	Avoid nitrofurantoin. Take an alternate therapy.	Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, including those with chronic nonspherocytic hemolytic anemia (CNSHA), are generally advised to avoid nitrofurantoin due to the increased risk of hemolytic anemia. Alternative antibiotics that do not pose a risk for hemolysis should be considered for these individuals.	0.1819388572400395	0.30182932768877496	0.23581197600393536	0.582125647027581	0.2939025	0.37423956	0.3249347	0.6517326	0.14110164	0.22473049	0.23995529	0.6657348	0.14930485	0.2649486	0.24695273	0.6931237	0.39520976	0.5106796	0.43996453	0.68446213	1
nitrofurantoin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking nitrofurantoin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid nitrofurantoin. Take an alternate therapy.', 'Take nitrofurantoin with a reduced dose.', 'Take nitrofurantoin with an increased dose.']	Proceed taking nitrofurantoin as normal. There is no recommendation.	Individuals with normal glucose-6-phosphate dehydrogenase (G6PD) enzyme levels typically do not have an increased risk of hemolysis when taking nitrofurantoin. For these patients, nitrofurantoin can be used according to standard clinical guidelines for conditions like urinary tract infections, without additional precautions related to G6PD deficiency. However, as always, monitoring for any adverse reactions is recommended.	0.5760316111280941	0.3669677340386021	0.24648041610768834	0.6372894824119774	0.51463485	0.44078708	0.26996592	0.6468892	0.46642673	0.3373817	0.21715677	0.6937028	0.38637877	0.17988822	0.10099339	0.57028943	0.5439676	0.44368872	0.32732594	0.61945957	1
norfloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking norfloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid norfloxacin. Take an alternate therapy.', 'Take norfloxacin with a reduced dose.', 'Take norfloxacin with an increased dose.']	Proceed taking norfloxacin as normal. There is no recommendation.	Norfloxacin, a fluoroquinolone antibiotic, can induce oxidative stress, which poses a risk of hemolytic anemia in individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD). Clinical guidance generally advises against the use of norfloxacin in G6PD-deficient patients due to this potential risk, recommending alternative antibiotics that do not carry the same hemolytic risk. Always consult with a healthcare provider for personalized medical advice.	0.5179858172499244	0.4197573121681903	0.3217381758563973	0.5619660774997818	0.47316724	0.46382844	0.2520679	0.52999604	0.44882408	0.31267017	0.12702455	0.51726985	0.47386461	0.39850238	0.28740165	0.58983487	0.48814288	0.46547186	0.35617176	0.5508493	0
norfloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking norfloxacin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid norfloxacin. Take an alternate therapy.', 'Take norfloxacin with a reduced dose.', 'Take norfloxacin with an increased dose.']	Proceed taking norfloxacin as normal. There is no recommendation.	For an individual with an indeterminate G6PD (glucose-6-phosphate dehydrogenase) status, caution is advised when prescribing norfloxacin, as G6PD deficiency can increase the risk of hemolysis with certain medications. It is recommended to screen for G6PD deficiency before starting norfloxacin. If G6PD deficiency is confirmed, alternative antibiotics that do not pose a risk for hemolysis should be considered.	0.5830922198710415	0.309914936540527	0.24666913539449994	0.5761590504501368	0.5724935	0.13171339	0.12475679	0.48002082	0.6152164	0.11167094	0.031879377	0.4970145	0.5541541	0.18691193	0.15330039	0.5648241	0.5108359	0.40342307	0.38039112	0.5333371	0
norfloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking norfloxacin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid norfloxacin. Take an alternate therapy.', 'Take norfloxacin with a reduced dose.', 'Take norfloxacin with an increased dose.']	Proceed taking norfloxacin as normal. There is no recommendation.	For an individual who is deficient in glucose-6-phosphate dehydrogenase (G6PD) and has chronic nonspherocytic hemolytic anemia (CNSHA), careful consideration is needed when prescribing norfloxacin. Fluoroquinolones, including norfloxacin, have been implicated in causing oxidative stress, potentially precipitating hemolysis in G6PD-deficient individuals. Therefore, alternative antibiotics should be considered, and healthcare providers should exercise caution, closely monitoring for signs of hemolysis if norfloxacin is deemed necessary.	0.4233984279531406	0.3461804676039831	0.3894550491827744	0.5342316523025347	0.5698486	0.47659534	0.4623836	0.46058425	0.52559894	0.44834948	0.3597622	0.5078609	0.5770959	0.41963285	0.36257717	0.5509836	0.53749853	0.4216625	0.4766591	0.53677464	0
norfloxacin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking norfloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid norfloxacin. Take an alternate therapy.', 'Take norfloxacin with a reduced dose.', 'Take norfloxacin with an increased dose.']	Proceed taking norfloxacin as normal. There is no recommendation.	For an individual who has normal G6PD (glucose-6-phosphate dehydrogenase) enzyme activity, there are no specific pharmacogenomic contraindications or special precautions required regarding the use of norfloxacin, an antibiotic. They can be prescribed norfloxacin following standard clinical guidelines, focusing on the usual considerations such as bacterial susceptibility, patient history, and potential drug interactions.	0.5959149238605483	0.3664402173781931	0.24981639116503498	0.6339682362666308	0.49799615	0.3409655	0.16035795	0.59386605	0.42792282	0.19446605	0.06388264	0.57535	0.33216548	0.13976498	0.08049328	0.6022334	0.52476513	0.40307853	0.30078965	0.6386801	1
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.75 for CYP2D6 with regards to taking nortriptyline? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking nortriptyline as normal. There is no recommendation.', 'Take nortriptyline with a reduced dose.', 'Take nortriptyline with an increased dose.']	Avoid nortriptyline. Take an alternate therapy.	For a patient who is an ultrarapid metabolizer with a CYP2D6 activity score of ≥3.75, standard doses of nortriptyline are likely to result in subtherapeutic plasma concentrations and decreased efficacy due to increased metabolic clearance. Clinical guidance suggests considering an alternative medication not metabolized by CYP2D6 or closely monitoring the patient for response, potentially adjusting the dose upward while remaining vigilant for side effects. Always consult a healthcare provider for personalized recommendations.	0.6742100454948678	0.5540521581058402	0.5186336186355698	0.6461027982988227	0.7466816	0.59421337	0.5395829	0.62742615	0.6922505	0.5001029	0.4762896	0.6581576	0.65343547	0.48090208	0.464874	0.5020922	0.6738585	0.5963231	0.55151445	0.62165946	1
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking nortriptyline? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose	['Avoid nortriptyline. Take an alternate therapy.', 'Take nortriptyline with a reduced dose.', 'Take nortriptyline with an increased dose.']	Proceed taking nortriptyline as normal. There is no recommendation.	For a patient identified as a Normal Metabolizer with a CYP2D6 activity score of 1.75, standard dosing of nortriptyline is typically recommended. This score suggests that the patient will likely metabolize nortriptyline at a typical rate, thereby attaining therapeutic drug levels without increased risk of adverse effects or therapeutic failure. As always, clinical monitoring is advised to tailor the dose to the individual’s response and tolerability.	0.4332224421861121	0.4857456940403314	0.47727284664720143	0.6498836593252234	0.4618071	0.33882666	0.41150102	0.5356457	0.4271599	0.4339437	0.35340515	0.67956823	0.40479958	0.36809292	0.34603155	0.5493002	0.46986535	0.51391894	0.5276429	0.6013594	1
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking nortriptyline? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking nortriptyline as normal. There is no recommendation.', 'Take nortriptyline with a reduced dose.', 'Take nortriptyline with an increased dose.']	Avoid nortriptyline. Take an alternate therapy.	For a patient who is an ultrarapid metabolizer with an activity score of 2.75 for CYP2D6, clinical guidelines suggest considering an alternative medication to nortriptyline that is not metabolized by CYP2D6. This is due to the likelihood of reduced efficacy as a result of accelerated drug metabolism. If nortriptyline is still preferred, monitoring therapeutic drug levels and adjusting the dosage accordingly may be necessary.	0.6713217514921994	0.5540521581058402	0.5186336186355698	0.6422230403886201	0.7723775	0.59421337	0.5395829	0.6055271	0.7147519	0.5001029	0.4762896	0.5992585	0.6875748	0.48090208	0.464874	0.521348	0.6927678	0.5963231	0.55151445	0.6216983	1
nortriptyline	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking nortriptyline? Give a 2-3 sentence summary.	Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking nortriptyline as normal. There is no recommendation.', 'Take nortriptyline with a reduced dose.', 'Take nortriptyline with an increased dose.']	Avoid nortriptyline. Take an alternate therapy.	For someone identified as an Ultrarapid Metabolizer (activity score ≥4.0) for CYP2D6 taking nortriptyline, clinical guidance typically recommends considering an alternative medication not metabolized by CYP2D6, such as an antidepressant from a different class. This recommendation is due to the likelihood of subtherapeutic plasma levels of nortriptyline leading to reduced efficacy. If nortriptyline is the chosen treatment, close monitoring, and possible adjustment to a markedly higher dosage under careful supervision may be necessary.	0.6891616550788343	0.5540521581058402	0.5186336186355698	0.6933727284338385	0.7864464	0.59421337	0.5395829	0.6752508	0.77135205	0.5001029	0.4762896	0.67973536	0.7333991	0.48090208	0.464874	0.5549934	0.6584692	0.5963231	0.55151445	0.6406355	1
ofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking ofloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid ofloxacin. Take an alternate therapy.', 'Take ofloxacin with a reduced dose.', 'Take ofloxacin with an increased dose.']	Proceed taking ofloxacin as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), the use of ofloxacin is generally advised with caution. This antibiotic may increase the risk of hemolysis in G6PD-deficient patients. Therefore, alternative antibiotics that do not pose this risk should be considered, and if ofloxacin is deemed necessary, close monitoring for hemolytic anemia is recommended.	0.5379716609891655	0.40736389055598504	0.2969668871830186	0.5417312278224978	0.58025306	0.52439606	0.32061037	0.6396507	0.571601	0.40802163	0.23111148	0.68484753	0.52149725	0.38465044	0.27130294	0.5767305	0.48303732	0.4309856	0.33088523	0.524094	0
ofloxacin	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking ofloxacin? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid ofloxacin. Take an alternate therapy.', 'Take ofloxacin with a reduced dose.', 'Take ofloxacin with an increased dose.']	Proceed taking ofloxacin as normal. There is no recommendation.	Clinical guidance for someone with an indeterminate G6PD (Glucose-6-Phosphate Dehydrogenase) status regarding the use of ofloxacin should be approached with caution. Ofloxacin, a fluoroquinolone antibiotic, has been associated with hemolytic anemia in G6PD-deficient individuals. Therefore, it is recommended to assess the G6PD status more definitively before prescribing ofloxacin, and consider alternative antibiotics if G6PD deficiency is confirmed or still indeterminate.	0.5940237555312171	0.3015163417089369	0.2275249946889749	0.514119220892021	0.5675143	0.23022352	0.23508716	0.5856616	0.6203515	0.2378169	0.14877345	0.6031578	0.5889649	0.19479704	0.16254325	0.52082014	0.48938438	0.39192247	0.39242944	0.5344715	0
ofloxacin	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking ofloxacin? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid ofloxacin. Take an alternate therapy.', 'Take ofloxacin with a reduced dose.', 'Take ofloxacin with an increased dose.']	Proceed taking ofloxacin as normal. There is no recommendation.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, including those with chronic nonspherocytic hemolytic anemia (CNSHA), the use of ofloxacin should be approached with caution. Ofloxacin, like other fluoroquinolones, can induce oxidative stress that may precipitate hemolysis in G6PD-deficient patients. Therefore, an alternative antibiotic with a safer profile for G6PD deficiency should be considered, and if ofloxacin is deemed necessary, close monitoring for signs of hemolysis is essential.	0.45481674639797737	0.3723324677373823	0.39830062533220273	0.508964484730888	0.5545706	0.47258335	0.47498974	0.5559984	0.48061156	0.4311583	0.40081978	0.5778773	0.5692454	0.44066787	0.40350303	0.5183667	0.5123808	0.41272175	0.49330428	0.4982553	1
ofloxacin	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking ofloxacin? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid ofloxacin. Take an alternate therapy.', 'Take ofloxacin with a reduced dose.', 'Take ofloxacin with an increased dose.']	Proceed taking ofloxacin as normal. There is no recommendation.	For individuals with normal G6PD activity, taking ofloxacin is generally considered safe as there is no increased risk of hemolytic anemia associated with this enzyme-deficiency. However, as with any medication, it is important to follow prescribing guidelines and monitor for any adverse effects. Always consult healthcare providers for personalized medical advice.	0.5315042453019059	0.3386969590145985	0.2210343181188719	0.6506190643039366	0.4830225	0.4036584	0.21641769	0.70471	0.45194507	0.2645305	0.14745687	0.7252454	0.3701731	0.12907806	0.053062085	0.6324249	0.49583873	0.38018793	0.2693993	0.59603447	1
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking omeprazole? Give a 2-3 sentence summary.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	['Proceed taking omeprazole as normal. There is no recommendation.', 'Avoid omeprazole. Take an alternate therapy.']	Take omeprazole with an altered dose.	In individuals who are CYP2C19 ultrarapid metabolizers, omeprazole is metabolized more quickly, reducing its efficacy in suppressing gastric acid secretion. Clinical guidelines often recommend considering an alternative proton pump inhibitor (PPI) that is less dependent on CYP2C19 for metabolism, such as esomeprazole or rabeprazole, to ensure effective treatment.	0.3087516929849059	0.4453759769848073	0.3690197413714159	0.6119254933013395	0.33327982	0.63719136	0.4758837	0.5277932	0.29604742	0.6020923	0.4942456	0.513309	0.31896743	0.5294077	0.45382705	0.5140242	0.2751194	0.5606365	0.3452252	0.6037542	0
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking omeprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking omeprazole as normal. There is no recommendation.', 'Avoid omeprazole. Take an alternate therapy.']	Take omeprazole with an altered dose.	For a patient identified as a likely poor metabolizer for CYP2C19, the clinical guidance for taking omeprazole may include dose adjustments due to the increased drug exposure and potential for enhanced therapeutic effects and adverse effects. Given that poor metabolizers exhibit slower clearance of the drug, they might require lower doses than typically prescribed. It is advisable to consult a healthcare provider to tailor the dosage appropriately.	0.4036433962285435	0.4312387054737586	0.41026541277960105	0.6617321616222019	0.43351123	0.4274976	0.38631967	0.60921955	0.43497986	0.39290318	0.40172082	0.56758356	0.39368507	0.40408826	0.4260251	0.52887654	0.47878143	0.51069117	0.39541346	0.68990505	0
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Intermediate Metabolizer for CYP2C19 with regards to taking omeprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking omeprazole as normal. There is no recommendation.', 'Avoid omeprazole. Take an alternate therapy.']	Take omeprazole with an altered dose.	For a patient who is a likely intermediate metabolizer of CYP2C19 taking omeprazole, clinical guidance often recommends standard dosing, as studies indicate that intermediate metabolizers generally achieve therapeutic levels comparable to normal metabolizers. However, monitoring for efficacy and adjusting the dose as necessary may be prudent to ensure optimal therapeutic outcomes.	0.4784252816422783	0.4312387054737586	0.41026541277960105	0.6305243830120922	0.5015338	0.4274976	0.38631967	0.580079	0.3956139	0.39290318	0.40172082	0.5457144	0.46045065	0.40408826	0.4260251	0.5183699	0.4687297	0.51069117	0.39541346	0.61362433	0
omeprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking omeprazole? Give a 2-3 sentence summary.	No recommendation	['Avoid omeprazole. Take an alternate therapy.', 'Take omeprazole with a reduced dose.', 'Take omeprazole with an increased dose.']	Proceed taking omeprazole as normal. There is no recommendation.	For individuals with an indeterminate CYP2C19 genotype, standard dosing of omeprazole is typically advised as there isn't sufficient genetic information to tailor the dose. Monitoring for therapeutic efficacy and potential side effects is recommended, and dose adjustments should be based on clinical response rather than genetic testing in this case.	0.24364597609326277	0.45051482337187665	0.19291574298472472	0.5608721487485001	0.20623754	0.34948725	0.17491752	0.5510223	0.101589024	0.2224892	0.094694875	0.57235414	-0.042516198	0.28686652	0.061659615	0.5081337	0.30147043	0.5508825	0.41253772	0.5742484	0
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking ondansetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking ondansetron as normal. There is no recommendation.', 'Take ondansetron with a reduced dose.', 'Take ondansetron with an increased dose.']	Avoid ondansetron. Take an alternate therapy.	For a patient who is an Ultrarapid Metabolizer (UM) with an activity score ≥6.0 for CYP2D6, clinical guidance suggests that ondansetron should be avoided. UMs rapidly metabolize ondansetron, which can result in significantly lower plasma levels and reduced efficacy of the drug. Alternative antiemetics that are not metabolized by CYP2D6, such as granisetron or other options, should be considered.	0.624770988865728	0.6061238391352334	0.47323810526323395	0.6612968626696121	0.69217646	0.5319946	0.4777294	0.66381806	0.7408901	0.4176924	0.3991066	0.6101528	0.7035622	0.5270999	0.52874094	0.55914783	0.64284223	0.57994187	0.5272296	0.59683734	1
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking ondansetron? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid ondansetron. Take an alternate therapy.', 'Take ondansetron with a reduced dose.', 'Take ondansetron with an increased dose.']	Proceed taking ondansetron as normal. There is no recommendation.	For a patient with an activity score of 1.75 for CYP2D6, which indicates they are a normal metabolizer, standard dosing of ondansetron is generally appropriate. This is because their enzyme activity should allow for typical drug metabolism and effectiveness, resulting in the desired therapeutic effects without the need for dose adjustment. It is always prudent to monitor for efficacy and potential adverse effects.	0.41973662554175456	0.4897247162361114	0.5304729310805695	0.6028782256579521	0.43828654	0.40120304	0.52573687	0.49434316	0.44453883	0.5187361	0.52486926	0.66289765	0.4039171	0.45777202	0.49198267	0.6126831	0.4247211	0.5024894	0.57286495	0.5777727	1
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking ondansetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking ondansetron as normal. There is no recommendation.', 'Take ondansetron with a reduced dose.', 'Take ondansetron with an increased dose.']	Avoid ondansetron. Take an alternate therapy.	For an individual identified as an ultrarapid metabolizer (URM) of CYP2D6 with an activity score of 2.75, clinical guidance would suggest caution when prescribing ondansetron. Due to their rapid metabolism, there is a potential for decreased therapeutic efficacy because the drug may be metabolized too quickly to exert its intended antiemetic effects. Alternative antiemetic therapies that are not significantly metabolized by CYP2D6 should be considered to ensure effective management of symptoms.	0.5482488669003547	0.6061238391352334	0.47323810526323395	0.6018791994944587	0.5292328	0.5319946	0.4777294	0.5812504	0.7351291	0.4176924	0.3991066	0.6031924	0.72264916	0.5270999	0.52874094	0.5717686	0.59924626	0.57994187	0.5272296	0.6018929	1
ondansetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking ondansetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking ondansetron as normal. There is no recommendation.', 'Take ondansetron with a reduced dose.', 'Take ondansetron with an increased dose.']	Avoid ondansetron. Take an alternate therapy.	For individuals identified as Ultrarapid Metabolizers of CYP2D6 with an activity score of ≥5.0, alternative antiemetic medications to ondansetron should be considered. This is because the ultrarapid metabolism can lead to reduced efficacy of ondansetron, as it is metabolized quickly, potentially decreasing its therapeutic effect in preventing nausea and vomiting.	0.5795642299385326	0.6061238391352334	0.47323810526323395	0.6170964184346793	0.6377464	0.5319946	0.4777294	0.644625	0.7240952	0.4176924	0.3991066	0.59159833	0.740218	0.5270999	0.52874094	0.5723074	0.62076	0.57994187	0.5272296	0.60989195	1
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking oxcarbazepine? Give a 2-3 sentence summary.	If patient is oxcarbazepine-naïve, do not use oxcarbazepine.	['Proceed taking oxcarbazepine as normal. There is no recommendation.', 'Take oxcarbazepine with a reduced dose.', 'Take oxcarbazepine with an increased dose.']	Avoid oxcarbazepine. Take an alternate therapy.	For individuals who are HLA-B*15:02 positive, oxcarbazepine use is generally contraindicated due to a significantly increased risk of developing severe cutaneous adverse reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Alternative medications not associated with this genetic risk should be considered to avoid these potentially life-threatening side effects.	0.6374139647291313	0.7135577494476439	0.6881147792554548	0.6548033072057499	0.60732037	0.65149117	0.5394059	0.5650998	0.68548036	0.713807	0.6159231	0.59100544	0.63994324	0.8032713	0.7270234	0.56134844	0.6726335	0.71865594	0.5948367	0.6586208	1
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking oxcarbazepine? Give a 2-3 sentence summary.	The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.	['Avoid oxcarbazepine. Take an alternate therapy.', 'Take oxcarbazepine with a reduced dose.', 'Take oxcarbazepine with an increased dose.']	Proceed taking oxcarbazepine as normal. There is no recommendation.	For individuals who test positive for the HLA-B*15:02 allele, clinical guidelines recommend avoiding the use of oxcarbazepine due to the significantly increased risk of severe cutaneous adverse reactions, such as Stevens-Johnson syndrome and toxic epidermal necrolysis. Alternative medications that do not carry this risk should be considered for these patients.	0.6163611940720406	0.5043615494276995	0.5343866311002987	0.5880862485124652	0.4845204	0.5658958	0.5124112	0.6086339	0.53490794	0.60963845	0.49816933	0.5806237	0.48732525	0.4968411	0.5035804	0.5164843	0.51961035	0.50254124	0.51570123	0.5852507	0
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking oxcarbazepine? Give a 2-3 sentence summary.	Use oxcarbazepine per standard dosing guidelines.	['Avoid oxcarbazepine. Take an alternate therapy.', 'Take oxcarbazepine with a reduced dose.', 'Take oxcarbazepine with an increased dose.']	Proceed taking oxcarbazepine as normal. There is no recommendation.	For individuals who are HLA-B*15:02 negative, there is no increased genetic risk of developing a severe cutaneous adverse reactions, such as Stevens-Johnson syndrome or toxic epidermal necrolysis, when taking oxcarbazepine. Therefore, oxcarbazepine can be used with standard clinical precautions, but routine monitoring for skin reactions and other side effects is still recommended.	0.5949661136535259	0.7546470038907067	0.7605964256002827	0.6016389142938905	0.5031489	0.72623116	0.7635477	0.6274579	0.50552976	0.84319997	0.8719776	0.61722755	0.45547056	0.8297167	0.7897199	0.4997172	0.57336676	0.79110354	0.7943649	0.53491855	0
oxcarbazepine	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking oxcarbazepine? Give a 2-3 sentence summary.	Use oxcarbazepine per standard dosing guidelines.	['Avoid oxcarbazepine. Take an alternate therapy.', 'Take oxcarbazepine with a reduced dose.', 'Take oxcarbazepine with an increased dose.']	Proceed taking oxcarbazepine as normal. There is no recommendation.	For individuals who are HLA-B*15:02 negative, there is no increased genetic risk for oxcarbazepine-induced Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN). Therefore, oxcarbazepine can be considered a safer option for these patients, but clinicians should still monitor for other potential side effects. It’s also important to consider other factors such as overall health and concomitant medications when prescribing oxcarbazepine.	0.5928967371381966	0.7546470038907067	0.7605964256002827	0.6082626076794254	0.46573085	0.72623116	0.7635477	0.6134111	0.49539414	0.84319997	0.8719776	0.58547986	0.4246729	0.8297167	0.7897199	0.47487813	0.5449112	0.79110354	0.7943649	0.53109074	0
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking pantoprazole? Give a 2-3 sentence summary.	Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.	['Proceed taking pantoprazole as normal. There is no recommendation.', 'Avoid pantoprazole. Take an alternate therapy.']	Take pantoprazole with an altered dose.	For an individual identified as a CYP2C19 Ultrarapid Metabolizer, the clinical guidance regarding pantoprazole, a proton pump inhibitor, typically does not require dose adjustments. Pantoprazole is less dependent on CYP2C19 for its metabolism compared to other PPIs like omeprazole, thus standard dosing is generally appropriate for achieving the desired therapeutic effect. However, monitoring the patient for efficacy is advisable.	0.38175903270311173	0.4603966159428621	0.38048218885651386	0.6911777177876975	0.3114712	0.6545137	0.48591155	0.46855882	0.4062709	0.63954663	0.53436863	0.580814	0.3508353	0.5164538	0.42759907	0.5023028	0.38853523	0.56627536	0.36993784	0.6256118	0
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Likely Poor Metabolizer for CYP2C19 with regards to taking pantoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking pantoprazole as normal. There is no recommendation.', 'Avoid pantoprazole. Take an alternate therapy.']	Take pantoprazole with an altered dose.	For individuals identified as likely poor metabolizers of CYP2C19, taking pantoprazole generally does not require significant dosage adjustment. Pantoprazole is primarily metabolized by CYP2C19 and CYP3A4, but poor metabolizers still achieve sufficient drug levels to effectively manage conditions like gastroesophageal reflux disease (GERD) and peptic ulcer disease. However, clinicians should monitor for potential adverse effects and adjust the dose if necessary based on clinical response.	0.31550198325532075	0.4279619440029625	0.4059516174318005	0.6529847150568424	0.31754056	0.4615042	0.42293584	0.47044414	0.38639086	0.44084695	0.46522802	0.5698516	0.3226978	0.39586946	0.38917634	0.5231343	0.41774923	0.53891414	0.42433164	0.7189917	0
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking pantoprazole? Give a 2-3 sentence summary.	Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.	['Proceed taking pantoprazole as normal. There is no recommendation.', 'Avoid pantoprazole. Take an alternate therapy.']	Take pantoprazole with an altered dose.	For an individual who is an intermediate metabolizer for CYP2C19, clinical guidance suggests that pantoprazole dosage adjustments are generally not necessary, as its metabolism is less dependent on CYP2C19 compared to other proton pump inhibitors (PPIs). Pantoprazole can be used at standard doses since its efficacy and safety profile remains effective in intermediate metabolizers.	0.3592167136346137	0.4279619440029625	0.4059516174318005	0.6637627100991659	0.44395512	0.4615042	0.42293584	0.54142433	0.42822763	0.44084695	0.46522802	0.5527261	0.39379448	0.39586946	0.38917634	0.5004721	0.43599942	0.53891414	0.42433164	0.6259239	0
pantoprazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking pantoprazole? Give a 2-3 sentence summary.	No recommendation	['Avoid pantoprazole. Take an alternate therapy.', 'Take pantoprazole with a reduced dose.', 'Take pantoprazole with an increased dose.']	Proceed taking pantoprazole as normal. There is no recommendation.	For an individual with an indeterminate CYP2C19 metabolizer status taking pantoprazole, standard dosing is generally recommended due to the medication's relatively low dependence on CYP2C19 for metabolism. However, clinical monitoring for both efficacy and adverse effects is advised, as there may be variations in drug response that require dose adjustments.	0.23272813515643526	0.4440314107866983	0.2060761888249579	0.651973433689993	0.11372512	0.32847852	0.1822713	0.59881115	0.07450948	0.22252661	0.112471975	0.6949909	0.016919615	0.29856536	0.09517783	0.6419455	0.301389	0.53262234	0.38784876	0.6115269	0
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking paromomycin as normal. There is no recommendation.', 'Take paromomycin with a reduced dose.', 'Take paromomycin with an increased dose.']	Avoid paromomycin. Take an alternate therapy.	For individuals at increased risk of aminoglycoside-induced hearing loss due to MT-RNR1 genetic variants, clinical guidance generally advises avoiding aminoglycosides, including paromomycin, when possible. Alternative antibiotics that do not carry the same risk of ototoxicity should be considered to prevent potential hearing loss.	0.7253263695194991	0.5106363701240785	0.42844853036422936	0.5933754181889532	0.8188153	0.6090969	0.4846443	0.62034225	0.77933717	0.47549066	0.47105184	0.58770174	0.8246695	0.4146249	0.4179778	0.48067886	0.65249026	0.5933154	0.48953977	0.6314985	1
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid paromomycin. Take an alternate therapy.', 'Take paromomycin with a reduced dose.', 'Take paromomycin with an increased dose.']	Proceed taking paromomycin as normal. There is no recommendation.	For individuals with a normal risk of aminoglycoside-induced hearing loss based on their MT-RNR1 genotype, the clinical guidance regarding the use of paromomycin would generally be more lenient compared to those at increased risk. Since paromomycin is an aminoglycoside antibiotic, monitoring for hearing loss is still prudent, but the lack of high-risk markers in MT-RNR1 suggests a reduced likelihood of ototoxicity. Thus, standard dosing and administration can be followed, with routine auditory monitoring as a precaution.	0.6316022111981188	0.4454525899714898	0.46264524085898556	0.6399550819752049	0.6237898	0.46919623	0.47202802	0.5156569	0.71091026	0.53912383	0.5289361	0.57012725	0.7601829	0.49476057	0.47414577	0.45900345	0.6562811	0.53017235	0.5722973	0.5816826	1
paromomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking paromomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid paromomycin. Take an alternate therapy.', 'Take paromomycin with a reduced dose.', 'Take paromomycin with an increased dose.']	Proceed taking paromomycin as normal. There is no recommendation.	For an individual with an uncertain risk of aminoglycoside-induced hearing loss related to the MT-RNR1 genetic variant, the clinical guidance typically involves exercising caution with aminoglycoside antibiotics, including paromomycin. Alternative antibiotics should be considered when available and appropriate, and if aminoglycosides are necessary, the patient should undergo close monitoring for ototoxicity, coupled with genetic counseling to fully assess their risk.	0.6782249509663509	0.4454525899714898	0.46264524085898556	0.5445371661100427	0.6321422	0.46919623	0.47202802	0.55453694	0.70654875	0.53912383	0.5289361	0.54265577	0.7704943	0.49476057	0.47414577	0.4552888	0.66474545	0.53017235	0.5722973	0.56741697	0
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking paroxetine? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6.	['Proceed taking paroxetine as normal. There is no recommendation.', 'Take paroxetine with a reduced dose.', 'Take paroxetine with an increased dose.']	Avoid paroxetine. Take an alternate therapy.	For a patient identified as a CYP2D6 ultrarapid metabolizer (activity score ≥6.0), paroxetine is likely to be metabolized very quickly, leading to reduced drug efficacy. Clinical guidance would generally recommend avoiding paroxetine for such patients and considering alternative medications that are not primarily metabolized by CYP2D6, to achieve therapeutic effectiveness.	0.514265595488564	0.499900226997756	0.3463046502898856	0.6213005948923236	0.60898334	0.39904898	0.33855036	0.61770517	0.66285616	0.23258665	0.23828566	0.5991989	0.63552004	0.34230372	0.33780447	0.6360048	0.5435479	0.5248599	0.4494817	0.67111754	1
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking paroxetine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose	['Avoid paroxetine. Take an alternate therapy.', 'Take paroxetine with a reduced dose.', 'Take paroxetine with an increased dose.']	Proceed taking paroxetine as normal. There is no recommendation.	For a patient who is a CYP2D6 normal metabolizer with an activity score of 1.75, the clinical guidance indicates that standard dosing of paroxetine is appropriate. This genotype suggests that the patient has typical enzyme activity, which means they are likely to metabolize the drug at a normal rate. Therefore, no dosage adjustment is generally required for paroxetine in such patients.	0.4350613401204893	0.4562907054264667	0.4735632789017192	0.6061498375317972	0.40479335	0.34955364	0.37743953	0.52234775	0.38415557	0.37572896	0.29313532	0.5982547	0.43225986	0.42626575	0.41252637	0.56927544	0.42470518	0.51262844	0.5601581	0.6042784	1
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking paroxetine? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6.	['Proceed taking paroxetine as normal. There is no recommendation.', 'Take paroxetine with a reduced dose.', 'Take paroxetine with an increased dose.']	Avoid paroxetine. Take an alternate therapy.	For someone who is an Ultrarapid Metabolizer (UM) with an activity score of 2.75 for CYP2D6, taking paroxetine may lead to significantly reduced efficacy due to rapid metabolism of the drug. Clinical guidance typically recommends considering an alternative antidepressant that is not primarily metabolized by CYP2D6, as this would help achieve better therapeutic outcomes and minimize the risk of treatment failure.	0.528971038343491	0.499900226997756	0.3463046502898856	0.6335677752221557	0.5569554	0.39904898	0.33855036	0.6114408	0.55038023	0.23258665	0.23828566	0.63873845	0.6393654	0.34230372	0.33780447	0.6024662	0.56446224	0.5248599	0.4494817	0.6926809	1
paroxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking paroxetine? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6.	['Proceed taking paroxetine as normal. There is no recommendation.', 'Take paroxetine with a reduced dose.', 'Take paroxetine with an increased dose.']	Avoid paroxetine. Take an alternate therapy.	For an individual identified as a CYP2D6 ultrarapid metabolizer (UM) with an activity score of ≥5.0, it is generally recommended to avoid the use of paroxetine. This is because ultrarapid metabolizers would likely have significantly lower plasma concentrations of the drug, potentially leading to reduced efficacy. Alternative medications not metabolized by CYP2D6 should be considered to achieve the desired therapeutic effect.	0.5411420384239484	0.499900226997756	0.3463046502898856	0.6114698304175743	0.67639357	0.39904898	0.33855036	0.6472122	0.6223731	0.23258665	0.23828566	0.6294088	0.67681867	0.34230372	0.33780447	0.5725527	0.57474077	0.5248599	0.4494817	0.65107256	1
pegloticase	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking pegloticase? Give a 2-3 sentence summary.	Avoid use	['Proceed taking pegloticase as normal. There is no recommendation.', 'Take pegloticase with a reduced dose.', 'Take pegloticase with an increased dose.']	Avoid pegloticase. Take an alternate therapy.	For individuals deficient in glucose-6-phosphate dehydrogenase (G6PD), the use of pegloticase is contraindicated. This is because G6PD deficiency can increase the risk of hemolysis and methemoglobinemia when undergoing pegloticase treatment. Clinicians should consider alternative therapies for managing conditions typically treated with pegloticase in these patients.	0.2596867682451368	0.29805768275866695	0.2569845324366969	0.6531878595348567	0.3223478	0.37155744	0.2916241	0.6746829	0.1794987	0.17479636	0.18571635	0.6628138	0.15811567	0.17363566	0.17409731	0.6883768	0.40650472	0.57963884	0.47259393	0.6272714	1
pegloticase	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking pegloticase? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid pegloticase. Take an alternate therapy.', 'Take pegloticase with a reduced dose.', 'Take pegloticase with an increased dose.']	Proceed taking pegloticase as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, the clinical guidance regarding the use of pegloticase is cautious. It is recommended to conduct a confirmatory G6PD deficiency test before initiating pegloticase due to the increased risk of hemolysis and methemoglobinemia in G6PD-deficient patients. If G6PD deficiency is confirmed, pegloticase should be avoided or used with extreme caution under close medical supervision.	0.6200539739918658	0.4142874767981409	0.3764894209709682	0.6269897374851412	0.61450636	0.2793679	0.32107347	0.62525976	0.6423666	0.37694287	0.33661446	0.70947874	0.643254	0.3999025	0.32525685	0.58744854	0.6102572	0.42390808	0.428396	0.5131946	1
pegloticase	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking pegloticase? Give a 2-3 sentence summary.	Avoid use	['Proceed taking pegloticase as normal. There is no recommendation.', 'Take pegloticase with a reduced dose.', 'Take pegloticase with an increased dose.']	Avoid pegloticase. Take an alternate therapy.	Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency and chronic non-spherocytic hemolytic anemia (CNSHA) should avoid taking pegloticase. Pegloticase can trigger severe hemolysis and methemoglobinemia in G6PD-deficient patients due to oxidative stress. Alternative gout treatments should be considered for these patients to mitigate the risk of hemolytic events.	0.21091921681038905	0.29805768275866695	0.2569845324366969	0.5978250886564871	0.35255042	0.37155744	0.2916241	0.6429608	0.17280851	0.17479636	0.18571635	0.6746734	0.070778124	0.17363566	0.17409731	0.57578087	0.4725008	0.57963884	0.47259393	0.7063259	1
pegloticase	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking pegloticase? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid pegloticase. Take an alternate therapy.', 'Take pegloticase with a reduced dose.', 'Take pegloticase with an increased dose.']	Proceed taking pegloticase as normal. There is no recommendation.	For individuals who are normal (i.e., have normal activity) for the glucose-6-phosphate dehydrogenase (G6PD) enzyme, there are no specific contraindications or special precautions required when taking pegloticase. Pegloticase can be safely administered, and its use does not pose a risk of hemolysis for patients with normal G6PD activity.	0.5917373018687085	0.4285086363268977	0.33600815079789553	0.6717424686899686	0.53372306	0.40980732	0.21756089	0.70810974	0.4938889	0.28910202	0.16120888	0.75413144	0.42195675	0.20689121	0.09266206	0.63798934	0.5672505	0.43167844	0.32591036	0.5973372	1
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking phenazopyridine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid phenazopyridine. Take an alternate therapy.', 'Take phenazopyridine with a reduced dose.', 'Take phenazopyridine with an increased dose.']	Proceed taking phenazopyridine as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) with chronic non-spherocytic hemolytic anemia (CNSHA) should avoid taking phenazopyridine. Phenazopyridine has a high risk of inducing hemolysis in G6PD-deficient patients, which could exacerbate their condition and lead to severe hemolytic anemia. Clinical guidance would recommend alternative treatments that are safer for managing urinary pain in these individuals.	0.4047805553485651	0.3539639815651706	0.392701939450759	0.568486686430876	0.5599211	0.5002357	0.5164551	0.6418205	0.56615406	0.4825498	0.47404912	0.56040925	0.50247204	0.3933968	0.36032382	0.54005474	0.5022169	0.4296753	0.48021826	0.5953674	0
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking phenazopyridine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid phenazopyridine. Take an alternate therapy.', 'Take phenazopyridine with a reduced dose.', 'Take phenazopyridine with an increased dose.']	Proceed taking phenazopyridine as normal. There is no recommendation.	For individuals who have normal glucose-6-phosphate dehydrogenase (G6PD) activity, taking phenazopyridine is generally considered safe. Such individuals are not at increased risk of hemolytic anemia, a condition that can occur in those with G6PD deficiency when exposed to certain medications, including phenazopyridine. However, as with any medication, it is important to follow dosing recommendations and consult with a healthcare provider for personalized advice.	0.6198229593441644	0.42877649217224095	0.31569979170281864	0.6329223644967753	0.48845115	0.39865577	0.19810331	0.6679696	0.45943767	0.2877494	0.14585657	0.70145	0.39210695	0.16834329	0.09964836	0.60948116	0.58917665	0.46084318	0.331821	0.6245455	1
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking phenazopyridine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid phenazopyridine. Take an alternate therapy.', 'Take phenazopyridine with a reduced dose.', 'Take phenazopyridine with an increased dose.']	Proceed taking phenazopyridine as normal. There is no recommendation.	For individuals with variable Glucose-6-phosphate dehydrogenase (G6PD) levels, caution is advised when prescribing phenazopyridine due to the risk of hemolysis. It is recommended to consider alternative therapies, and if phenazopyridine is used, to closely monitor for signs of hemolytic anemia.	0.6128128380928619	0.4887673895558014	0.3838660313663884	0.5974157954436029	0.6291987	0.5575639	0.35187915	0.5819973	0.6831609	0.49766055	0.30313754	0.6028282	0.6217133	0.4416389	0.33736968	0.6023396	0.5440881	0.5493739	0.41835925	0.4945544	0
phenazopyridine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking phenazopyridine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid phenazopyridine. Take an alternate therapy.', 'Take phenazopyridine with a reduced dose.', 'Take phenazopyridine with an increased dose.']	Proceed taking phenazopyridine as normal. There is no recommendation.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, taking phenazopyridine is contraindicated due to the increased risk of hemolysis. Hemolytic anemia can occur because G6PD-deficient red blood cells are more susceptible to oxidative stress. Clinicians should consider alternative treatments that do not carry this risk.	0.6297575316617137	0.4887673895558014	0.3838660313663884	0.5699861076061684	0.591066	0.5575639	0.35187915	0.5925548	0.6176345	0.49766055	0.30313754	0.61670256	0.55892533	0.4416389	0.33736968	0.53330225	0.5748729	0.5493739	0.41835925	0.6117242	0
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 negative for HLA-B with regards to taking phenytoin? Give a 2-3 sentence summary.	No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.	['Avoid phenytoin. Take an alternate therapy.', 'Take phenytoin with a reduced dose.', 'Take phenytoin with an increased dose.']	Proceed taking phenytoin as normal. There is no recommendation.	If an individual tests negative for the HLA-B*15:02 allele, they are not at increased genetic risk for developing Stevens-Johnson syndrome (SJS) or toxic epidermal necrolysis (TEN) from phenytoin. Therefore, phenytoin can be prescribed without additional risk related to these specific severe cutaneous adverse reactions. However, other metabolic factors and individual risk should still be considered in the overall clinical decision-making process.	0.7749633162218172	0.594051729723197	0.5564096036683311	0.5645859818610852	0.7208868	0.63120824	0.5283108	0.60097647	0.77801734	0.628549	0.5542701	0.5831802	0.6974745	0.52416676	0.5305266	0.41803586	0.78280884	0.52779835	0.50937027	0.5583327	1
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin? Give a 2-3 sentence summary.	For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	['Proceed taking phenytoin as normal. There is no recommendation.', 'Avoid phenytoin. Take an alternate therapy.']	Take phenytoin with an altered dose.	For an individual with no HLA-B genotyping results regarding the use of phenytoin, standard clinical practice would be to proceed with prescribing phenytoin while carefully monitoring for adverse reactions, particularly severe cutaneous adverse reactions such as Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Healthcare providers may also consider alternative medications, especially in populations with a higher prevalence of HLA-B*15:02, such as those of Asian descent, where the risk for these adverse effects is elevated.	0.7801076896637515	0.5853593788428818	0.5957674918865683	0.5952078825055995	0.6896336	0.55391777	0.60406566	0.45100603	0.702059	0.5490834	0.675289	0.43413046	0.68869376	0.54993576	0.5374485	0.4439675	0.70167136	0.55776227	0.5125805	0.533063	0
phenytoin	HLA-B	What would be the clinical guidance for someone who is No HLA-B Result for HLA-B with regards to taking phenytoin? Give a 2-3 sentence summary.	For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.	['Proceed taking phenytoin as normal. There is no recommendation.', 'Avoid phenytoin. Take an alternate therapy.']	Take phenytoin with an altered dose.	If someone has no HLA-B test result for phenytoin, it is recommended to proceed with caution. While the presence of certain HLA-B alleles (such as HLA-B*15:02) is known to increase the risk of severe adverse skin reactions like Stevens-Johnson syndrome, in the absence of genotypic information, healthcare providers should monitor the patient closely for any adverse reactions and consider alternative medications if the patient is of Asian ancestry, where these alleles are more prevalent. Genetic testing could be pursued if deemed necessary based on the patient's ethnic background and clinical history.	0.7275006769639613	0.5851391084441523	0.5961775584055073	0.5369107048399606	0.5396784	0.5456533	0.5921931	0.35632008	0.5937574	0.5445963	0.66846526	0.38031214	0.6148923	0.55336016	0.53762925	0.39344865	0.64760345	0.5597986	0.51231265	0.441935	0
phenytoin	HLA-B	What would be the clinical guidance for someone who is HLA-B*15:02 positive for HLA-B with regards to taking phenytoin? Give a 2-3 sentence summary.	If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.	['Avoid phenytoin. Take an alternate therapy.', 'Take phenytoin with a reduced dose.', 'Take phenytoin with an increased dose.']	Proceed taking phenytoin as normal. There is no recommendation.	Individuals who are HLA-B*15:02 positive should generally avoid taking phenytoin due to a significantly increased risk of developing Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN). Alternative antiepileptic medications without this risk should be considered to ensure patient safety.	0.6657139208144777	0.5608920084698596	0.5545390484920156	0.5701654674018215	0.58902854	0.591547	0.52103406	0.6403617	0.61717486	0.6434727	0.5483785	0.6223159	0.54705304	0.5169033	0.528249	0.56002504	0.50217575	0.48335147	0.49020788	0.6248703	0
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking piroxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid piroxicam. Take an alternate therapy.', 'Take piroxicam with a reduced dose.', 'Take piroxicam with an increased dose.']	Proceed taking piroxicam as normal. There is no recommendation.	Individuals who are Normal Metabolizers (activity score of 2.0) for the CYP2C9 enzyme typically do not require any dose adjustments when taking piroxicam. They are expected to metabolize the drug at the standard rate, allowing for typical therapeutic outcomes and side effect profiles. Therefore, standard dosage recommendations as per clinical guidelines can be followed for these patients.	0.3924460285529196	0.43233387916315996	0.43792077228779175	0.656703516394753	0.44260764	0.35056257	0.294696	0.5725326	0.39656737	0.41325998	0.24804376	0.62381214	0.37717676	0.3800089	0.36730957	0.5373234	0.4324162	0.46738806	0.45559964	0.66885126	1
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking piroxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid piroxicam. Take an alternate therapy.', 'Take piroxicam with a reduced dose.', 'Take piroxicam with an increased dose.']	Proceed taking piroxicam as normal. There is no recommendation.	For an individual identified as an intermediate metabolizer with a CYP2C9 activity score of 1.5, clinical guidance typically suggests caution when prescribing piroxicam due to the potential for increased drug levels and risk of adverse effects. It may be advisable to consider a lower starting dose or an alternative nonsteroidal anti-inflammatory drug (NSAID) that is less dependent on CYP2C9 metabolism. Regular monitoring for efficacy and adverse effects is recommended.	0.4276703084893355	0.43233387916315996	0.43792077228779175	0.6484724599462875	0.4256814	0.35056257	0.294696	0.57625365	0.37675187	0.41325998	0.24804376	0.59843016	0.35236898	0.3800089	0.36730957	0.5935938	0.447422	0.46738806	0.45559964	0.6251085	0
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking piroxicam? Give a 2-3 sentence summary.	No recommendation	['Avoid piroxicam. Take an alternate therapy.', 'Take piroxicam with a reduced dose.', 'Take piroxicam with an increased dose.']	Proceed taking piroxicam as normal. There is no recommendation.	For individuals with an indeterminate CYP2C9 genotype, the clinical guidance for piroxicam suggests proceeding with caution. Since CYP2C9 metabolizes piroxicam, altered enzyme activity could impact drug clearance and increase the risk of adverse effects. It may be appropriate to consider alternative therapies or closely monitor for toxicity and therapeutic efficacy if piroxicam is used. Always consult a healthcare professional for personalized recommendations.	0.2760449599221966	0.4628053715279538	0.23501986608190753	0.6527573571954876	0.13435009	0.37049446	0.2272154	0.59905696	0.097879186	0.26741773	0.18145466	0.606647	-0.044446748	0.3282595	0.080221035	0.47654846	0.35984966	0.5253647	0.37665525	0.62960833	0
piroxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2C9 with regards to taking piroxicam? Give a 2-3 sentence summary.	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	['Proceed taking piroxicam as normal. There is no recommendation.', 'Take piroxicam with a reduced dose.', 'Take piroxicam with an increased dose.']	Avoid piroxicam. Take an alternate therapy.	For an individual identified as an Intermediate Metabolizer with a CYP2C9 activity score of 1.0, clinical guidance suggests using alternative non-steroidal anti-inflammatory drugs (NSAIDs) that are not metabolized by CYP2C9, such as aspirin or ibuprofen. This is because intermediate metabolizers have a reduced capacity to process piroxicam, which can lead to higher plasma concentrations and an increased risk of adverse effects. If piroxicam is considered necessary, a dose reduction and close monitoring for toxicity are recommended.	0.7119761454867416	0.6195424686978562	0.5102875155635677	0.6530625941168217	0.7882647	0.53939456	0.43539992	0.40563422	0.7794437	0.32969296	0.27722454	0.45797792	0.64034784	0.42809737	0.38362703	0.5467416	0.70361686	0.55366534	0.5251735	0.64023304	0
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking pitavastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid pitavastatin. Take an alternate therapy.', 'Take pitavastatin with a reduced dose.', 'Take pitavastatin with an increased dose.']	Proceed taking pitavastatin as normal. There is no recommendation.	For an individual with Increased Function of the SLCO1B1 gene, standard dosing of pitavastatin can generally be used without dose adjustment. Increased Function in SLCO1B1 is associated with enhanced hepatic uptake of the drug, potentially leading to improved efficacy and a lower risk of statin-associated myopathy compared to normal or decreased function variants. As always, it's important to monitor the patient for any adverse effects and adjust the treatment as necessary based on clinical response.	0.3897079857691637	0.3737630940950719	0.3664473720875596	0.5850022045484186	0.38928553	0.29842988	0.37568796	0.6388923	0.4582326	0.4484524	0.33967724	0.6776169	0.3871727	0.35794967	0.31679416	0.5103905	0.507399	0.47839725	0.5690939	0.5715485	1
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking pitavastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid pitavastatin. Take an alternate therapy.', 'Take pitavastatin with a reduced dose.', 'Take pitavastatin with an increased dose.']	Proceed taking pitavastatin as normal. There is no recommendation.	For an individual with normal function SLCO1B1, standard dosing of pitavastatin is recommended. This is because normal SLCO1B1 function suggests typical transporter activity, leading to normal pitavastatin pharmacokinetics and reduced risk of adverse effects such as statin-associated muscle symptoms. Therefore, no special dose adjustment or additional monitoring is generally needed.	0.39472815520284393	0.3737630940950719	0.3664473720875596	0.6800732365937321	0.49525726	0.29842988	0.37568796	0.58022296	0.51440567	0.4484524	0.33967724	0.69489646	0.4202913	0.35794967	0.31679416	0.57293147	0.3920082	0.47839725	0.5690939	0.6392487	1
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking pitavastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid pitavastatin. Take an alternate therapy.', 'Take pitavastatin with a reduced dose.', 'Take pitavastatin with an increased dose.']	Proceed taking pitavastatin as normal. There is no recommendation.	For an individual with an indeterminate result for the SLCO1B1 genotype, standard prescribing guidelines for pitavastatin can generally be followed. This is because pitavastatin is not significantly affected by variations in the SLCO1B1 gene, unlike other statins such as simvastatin. Therefore, no specific dosing adjustment is necessary based solely on an indeterminate SLCO1B1 status.	0.23873060742072894	0.4630618454204562	0.22193993993536645	0.6219118126093879	0.164747	0.29748428	0.1445972	0.58604443	0.040991865	0.1831894	0.07401031	0.58738244	0.0005773139	0.26902944	0.061543897	0.5217916	0.23685384	0.49070165	0.3865285	0.56084436	1
pitavastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking pitavastatin? Give a 2-3 sentence summary.	Prescribe ≤ 2mg as a starting dose and adjust doses of pitavastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >1mg. If dose >2mg needed for desired efficacy, consider an alternative statin (see Figure 1 of PMID: 35152405 for recommendations for alternative statins) or combination therapy (i.e. pitavastatin plus non-statin guideline directed medical therapy) (PMID: 30423391).	['Proceed taking pitavastatin as normal. There is no recommendation.', 'Avoid pitavastatin. Take an alternate therapy.']	Take pitavastatin with an altered dose.	For individuals with the Possible Decreased Function genotype of SLCO1B1, there is no need to adjust the dose of pitavastatin since it is not significantly affected by SLCO1B1 genotype. Clinical guidelines suggest that standard dosing can be used, with attention to monitoring for any potential adverse effects as with any patient on statin therapy.	0.6678803210213377	0.7079301600874583	0.6747860351461363	0.6208389957845416	0.68064636	0.662541	0.6088896	0.51859653	0.7233017	0.6653469	0.7214	0.56516165	0.65796894	0.6414486	0.60543317	0.56720996	0.6593137	0.69705236	0.60709536	0.6388083	0
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking plazomicin as normal. There is no recommendation.', 'Take plazomicin with a reduced dose.', 'Take plazomicin with an increased dose.']	Avoid plazomicin. Take an alternate therapy.	For patients with variants in the mitochondrial gene MT-RNR1, such as the m.1555A>G mutation, there is an increased risk of aminoglycoside-induced hearing loss. Clinical guidance would suggest avoiding aminoglycosides, including plazomicin, due to this significantly elevated risk. Alternative antibiotics should be considered to mitigate this risk.	0.6249846477220393	0.44713453050304053	0.3727812989366454	0.5582938989853617	0.7110009	0.54121494	0.4360198	0.5661242	0.6533003	0.35951793	0.36452243	0.5090172	0.69352037	0.38931897	0.39547262	0.44291496	0.6063685	0.5577428	0.44866768	0.5678589	1
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid plazomicin. Take an alternate therapy.', 'Take plazomicin with a reduced dose.', 'Take plazomicin with an increased dose.']	Proceed taking plazomicin as normal. There is no recommendation.	For individuals with a normal risk of aminoglycoside-induced hearing loss based on their MT-RNR1 genotype, no special precautions beyond standard clinical care are needed when prescribing plazomicin. Standard monitoring for ototoxicity is recommended for all patients taking aminoglycosides, but specific genetic concerns are minimal for those without risk-raising MT-RNR1 variants.	0.548997232976447	0.3900187973507548	0.3816843022229403	0.6129564423221625	0.57947135	0.42339256	0.42624438	0.581218	0.59126383	0.45138952	0.4431187	0.58624655	0.6726837	0.48940748	0.48607183	0.51206845	0.5844	0.45863158	0.50893956	0.5308975	0
plazomicin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking plazomicin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid plazomicin. Take an alternate therapy.', 'Take plazomicin with a reduced dose.', 'Take plazomicin with an increased dose.']	Proceed taking plazomicin as normal. There is no recommendation.	For individuals with uncertain risk of aminoglycoside-induced hearing loss related to MT-RNR1 mutations, genetic testing is recommended to determine their susceptibility. If a high-risk MT-RNR1 variant is present, alternatives to aminoglycosides, including plazomicin, should be considered due to the significant risk of ototoxicity. Genetic counseling may also be beneficial to help interpret the results and guide treatment options.	0.5472954223065659	0.3900187973507548	0.3816843022229403	0.4244783720006264	0.5130479	0.42339256	0.42624438	0.4273978	0.58980197	0.45138952	0.4431187	0.42413476	0.65630347	0.48940748	0.48607183	0.39435193	0.5811435	0.45863158	0.50893956	0.37941918	0
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking pravastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid pravastatin. Take an alternate therapy.', 'Take pravastatin with a reduced dose.', 'Take pravastatin with an increased dose.']	Proceed taking pravastatin as normal. There is no recommendation.	For individuals with the Increased Function (also known as *1b/*1b or *17/*17) genotype of the SLCO1B1 gene, there is generally no need for dosage adjustment or additional clinical concern when taking pravastatin. Increased Function can lead to higher hepatic uptake of the drug, which typically translates to an effective therapeutic response with the standard dose. However, as always, individual patient circumstances should be considered, and monitoring for efficacy and tolerance is recommended.	0.3647212248074096	0.3605128933336128	0.35423014280798865	0.5607000200033306	0.3369945	0.31167486	0.37594125	0.51783365	0.44312423	0.44127464	0.32952705	0.65775025	0.37566537	0.34740877	0.31569842	0.48757273	0.4799927	0.49523878	0.57142025	0.57799923	1
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking pravastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid pravastatin. Take an alternate therapy.', 'Take pravastatin with a reduced dose.', 'Take pravastatin with an increased dose.']	Proceed taking pravastatin as normal. There is no recommendation.	For individuals with normal function SLCO1B1, standard clinical guidelines suggest that there is no need for dosage adjustment when taking pravastatin. These patients are at normal risk for statin-associated side effects, such as myopathy, and can follow the typical dosing recommendations to achieve the desired lipid-lowering effects.	0.4099811647535072	0.3605128933336128	0.35423014280798865	0.6727772825473659	0.4110055	0.31167486	0.37594125	0.6669912	0.42883915	0.44127464	0.32952705	0.6889568	0.36013594	0.34740877	0.31569842	0.57542074	0.4599903	0.49523878	0.57142025	0.6381439	1
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking pravastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid pravastatin. Take an alternate therapy.', 'Take pravastatin with a reduced dose.', 'Take pravastatin with an increased dose.']	Proceed taking pravastatin as normal. There is no recommendation.	For an individual with an indeterminate SLCO1B1 genotype taking pravastatin, clinical guidance is not explicitly altered solely based on this genotype status, given that the SLCO1B1 variant significantly impacts statins like simvastatin more than pravastatin. Standard clinical practice would involve starting pravastatin at the recommended dose and monitoring the patient for efficacy and possible side effects, adjusting the treatment plan as necessary based on their clinical response and tolerance.	0.21834078547118757	0.4605310803309176	0.2121467677977377	0.5862151623795684	0.092730895	0.30104128	0.14220761	0.5580448	0.05163043	0.18772747	0.07142186	0.59552556	-0.027764093	0.28907138	0.06006204	0.5018797	0.24488758	0.5008195	0.40348327	0.5441803	0
pravastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking pravastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of pravastatin based on disease-specific guidelines. Prescriber should be aware of possible increased risk for myopathy with pravastatin especially with doses >40mg per day.	['Avoid pravastatin. Take an alternate therapy.', 'Take pravastatin with a reduced dose.', 'Take pravastatin with an increased dose.']	Proceed taking pravastatin as normal. There is no recommendation.	For individuals with decreased function alleles of the SLCO1B1 gene taking pravastatin, clinical guidelines from resources such as CPIC (Clinical Pharmacogenetics Implementation Consortium) suggest a cautious approach. Although pravastatin is less affected by SLCO1B1 variations compared to other statins like simvastatin, clinicians may still consider using lower doses or monitoring cholesterol levels and potential statin-related side effects more closely to ensure efficacy and minimize risk.	0.6776113473155273	0.6201803171081698	0.6546708881197681	0.5784849670575437	0.5752833	0.5304786	0.5443112	0.55554867	0.5345317	0.656276	0.51624763	0.59066635	0.4303537	0.52027243	0.5000933	0.48671544	0.48251778	0.5667449	0.6025364	0.49184367	0
primaquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking primaquine? Give a 2-3 sentence summary.	Avoid primaquine, except in the following cases where established expert consensus guidelines for the treatment of malaria should be followed: (1) Treating Plasmodium vivax or Plasmodium ovale malaria for radical cure of liver-stage infections: 0.75 mg/kg once weekly x8 weeks (WHO) or 45 mg once weekly x8 weeks (CDC) - with close monitoring for hemolysis; (2) Treating Plasmodium falciparum malaria by using primaquine single dose as a gametocytocide at 0.25 mg/kg (WHO) - without need for monitoring for hemolysis.	['Proceed taking primaquine as normal. There is no recommendation.', 'Take primaquine with a reduced dose.', 'Take primaquine with an increased dose.']	Avoid primaquine. Take an alternate therapy.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), taking primaquine can pose a significant risk as it may induce hemolytic anemia. Clinical guidance generally recommends either avoiding primaquine or using it with extreme caution, with close monitoring of hemoglobin levels and potential alternative treatments considered. Genetic testing for G6PD deficiency should be performed prior to initiating primaquine therapy.	0.7019202500938365	0.6726697594343474	0.6680278298285139	0.602920379233912	0.61221266	0.5828728	0.54003143	0.5732484	0.6518047	0.5808973	0.5449775	0.6083846	0.5590982	0.6139143	0.56615263	0.5995722	0.50864905	0.5496724	0.5399325	0.6191976	0
primaquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking primaquine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid primaquine. Take an alternate therapy.', 'Take primaquine with a reduced dose.', 'Take primaquine with an increased dose.']	Proceed taking primaquine as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, primaquine should be administered with caution due to the risk of hemolysis. It is typically advised to conduct a confirmatory G6PD test to ensure safety before prescribing primaquine. If testing is not feasible, close monitoring for signs of hemolysis during primaquine therapy is recommended.	0.624372801675433	0.39566420069049946	0.33566618654399	0.5918771239864457	0.55669135	0.23415242	0.29331616	0.59212327	0.547294	0.29548293	0.21225019	0.664244	0.5897755	0.28192827	0.21875137	0.5997899	0.5747869	0.40196037	0.39547744	0.5175584	0
primaquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking primaquine? Give a 2-3 sentence summary.	Avoid primaquine	['Proceed taking primaquine as normal. There is no recommendation.', 'Take primaquine with a reduced dose.', 'Take primaquine with an increased dose.']	Avoid primaquine. Take an alternate therapy.	For individuals who are G6PD-deficient, particularly those with chronic non-spherocytic hemolytic anemia (CNSHA), the use of primaquine is contraindicated. This is because primaquine can cause severe hemolysis in G6PD-deficient patients, leading to potentially life-threatening complications. Alternative antimalarial medications that do not trigger hemolysis in G6PD-deficient individuals should be considered.	0.636527362967418	0.794146442163389	0.7328149519703304	0.589900698236445	0.6558274	0.79070204	0.6753637	0.5819173	0.5800147	0.81679314	0.7111111	0.54071665	0.6228762	0.85295165	0.70648694	0.57670057	0.6365413	0.91153234	0.7195818	0.58292776	1
primaquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking primaquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid primaquine. Take an alternate therapy.', 'Take primaquine with a reduced dose.', 'Take primaquine with an increased dose.']	Proceed taking primaquine as normal. There is no recommendation.	For individuals with a normal glucose-6-phosphate dehydrogenase (G6PD) status, primaquine can be used safely for the treatment and prevention of malaria, as they do not have the risk for hemolytic anemia associated with G6PD deficiency. This assessment should be confirmed through appropriate diagnostic testing before prescribing primaquine to ensure patient safety.	0.6217301566038306	0.4431608929224357	0.3199344662133465	0.5822149416926382	0.47863492	0.37534258	0.1933286	0.57323486	0.3721544	0.2533321	0.11490488	0.63153356	0.32606837	0.1868879	0.11046171	0.56472605	0.5326931	0.42969748	0.3160666	0.51724064	1
quinine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking quinine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid quinine. Take an alternate therapy.', 'Take quinine with a reduced dose.', 'Take quinine with an increased dose.']	Proceed taking quinine as normal. There is no recommendation.	Individuals who are deficient in Glucose-6-Phosphate Dehydrogenase (G6PD) should avoid taking quinine due to the risk of hemolytic anemia. G6PD deficiency can lead to the breakdown of red blood cells when exposed to oxidative stressors like quinine, resulting in potentially severe health complications. Clinical guidance typically involves choosing alternative treatments that do not pose a risk of hemolysis.	0.6371005672241384	0.4969051200897552	0.3769175480554918	0.5370477267832675	0.5747695	0.5371987	0.32859662	0.63803715	0.5858462	0.43740442	0.26512936	0.6799399	0.5652505	0.4240034	0.32977447	0.5274391	0.5379965	0.50530875	0.39155793	0.54819745	0
quinine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking quinine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid quinine. Take an alternate therapy.', 'Take quinine with a reduced dose.', 'Take quinine with an increased dose.']	Proceed taking quinine as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, it is important to exercise caution when prescribing quinine due to the potential risk of hemolytic anemia. Clinicians should consider alternative treatments and, if quinine use is deemed necessary, closely monitor the patient for signs of hemolysis. Genetic testing to definitively determine G6PD status is also recommended before initiating treatment.	0.6676346226903044	0.4033952925443295	0.3370441602168621	0.5804393358387685	0.594446	0.2657501	0.28618404	0.5895927	0.59718096	0.30287373	0.23640965	0.67112267	0.60878426	0.23715201	0.20171905	0.5170789	0.60499257	0.40367135	0.38905132	0.5373284	0
quinine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking quinine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid quinine. Take an alternate therapy.', 'Take quinine with a reduced dose.', 'Take quinine with an increased dose.']	Proceed taking quinine as normal. There is no recommendation.	Individuals with G6PD deficiency and chronic non-spherocytic hemolytic anemia (CNSHA) are at risk for hemolysis when taking quinine. Clinical guidance typically advises avoiding quinine in these patients to prevent hemolytic episodes. Alternative treatments should be considered, and any use of quinine must be closely monitored by healthcare professionals.	0.4585192773415873	0.403767383188856	0.43113344576740625	0.5476227771275276	0.57833064	0.496057	0.4700341	0.6830279	0.5312291	0.4365066	0.40236148	0.68504184	0.48653314	0.36027148	0.3220807	0.52110946	0.5626544	0.4022845	0.46001709	0.5258772	0
quinine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking quinine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid quinine. Take an alternate therapy.', 'Take quinine with a reduced dose.', 'Take quinine with an increased dose.']	Proceed taking quinine as normal. There is no recommendation.	For a patient with normal G6PD (glucose-6-phosphate dehydrogenase) levels, there are no specific restrictions or additional risks when taking quinine. Such patients can typically use quinine without an elevated risk of hemolytic anemia, which is a concern for individuals with G6PD deficiency. However, standard precautions and monitoring for side effects as per general clinical guidelines for quinine use remain applicable.	0.6267088491448318	0.428209212634223	0.3001367924520412	0.6345137979618541	0.49554974	0.40508375	0.18798836	0.67029214	0.45627317	0.2789764	0.12627238	0.7112098	0.43616658	0.13878313	0.08471274	0.51836073	0.5410951	0.41710627	0.29671526	0.54962265	1
rasburicase	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking rasburicase? Give a 2-3 sentence summary.	Avoid use	['Proceed taking rasburicase as normal. There is no recommendation.', 'Take rasburicase with a reduced dose.', 'Take rasburicase with an increased dose.']	Avoid rasburicase. Take an alternate therapy.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), the use of rasburicase is contraindicated. This is due to the increased risk of hemolysis and methemoglobinemia, which can cause severe and potentially life-threatening complications in G6PD-deficient patients. Clinicians should consider alternative therapies that do not carry this risk.	0.2834792147134066	0.30640423271348366	0.2594581760092361	0.6432461624996142	0.37662017	0.43802205	0.3459866	0.61939967	0.23612204	0.24215315	0.23364848	0.6430009	0.17535931	0.18794435	0.17483377	0.65344465	0.46527827	0.59386885	0.47473124	0.6276633	1
rasburicase	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking rasburicase? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid rasburicase. Take an alternate therapy.', 'Take rasburicase with a reduced dose.', 'Take rasburicase with an increased dose.']	Proceed taking rasburicase as normal. There is no recommendation.	For a patient with an indeterminate G6PD status, it is generally recommended to avoid using rasburicase due to the risk of severe hemolytic anemia. Confirmatory G6PD testing should be performed prior to administration to ensure patient safety and guide appropriate treatment decisions. If G6PD deficiency is confirmed or cannot be ruled out, alternative therapies should be considered.	0.667002990739214	0.3963689143210648	0.3328201957120809	0.5960315635056735	0.49119624	0.33025688	0.32421276	0.63265246	0.63600945	0.32620984	0.31580436	0.6196561	0.68823415	0.32952443	0.28478158	0.61992115	0.5633266	0.36802074	0.3729742	0.5322985	0
rasburicase	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking rasburicase? Give a 2-3 sentence summary.	Avoid use	['Proceed taking rasburicase as normal. There is no recommendation.', 'Take rasburicase with a reduced dose.', 'Take rasburicase with an increased dose.']	Avoid rasburicase. Take an alternate therapy.	Rasburicase is contraindicated in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency, including those with chronic non-spherocytic hemolytic anemia (CNSHA), due to the high risk of severe hemolysis and methemoglobinemia. Alternative therapies for the management of hyperuricemia should be considered in these individuals.	0.23539177524441152	0.30640423271348366	0.2594581760092361	0.6567831643749447	0.3091305	0.43802205	0.3459866	0.606527	0.16908237	0.24215315	0.23364848	0.6099778	0.07766628	0.18794435	0.17483377	0.64735186	0.38872325	0.59386885	0.47473124	0.62772137	1
rasburicase	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking rasburicase? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid rasburicase. Take an alternate therapy.', 'Take rasburicase with a reduced dose.', 'Take rasburicase with an increased dose.']	Proceed taking rasburicase as normal. There is no recommendation.	For individuals who are normal for G6PD (Glucose-6-Phosphate Dehydrogenase), administration of rasburicase is generally safe. G6PD deficiency is associated with a higher risk of hemolysis when taking rasburicase, but those with normal G6PD levels do not have this increased risk. Hence, routine monitoring for hemolysis specifically induced by rasburicase is not necessary in these patients.	0.5983106267081671	0.4324959435393275	0.3208296821589788	0.635770134847084	0.53244954	0.43342662	0.2530469	0.6207957	0.5005169	0.2855618	0.18659027	0.65387094	0.3978993	0.16439039	0.07426435	0.6168536	0.57049125	0.39573997	0.3026149	0.51641226	1
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking ribostamycin as normal. There is no recommendation.', 'Take ribostamycin with a reduced dose.', 'Take ribostamycin with an increased dose.']	Avoid ribostamycin. Take an alternate therapy.	Individuals who have a genetic variant in the MT-RNR1 gene associated with an increased risk of aminoglycoside-induced hearing loss should generally avoid the use of aminoglycosides, including ribostamycin, due to the heightened risk of ototoxicity. Alternative antibiotics that do not carry the same risk of hearing impairment should be considered, and a healthcare professional should be consulted to determine the safest and most effective treatment option.	0.7151456718522234	0.4879245768214349	0.4221127640228892	0.5670284465377663	0.7902655	0.61764467	0.48445663	0.59544224	0.7781612	0.49742377	0.47291005	0.58174145	0.7835694	0.4541491	0.44387388	0.55690825	0.67281264	0.60501087	0.4826611	0.61651045	1
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid ribostamycin. Take an alternate therapy.', 'Take ribostamycin with a reduced dose.', 'Take ribostamycin with an increased dose.']	Proceed taking ribostamycin as normal. There is no recommendation.	For individuals with a normal risk of aminoglycoside-induced hearing loss due to the MT-RNR1 gene, clinical guidelines suggest that they are not at an increased risk of developing hearing loss from aminoglycoside antibiotics, including ribostamycin. Therefore, standard dosing and precautions for aminoglycoside administration can be followed, but routine monitoring for ototoxicity is still recommended as with all patients.	0.6511056794887315	0.43800331469768117	0.4380481909803425	0.584813449141893	0.6035189	0.44586873	0.48870465	0.5918295	0.6816632	0.5271012	0.5449567	0.60975665	0.7530986	0.50566316	0.505999	0.46640188	0.5727441	0.48059472	0.53322953	0.54200727	1
ribostamycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking ribostamycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid ribostamycin. Take an alternate therapy.', 'Take ribostamycin with a reduced dose.', 'Take ribostamycin with an increased dose.']	Proceed taking ribostamycin as normal. There is no recommendation.	For individuals uncertain about their risk of aminoglycoside-induced hearing loss due to MT-RNR1 variants, it is recommended to avoid aminoglycosides such as ribostamycin or to consider alternative antibiotics whenever possible. Genetic testing for MT-RNR1 mutations can provide more clarity about their susceptibility, and consulting with a healthcare provider for personalized advice is advised to minimize potential ototoxicity.	0.5877749311613655	0.43800331469768117	0.4380481909803425	0.5097011107132946	0.5273379	0.44586873	0.48870465	0.59296286	0.65768903	0.5271012	0.5449567	0.5265178	0.68249166	0.50566316	0.505999	0.4272261	0.604298	0.48059472	0.53322953	0.4820018	0
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Increased Function for SLCO1B1 with regards to taking rosuvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.	['Avoid rosuvastatin. Take an alternate therapy.', 'Take rosuvastatin with a reduced dose.', 'Take rosuvastatin with an increased dose.']	Proceed taking rosuvastatin as normal. There is no recommendation.	For patients with normal function of the ABCG2 gene and increased function of the SLCO1B1 gene, the clinical guidance for taking rosuvastatin typically indicates no need for dose adjustments based solely on these genetic factors. These patients are likely to have normal drug metabolism and reduced risk of statin-induced myopathy. However, individual clinical factors and potential drug interactions should still be considered when determining the appropriate rosuvastatin dose.	0.5953767388289213	0.5866126035048139	0.6182490413562952	0.5791370098346894	0.5690863	0.42433625	0.52305967	0.61021715	0.67369556	0.721686	0.62849593	0.6667015	0.6381892	0.52674925	0.53638107	0.5354503	0.6109516	0.66564703	0.70435256	0.60469395	1
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Normal Function for ABCG2 and Decreased Function for SLCO1B1 with regards to taking rosuvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines. Prescriber should be aware of possible increased risk for myopathy especially for doses >20mg.	['Avoid rosuvastatin. Take an alternate therapy.', 'Take rosuvastatin with a reduced dose.', 'Take rosuvastatin with an increased dose.']	Proceed taking rosuvastatin as normal. There is no recommendation.	For a patient with Normal Function for ABCG2 and Decreased Function for SLCO1B1, clinical guidance suggests considering a lower dose of rosuvastatin to minimize the risk of adverse effects, particularly myopathy. This is because decreased function of SLCO1B1 can lead to increased systemic exposure of rosuvastatin, heightening the potential for toxicity. Regular monitoring and possible dose adjustments based on the patient's response and tolerance are also recommended.	0.6863380677346086	0.6027791998001257	0.6433970415825884	0.5783393860043634	0.66957384	0.51403755	0.5700907	0.5769961	0.6836941	0.68006396	0.5572726	0.7055943	0.5725232	0.5050035	0.49876913	0.5086622	0.6358513	0.57443494	0.60648257	0.5420311	0
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and Normal Function for SLCO1B1 with regards to taking rosuvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific and specific population guidelines.	['Avoid rosuvastatin. Take an alternate therapy.', 'Take rosuvastatin with a reduced dose.', 'Take rosuvastatin with an increased dose.']	Proceed taking rosuvastatin as normal. There is no recommendation.	Patients with a decreased function in the ABCG2 gene may have higher plasma levels of rosuvastatin, raising the risk of side effects like muscle toxicity. Given the normal function of SLCO1B1, this would not affect rosuvastatin metabolism significantly, but clinicians should consider starting at a lower dose and monitoring the patient closely for adverse reactions. Adjustments can be made based on the patient's response and tolerance.	0.5308670462390727	0.5866126035048139	0.6182490413562952	0.5054503001570351	0.43832964	0.42433625	0.52305967	0.5728961	0.5819162	0.721686	0.62849593	0.63086027	0.49673682	0.52674925	0.53638107	0.4755981	0.48179218	0.66564703	0.70435256	0.49902353	0
rosuvastatin	ABCG2;SLCO1B1	What would be the clinical guidance for someone who is Decreased Function for ABCG2 and No Result for SLCO1B1 with regards to taking rosuvastatin? Give a 2-3 sentence summary.	Based on ABCG2 status, prescribe desired starting dose and adjust doses of rosuvastatin based on disease-specific guidelines and specific population guidelines. SLCO1B1 genotype result is not available.	['Avoid rosuvastatin. Take an alternate therapy.', 'Take rosuvastatin with a reduced dose.', 'Take rosuvastatin with an increased dose.']	Proceed taking rosuvastatin as normal. There is no recommendation.	For an individual with decreased function of the ABCG2 gene and no result for the SLCO1B1 gene, clinical guidance would typically suggest starting rosuvastatin at a lower dose to minimize the risk of rosuvastatin-associated myopathy. ABCG2 decreases the efflux of rosuvastatin, leading to increased plasma concentrations. Therefore, cautious dosing and monitoring for adverse effects are recommended.	0.8225090811142294	0.5745060604197239	0.6018118532920312	0.5384398537269832	0.72703284	0.58718556	0.48963356	0.5716042	0.7981206	0.67801774	0.5919896	0.63783807	0.751897	0.50296926	0.48327026	0.5305974	0.77009517	0.6010229	0.5738714	0.55679387	0
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is No Result for CYP2B6 and Indeterminate for CYP2C19 with regards to taking sertraline? Give a 2-3 sentence summary.	No recommendation	['Avoid sertraline. Take an alternate therapy.', 'Take sertraline with a reduced dose.', 'Take sertraline with an increased dose.']	Proceed taking sertraline as normal. There is no recommendation.	"Clinical guidance regarding the use of sertraline for a patient with ""No Result"" for CYP2B6 and ""Indeterminate"" for CYP2C19 genotyping would likely emphasize caution and close monitoring. Since genotyping results are not definitive, it may be important to start the patient at a standard dose while closely monitoring for adverse effects or inefficacy, and adjust the dose accordingly. Consulting with a pharmacogenomics specialist could further personalize the treatment approach."	0.2695940971887288	0.43277317209882915	0.20947415282080495	0.5959621783487544	0.16760838	0.31504312	0.16553697	0.60685974	0.047176033	0.17384872	0.10388877	0.6265956	0.028657876	0.3057449	0.091744155	0.48826867	0.24529622	0.5215011	0.3970836	0.60283977	0
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid sertraline. Take an alternate therapy.', 'Take sertraline with a reduced dose.', 'Take sertraline with an increased dose.']	Proceed taking sertraline as normal. There is no recommendation.	For a patient who is an ultrarapid metabolizer of CYP2B6 (CYP2B6*1A/*1A) and has no result for CYP2C19, the clinical guidance for taking sertraline would typically focus primarily on sertraline's interaction with CYP2C19, as it is a major pathway for its metabolism. Since there is no result for CYP2C19, it would be prudent to monitor the patient closely for therapeutic efficacy and potential side effects, adjusting the dose as necessary based on clinical response, instead of relying solely on pharmacogenetic data. It is always essential to tailor treatment to the individual, considering both genetic information and clinical observations.	0.35163210414201496	0.46294307986328287	0.49694104974587955	0.5830558220234817	0.3830155	0.38907078	0.4236897	0.5394349	0.32597613	0.48816007	0.40268946	0.61781484	0.33164465	0.4401629	0.43594792	0.51484776	0.36853927	0.51360846	0.58839625	0.6027084	0
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2B6 and Ultrarapid Metabolizer for CYP2C19 with regards to taking sertraline? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid sertraline. Take an alternate therapy.', 'Take sertraline with a reduced dose.', 'Take sertraline with an increased dose.']	Proceed taking sertraline as normal. There is no recommendation.	For someone who is an Ultrarapid Metabolizer for CYP2C19 and Indeterminate for CYP2B6, clinical guidance for taking sertraline would generally start with standard dosing. Monitoring for efficacy and side effects is critical, as the ultrarapid CYP2C19 metabolism may lead to lower drug levels, potentially reducing the medication's efficacy. Adjustments might be needed based on the clinical response and tolerability.	0.44325516921840874	0.46294307986328287	0.49694104974587955	0.6193838600962057	0.53709686	0.38907078	0.4236897	0.5968846	0.45544916	0.48816007	0.40268946	0.71400315	0.44735935	0.4401629	0.43594792	0.53478134	0.519811	0.51360846	0.58839625	0.6398409	0
sertraline	CYP2B6;CYP2C19	What would be the clinical guidance for someone who is Rapid Metabolizer for CYP2B6 and No Result for CYP2C19 with regards to taking sertraline? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid sertraline. Take an alternate therapy.', 'Take sertraline with a reduced dose.', 'Take sertraline with an increased dose.']	Proceed taking sertraline as normal. There is no recommendation.	For a rapid metabolizer of CYP2B6 taking sertraline, clinical guidance suggests that standard dosages are typically appropriate, as this enzyme is less involved in sertraline metabolism compared to CYP2C19. The lack of a result for CYP2C19 makes it difficult to predict the enzyme's impact, but close monitoring for efficacy and adverse effects is advisable due to the important role of CYP2C19 in metabolizing sertraline.	0.36894680532107105	0.46294307986328287	0.49694104974587955	0.5858183783426817	0.36926338	0.38907078	0.4236897	0.5631586	0.35673195	0.48816007	0.40268946	0.6158476	0.33912054	0.4401629	0.43594792	0.5523144	0.3433642	0.51360846	0.58839625	0.6030883	1
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking sevoflurane? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking sevoflurane as normal. There is no recommendation.', 'Take sevoflurane with a reduced dose.', 'Take sevoflurane with an increased dose.']	Avoid sevoflurane. Take an alternate therapy.	"In cases where an individual has a ""No Result"" for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S, clinical guidance typically involves exercising caution when administering sevoflurane, as both RYR1 and CACNA1S variants are linked to malignant hyperthermia (MH). While the absence of test results may not definitively rule out MH susceptibility, healthcare providers often opt for alternative anesthesia methods or agents to mitigate potential risks."	0.6673299193080776	0.4575896321223662	0.3947705506435016	0.49635972797553357	0.6850448	0.5242742	0.41952014	0.5727198	0.72720087	0.3899753	0.32202262	0.56078	0.70132977	0.38056022	0.37776622	0.47763315	0.66403043	0.51105374	0.48754653	0.52254134	0
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking sevoflurane? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking sevoflurane as normal. There is no recommendation.', 'Take sevoflurane with a reduced dose.', 'Take sevoflurane with an increased dose.']	Avoid sevoflurane. Take an alternate therapy.	Individuals who have Malignant Hyperthermia Susceptibility (MHS) associated with RYR1 or CACNA1S mutations should avoid the use of sevoflurane and other volatile anesthetics, as these agents can trigger a malignant hyperthermia crisis. Clinical guidelines recommend using alternative non-triggering anesthetics, such as intravenous anesthetics, and ensure that dantrolene is readily available for emergency use.	0.7720301705693873	0.45459559531831256	0.39042562158663485	0.515865655129211	0.8277407	0.53018004	0.42703304	0.6380814	0.79262	0.40283647	0.3430284	0.5688911	0.80691034	0.40479824	0.40274474	0.48273307	0.6742132	0.520688	0.492772	0.60668826	1
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and No Result for CACNA1S with regards to taking sevoflurane? Give a 2-3 sentence summary.	No CACNA1S genotype is available. Based on RYR1 status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid sevoflurane. Take an alternate therapy.', 'Take sevoflurane with a reduced dose.', 'Take sevoflurane with an increased dose.']	Proceed taking sevoflurane as normal. There is no recommendation.	Given the genetic findings of Uncertain Susceptibility for the RYR1 gene and No Result for the CACNA1S gene, there is an unclear risk for malignant hyperthermia (MH) with the use of sevoflurane. It would be prudent for clinicians to exercise caution and consider an alternative anesthetic agent or recommend further genetic testing and/or a muscle biopsy to ascertain MH susceptibility before administering sevoflurane.	0.6635945336348398	0.40464234023458406	0.3503658986192588	0.5100495301457634	0.6868187	0.44700617	0.30187812	0.51107293	0.6438337	0.28511003	0.27155432	0.49262452	0.48614684	0.34939757	0.28251502	0.4844463	0.6928943	0.41315052	0.3649827	0.49306425	1
sevoflurane	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking sevoflurane? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid sevoflurane. Take an alternate therapy.', 'Take sevoflurane with a reduced dose.', 'Take sevoflurane with an increased dose.']	Proceed taking sevoflurane as normal. There is no recommendation.	For a patient with no result for RYR1 and uncertain susceptibility for CACNA1S, there is insufficient information to definitively assess the risk for malignant hyperthermia (MH) when exposed to sevoflurane. Given this uncertainty, it is advisable to proceed with caution and consider alternative non-triggering anesthetic agents, or consult with a specialist in MH or clinical pharmacogenomics for further evaluation before using sevoflurane.	0.6723000082694708	0.4204553149768568	0.36874359599217915	0.5826792509729266	0.6334818	0.44580105	0.28976867	0.5427206	0.61051536	0.2849356	0.26839408	0.5366182	0.4956407	0.3944336	0.3255848	0.48976666	0.70119244	0.4129067	0.3670446	0.5569684	0
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Increased Function for SLCO1B1 with regards to taking simvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid simvastatin. Take an alternate therapy.', 'Take simvastatin with a reduced dose.', 'Take simvastatin with an increased dose.']	Proceed taking simvastatin as normal. There is no recommendation.	For an individual with increased SLCO1B1 function, the clinical guidance suggests they may have enhanced hepatic uptake of simvastatin, potentially reducing the risk of statin-associated myopathy. Therefore, standard dosing of simvastatin can typically be used without adjustment, as the increased function should help in the efficient clearance of the drug, contributing to a favorable safety profile. However, it's always essential to monitor the patient for efficacy and any adverse effects.	0.37530613305252897	0.35523205264065777	0.3624732560941654	0.5795520867013156	0.44660944	0.29368174	0.3737919	0.64079416	0.48645118	0.4399604	0.33405912	0.7201174	0.38755265	0.36816946	0.32725692	0.590819	0.52830935	0.5187252	0.58938473	0.58250374	1
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Normal Function for SLCO1B1 with regards to taking simvastatin? Give a 2-3 sentence summary.	Prescribe desired starting dose and adjust doses based on disease-specific guidelines.	['Avoid simvastatin. Take an alternate therapy.', 'Take simvastatin with a reduced dose.', 'Take simvastatin with an increased dose.']	Proceed taking simvastatin as normal. There is no recommendation.	For individuals with normal function of the SLCO1B1 gene, standard dosing guidelines for simvastatin can generally be followed. Clinical evidence indicates that these individuals are less likely to experience statin-induced myopathy and can tolerate the typical therapeutic doses of simvastatin recommended for managing hyperlipidemia. It is still important to monitor for any adverse effects as with any statin therapy.	0.3927794294882144	0.35523205264065777	0.3624732560941654	0.5963110173731441	0.47290778	0.29368174	0.3737919	0.60359484	0.42459542	0.4399604	0.33405912	0.7193207	0.3595302	0.36816946	0.32725692	0.5724011	0.4722107	0.5187252	0.58938473	0.60349405	1
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Indeterminate for SLCO1B1 with regards to taking simvastatin? Give a 2-3 sentence summary.	No recommendation	['Avoid simvastatin. Take an alternate therapy.', 'Take simvastatin with a reduced dose.', 'Take simvastatin with an increased dose.']	Proceed taking simvastatin as normal. There is no recommendation.	For a patient who is Indeterminate for SLCO1B1 genotype, clinical guidance generally suggests starting simvastatin at the lowest possible dose and closely monitoring for signs of muscle toxicity, such as myopathy. If adverse effects occur, considering alternative statins or lipid-lowering therapies with a different metabolic pathway may be appropriate to safely achieve treatment goals.	0.2236366162928019	0.46253864155644125	0.2085848343734027	0.5650371693519878	0.20296377	0.2978554	0.1444722	0.63775283	0.111748576	0.19657004	0.08326495	0.6661544	0.04547799	0.3180475	0.08048644	0.59503835	0.27140146	0.52485114	0.40065336	0.56389445	0
simvastatin	SLCO1B1	What would be the clinical guidance for someone who is Possible Decreased Function for SLCO1B1 with regards to taking simvastatin? Give a 2-3 sentence summary.	Prescribe an alternative statin depending on the desired potency (see Figure 1 of PMID: 35152405 for recommendations for alternative statins). If simvastatin therapy is warranted, limit dose to <20mg/day.	['Proceed taking simvastatin as normal. There is no recommendation.', 'Take simvastatin with a reduced dose.', 'Take simvastatin with an increased dose.']	Avoid simvastatin. Take an alternate therapy.	For individuals identified as having a Possible Decreased Function SLCO1B1 genotype, there is an increased risk for simvastatin-induced myopathy. Clinical guidelines recommend either prescribing a lower dose of simvastatin or considering an alternative statin, such as pravastatin or rosuvastatin, which are less dependent on the SLCO1B1 transporter and thus carry a lower risk of myopathy.	0.6753923038012147	0.7277901300815722	0.652901553746213	0.6099404200758389	0.68330365	0.73048866	0.6647575	0.6420806	0.65375763	0.81392705	0.7618963	0.6563997	0.5460813	0.55765635	0.5678298	0.605547	0.5318976	0.6680072	0.593826	0.6250266	1
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking streptomycin as normal. There is no recommendation.', 'Take streptomycin with a reduced dose.', 'Take streptomycin with an increased dose.']	Avoid streptomycin. Take an alternate therapy.	Individuals with specific variants in the MT-RNR1 gene, such as the m.1555A>G mutation, are at increased risk of developing aminoglycoside-induced hearing loss. As a result, clinical guidance typically recommends avoiding aminoglycosides like streptomycin in these patients when possible. Alternative antibiotics should be considered to prevent potential ototoxicity.	0.6692192175655188	0.5141613250906227	0.4286335476787489	0.4782295536375931	0.7168467	0.60813195	0.48939642	0.54940045	0.73328316	0.51122487	0.48077095	0.53374225	0.76873785	0.41462842	0.4065721	0.37779626	0.62653303	0.5992293	0.5111726	0.56479025	1
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid streptomycin. Take an alternate therapy.', 'Take streptomycin with a reduced dose.', 'Take streptomycin with an increased dose.']	Proceed taking streptomycin as normal. There is no recommendation.	For individuals classified as normal risk for aminoglycoside-induced hearing loss based on MT-RNR1 pharmacogenomics, standard clinical guidelines recommend the use of streptomycin without specific genetic-related dosage adjustments. However, it is still important to monitor these patients for ototoxicity, as other non-genetic factors can also contribute to hearing loss.	0.6871228167230953	0.4546156198967064	0.45307208590469505	0.5618067181670167	0.58279175	0.4591264	0.49132946	0.5770783	0.67393494	0.5299308	0.5460023	0.5725944	0.6747664	0.4724817	0.4446281	0.4546796	0.6384799	0.5356523	0.5680272	0.56311035	0
streptomycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking streptomycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid streptomycin. Take an alternate therapy.', 'Take streptomycin with a reduced dose.', 'Take streptomycin with an increased dose.']	Proceed taking streptomycin as normal. There is no recommendation.	Individuals with certain genetic variants in the MT-RNR1 gene are at risk of aminoglycoside-induced hearing loss, even at standard doses. Clinical guidance generally recommends avoiding aminoglycosides, like streptomycin, in these patients when possible, to prevent irreversible hearing damage. Genetic testing for MT-RNR1 variants can help determine the level of risk and inform safer antibiotic choices.	0.6139514520562767	0.4546156198967064	0.45307208590469505	0.44778456394916055	0.4874682	0.4591264	0.49132946	0.50914466	0.6168532	0.5299308	0.5460023	0.49843705	0.67127603	0.4724817	0.4446281	0.384278	0.58206177	0.5356523	0.5680272	0.43895948	0
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Uncertain Susceptibility for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking succinylcholine? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking succinylcholine as normal. There is no recommendation.', 'Take succinylcholine with a reduced dose.', 'Take succinylcholine with an increased dose.']	Avoid succinylcholine. Take an alternate therapy.	For individuals with uncertain susceptibility for the RYR1 gene and a confirmed malignant hyperthermia susceptibility (MHS) for the CACNA1S gene, the clinical guidance would typically recommend caution or avoidance of succinylcholine. Succinylcholine is a known trigger for malignant hyperthermia, and individuals with MHS are at increased risk for this life-threatening condition when exposed to the drug. Alternative anesthetic agents that do not pose this risk should be considered.	0.7693720420371962	0.5278563757058227	0.4822130187439477	0.5408717884764229	0.74475765	0.5853606	0.49024776	0.5299846	0.8418445	0.51908237	0.42098665	0.5713564	0.81103504	0.5455103	0.48073363	0.5058505	0.68321216	0.53655106	0.5072245	0.58126324	1
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Malignant Hyperthermia Susceptibility for CACNA1S with regards to taking succinylcholine? Give a 2-3 sentence summary.	Based on CACNA1S status, halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking succinylcholine as normal. There is no recommendation.', 'Take succinylcholine with a reduced dose.', 'Take succinylcholine with an increased dose.']	Avoid succinylcholine. Take an alternate therapy.	If a patient has no detectable result for RYR1 but is positive for malignant hyperthermia susceptibility related to CACNA1S, caution is advised when considering the administration of succinylcholine. Due to the increased risk of triggering malignant hyperthermia, an alternative non-depolarizing neuromuscular blocking agent should be considered, and appropriate measures to manage malignant hyperthermia should be in place if succinylcholine must be used.	0.7552988616129044	0.5233957260538572	0.48135030152043873	0.5697914647505075	0.8296482	0.57796437	0.49079123	0.56885237	0.8500813	0.49551424	0.3947216	0.55503124	0.8039824	0.5378753	0.46728262	0.51352453	0.75688446	0.53304625	0.5071434	0.55907303	1
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is Malignant Hyperthermia Susceptibility for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking succinylcholine? Give a 2-3 sentence summary.	Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.	['Proceed taking succinylcholine as normal. There is no recommendation.', 'Take succinylcholine with a reduced dose.', 'Take succinylcholine with an increased dose.']	Avoid succinylcholine. Take an alternate therapy.	For an individual with Malignant Hyperthermia Susceptibility (MHS) associated with the RYR1 gene and Uncertain Susceptibility for the CACNA1S gene, it is clinically recommended to avoid succinylcholine due to the significant risk of triggering malignant hyperthermia, a potentially fatal hypermetabolic reaction. Alternative muscle relaxants that do not pose this risk should be considered for these patients.	0.7860449458033545	0.5278563757058227	0.4822130187439477	0.5505022009042847	0.7794083	0.5853606	0.49024776	0.53513885	0.8329072	0.51908237	0.42098665	0.5819252	0.7857774	0.5455103	0.48073363	0.56189084	0.72757846	0.53655106	0.5072245	0.59593326	1
succinylcholine	RYR1;CACNA1S	What would be the clinical guidance for someone who is No Result for RYR1 and Uncertain Susceptibility for CACNA1S with regards to taking succinylcholine? Give a 2-3 sentence summary.	No RYR1 genotype is available. Based on CACNA1S status, clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.	['Avoid succinylcholine. Take an alternate therapy.', 'Take succinylcholine with a reduced dose.', 'Take succinylcholine with an increased dose.']	Proceed taking succinylcholine as normal. There is no recommendation.	"For an individual with ""No Result"" for RYR1 and ""Uncertain Susceptibility"" for CACNA1S, the clinical guidance would generally recommend using caution with succinylcholine. Given the uncertain risk for malignant hyperthermia (MH), it's advisable to consider alternative non-triggering anesthetic agents and to consult with a specialist in genetic or anesthetic care for a more personalized assessment of the patient's risk."	0.7240986502906592	0.40127903431048495	0.3691179883108837	0.6268153003894864	0.6984908	0.49628863	0.31289107	0.574409	0.71448463	0.33169317	0.32866174	0.5016494	0.63173854	0.42874748	0.34859183	0.54617643	0.74901646	0.41059834	0.34475017	0.58343834	0
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfadiazine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfadiazine. Take an alternate therapy.', 'Take sulfadiazine with a reduced dose.', 'Take sulfadiazine with an increased dose.']	Proceed taking sulfadiazine as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), taking sulfadiazine is generally not recommended due to the increased risk of hemolytic anemia. It would be advisable to seek alternative treatments to avoid potential hemolysis and related complications. Close monitoring and consultation with a healthcare provider are essential if the use of sulfadiazine is deemed necessary.	0.5872368420675823	0.4941977533762622	0.3856714122881468	0.6184260280125081	0.58221334	0.55285805	0.34279823	0.66234297	0.60093975	0.474299	0.2665436	0.73579663	0.58290225	0.44109863	0.34756494	0.6429581	0.51223886	0.49533147	0.35990217	0.6448222	0
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfadiazine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfadiazine. Take an alternate therapy.', 'Take sulfadiazine with a reduced dose.', 'Take sulfadiazine with an increased dose.']	Proceed taking sulfadiazine as normal. There is no recommendation.	For an individual with an indeterminate G6PD status, extreme caution should be exercised when considering sulfadiazine due to the risk of hemolytic anemia, a known adverse reaction in G6PD-deficient patients. Clinicians should consider an alternative therapy and confirm G6PD status through quantitative testing before administering sulfadiazine. If sulfadiazine is deemed necessary, close monitoring for signs of hemolysis is essential.	0.6584782960704498	0.4121146864294922	0.3487346085954169	0.5603399318294802	0.533425	0.25197884	0.28624004	0.61909044	0.6113113	0.32540885	0.23879959	0.65585065	0.58745193	0.2563364	0.24435584	0.5691639	0.5770067	0.44424897	0.41114068	0.57493	0
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfadiazine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfadiazine. Take an alternate therapy.', 'Take sulfadiazine with a reduced dose.', 'Take sulfadiazine with an increased dose.']	Proceed taking sulfadiazine as normal. There is no recommendation.	For a person with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency with Central Nervous System Hemolytic Anemia (CNSHA), sulfadiazine should generally be avoided. This medication can trigger hemolytic anemia in individuals with G6PD deficiency, leading to severe complications. It's crucial to consult with a healthcare provider to explore safer alternatives.	0.3971433528090839	0.36837282767857255	0.41124110237032774	0.5243619526795125	0.5098769	0.48263645	0.48289073	0.6911587	0.5048138	0.48220178	0.4270879	0.6821756	0.46998718	0.4086934	0.37994277	0.5980909	0.50791055	0.40056074	0.44079295	0.58866274	0
sulfadiazine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfadiazine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfadiazine. Take an alternate therapy.', 'Take sulfadiazine with a reduced dose.', 'Take sulfadiazine with an increased dose.']	Proceed taking sulfadiazine as normal. There is no recommendation.	For an individual who has a normal G6PD (glucose-6-phosphate dehydrogenase) enzyme status, there is no increased risk of hemolytic anemia when taking sulfadiazine. Therefore, standard dosing regimens of sulfadiazine can be safely followed as per clinical recommendations for their specific condition. Nonetheless, as with any medication, general monitoring for adverse effects is advisable.	0.5994564789180413	0.44098275654407987	0.3256866241418101	0.6478486214558409	0.44698757	0.40331697	0.2006672	0.6344008	0.3692244	0.29268026	0.13621283	0.6844306	0.3858387	0.1949285	0.13273613	0.6009586	0.49614334	0.42000517	0.2845944	0.64000195	1
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfadimidine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfadimidine. Take an alternate therapy.', 'Take sulfadimidine with a reduced dose.', 'Take sulfadimidine with an increased dose.']	Proceed taking sulfadimidine as normal. There is no recommendation.	For individuals who have a glucose-6-phosphate dehydrogenase (G6PD) deficiency, taking sulfadimidine is generally contraindicated. This is because sulfadimidine, being a sulfonamide antibiotic, can induce hemolytic anemia in G6PD-deficient patients due to increased oxidative stress on red blood cells. It is important to seek alternative medications that do not pose such risks.	0.6040035111463739	0.5367431641877406	0.4173760001247741	0.631801192071764	0.60535663	0.5638277	0.3748052	0.61537606	0.63667697	0.50654244	0.31411883	0.6591319	0.58105725	0.4707896	0.38082513	0.615241	0.5456726	0.5309053	0.40097323	0.62344915	0
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfadimidine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfadimidine. Take an alternate therapy.', 'Take sulfadimidine with a reduced dose.', 'Take sulfadimidine with an increased dose.']	Proceed taking sulfadimidine as normal. There is no recommendation.	Individuals who are indeterminate for G6PD deficiency have an uncertain risk for hemolysis when exposed to oxidative drugs like sulfadimidine. Clinical guidance generally advises caution: healthcare providers may consider alternative antibiotics and should monitor for hemolytic anemia if sulfadimidine is deemed necessary. Genetic testing or enzymatic assays to confirm G6PD status could provide more definitive guidance.	0.6691173878276768	0.4629782372810163	0.3868407567732985	0.5719574117546429	0.6327004	0.27649778	0.34482357	0.52456224	0.6635862	0.38954479	0.3492296	0.58209866	0.6157882	0.27975485	0.2660843	0.5135892	0.5893962	0.45810997	0.41824174	0.5760133	0
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfadimidine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfadimidine. Take an alternate therapy.', 'Take sulfadimidine with a reduced dose.', 'Take sulfadimidine with an increased dose.']	Proceed taking sulfadimidine as normal. There is no recommendation.	Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with chronic non-spherocytic hemolytic anemia (CNSHA), are at an increased risk of developing hemolytic anemia when exposed to oxidative stressors, including certain medications like sulfadimidine. Clinical guidance advises avoiding the use of sulfadimidine in these patients to prevent potential hemolysis and its associated complications. Alternative antibiotics that are safer for G6PD-deficient individuals should be considered.	0.45668149335669045	0.4210051913034728	0.4383061352612277	0.5428842921817156	0.55903196	0.48220834	0.52227277	0.49931675	0.48965597	0.4877765	0.47218668	0.55042416	0.5282226	0.443325	0.4077325	0.49755687	0.5312966	0.3986233	0.4475164	0.5374482	0
sulfadimidine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfadimidine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfadimidine. Take an alternate therapy.', 'Take sulfadimidine with a reduced dose.', 'Take sulfadimidine with an increased dose.']	Proceed taking sulfadimidine as normal. There is no recommendation.	For a patient with normal G6PD (glucose-6-phosphate dehydrogenase) enzyme activity, taking sulfadimidine (a sulfonamide antibiotic) generally poses no increased risk of hemolysis, which is a primary concern in individuals with G6PD deficiency. Therefore, sulfadimidine can be taken according to standard dosing guidelines, without the need for special precautions related to G6PD status. However, all patients should be monitored for potential adverse reactions related to sulfonamide use.	0.6402226868345214	0.47146112295167697	0.3464353528661339	0.6502807043689055	0.5177425	0.41365236	0.22407985	0.6267069	0.47829083	0.32886207	0.17572951	0.693601	0.47201645	0.22115462	0.15708718	0.5745734	0.593993	0.45304385	0.32986143	0.6053746	1
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfamethoxazole / trimethoprim? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.', 'Take sulfamethoxazole / trimethoprim with a reduced dose.', 'Take sulfamethoxazole / trimethoprim with an increased dose.']	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.	For individuals who are classified as normal for G6PD (glucose-6-phosphate dehydrogenase) activity, there is typically no increased risk of hemolysis when taking sulfamethoxazole/trimethoprim. Therefore, standard dosing and administration guidelines for sulfamethoxazole/trimethoprim can be followed in these patients. However, it remains important to monitor for any adverse reactions and to consider other potential contraindications or drug interactions that may be relevant.	0.5799908900242073	0.4305539547143541	0.3247422672524521	0.6649323024847872	0.5084053	0.41712695	0.20478149	0.6527816	0.4453373	0.30901247	0.14787401	0.69157106	0.37692335	0.16224152	0.099790156	0.5848065	0.4855681	0.40820155	0.28756556	0.69553095	1
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking sulfamethoxazole / trimethoprim? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.', 'Take sulfamethoxazole / trimethoprim with a reduced dose.', 'Take sulfamethoxazole / trimethoprim with an increased dose.']	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.	"Individuals who are classified as ""variable"" for the G6PD gene have a partially deficient glucose-6-phosphate dehydrogenase enzyme. This condition can increase the risk of hemolytic anemia when taking oxidizing drugs like sulfamethoxazole/trimethoprim. Clinical guidance typically advises caution and close monitoring for signs of hemolysis, such as jaundice, dark urine, or a sudden drop in hemoglobin levels, and in some cases, alternative medications may be considered."	0.648653784843088	0.4705003269281026	0.3791774987224179	0.4218747700527945	0.5522246	0.5506342	0.3296368	0.4646135	0.5565578	0.46586448	0.25076166	0.50017065	0.56985766	0.40578207	0.3063097	0.43278745	0.5056202	0.46622598	0.33565798	0.5656762	0
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfamethoxazole / trimethoprim? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.', 'Take sulfamethoxazole / trimethoprim with a reduced dose.', 'Take sulfamethoxazole / trimethoprim with an increased dose.']	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.	For individuals who are G6PD-deficient, taking sulfamethoxazole/trimethoprim should be approached with caution due to the risk of hemolysis. It is generally advised to avoid this combination unless no safer alternatives are available and the patient can be closely monitored for hemolytic reactions. Clinical decisions should be individualized, weighing the risks and benefits for the specific patient.	0.5970548697946346	0.4705003269281026	0.3791774987224179	0.6357969542699914	0.66672903	0.5506342	0.3296368	0.6954585	0.65434796	0.46586448	0.25076166	0.7428923	0.61387765	0.40578207	0.3063097	0.6531192	0.53901845	0.46622598	0.33565798	0.6656372	0
sulfamethoxazole / trimethoprim	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfamethoxazole / trimethoprim? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfamethoxazole / trimethoprim. Take an alternate therapy.', 'Take sulfamethoxazole / trimethoprim with a reduced dose.', 'Take sulfamethoxazole / trimethoprim with an increased dose.']	Proceed taking sulfamethoxazole / trimethoprim as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, caution is advised when considering the use of sulfamethoxazole/trimethoprim. Although the G6PD status is unclear, it is prudent to monitor for signs of hemolysis, such as jaundice or dark urine, and consider alternative antibiotics if possible to mitigate potential risks. Consultation with a healthcare provider for personalized management based on clinical judgment and further testing is recommended.	0.6667802784396056	0.40353402831877017	0.34797668862726366	0.5884311134577658	0.5755288	0.24292305	0.27221873	0.59371567	0.6242954	0.31526816	0.23093796	0.64249027	0.5497814	0.21937127	0.1965431	0.60996556	0.5864913	0.43268228	0.36607432	0.6318756	0
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfanilamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfanilamide. Take an alternate therapy.', 'Take sulfanilamide with a reduced dose.', 'Take sulfanilamide with an increased dose.']	Proceed taking sulfanilamide as normal. There is no recommendation.	For an individual who tests normal for glucose-6-phosphate dehydrogenase (G6PD) deficiency, there is generally no increased risk of hemolysis when taking sulfanilamide. Therefore, the use of sulfanilamide is considered safe in patients with normal G6PD activity. However, as with any medication, monitoring for potential side effects is recommended.	0.6088355531201964	0.4343689939233485	0.29472699010422726	0.6170863944544825	0.50980157	0.40560558	0.21576683	0.64783305	0.46303344	0.29410854	0.13966401	0.6763306	0.3822168	0.19536647	0.1379577	0.5666363	0.55824333	0.4379079	0.32616195	0.5642326	1
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfanilamide? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfanilamide. Take an alternate therapy.', 'Take sulfanilamide with a reduced dose.', 'Take sulfanilamide with an increased dose.']	Proceed taking sulfanilamide as normal. There is no recommendation.	An individual with an indeterminate G6PD status may have uncertain enzymatic activity, making it challenging to predict their risk for hemolytic events with certain medications. Given the potential for hemolysis in G6PD-deficient individuals, it would be prudent to avoid sulfanilamide or consider alternative treatments. If sulfanilamide must be used, closely monitoring the patient for signs of hemolysis is crucial. Consultation with a healthcare professional or genetic specialist is recommended to guide safe treatment options.	0.680322975889354	0.41821203408444496	0.3372936753727294	0.5436322366575306	0.6019043	0.22919762	0.2811618	0.5407528	0.70449805	0.2997207	0.22220074	0.5247	0.6551432	0.2560378	0.24801756	0.45952928	0.54819006	0.4485257	0.44223014	0.53513396	0
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfanilamide? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfanilamide. Take an alternate therapy.', 'Take sulfanilamide with a reduced dose.', 'Take sulfanilamide with an increased dose.']	Proceed taking sulfanilamide as normal. There is no recommendation.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) are at risk for hemolytic anemia when exposed to sulfanilamide. Clinical guidance strongly advises against the use of sulfanilamide in these patients to prevent potential hemolytic episodes. It is crucial to explore alternative medications that do not pose such risks.	0.41575557681292225	0.4042954075655616	0.4207920723669106	0.5451277523071659	0.56446177	0.49054238	0.52015805	0.6117899	0.520675	0.4950159	0.45352992	0.60940266	0.48711765	0.39184266	0.36526334	0.5255241	0.55857205	0.39136577	0.46028605	0.60381454	0
sulfanilamide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfanilamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfanilamide. Take an alternate therapy.', 'Take sulfanilamide with a reduced dose.', 'Take sulfanilamide with an increased dose.']	Proceed taking sulfanilamide as normal. There is no recommendation.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, the use of sulfanilamide is generally contraindicated due to the risk of hemolytic anemia. Clinicians typically recommend avoiding sulfanilamide and considering alternative antibiotics that do not pose a risk of triggering hemolysis in these patients.	0.602425508049573	0.5002121898882386	0.37381690585524163	0.5867087806927864	0.6257067	0.55556124	0.36481416	0.6572297	0.6446427	0.4759739	0.2676664	0.6556617	0.5652608	0.44162744	0.36039743	0.5956136	0.5592371	0.5064909	0.3976719	0.580777	0
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfasalazine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfasalazine. Take an alternate therapy.', 'Take sulfasalazine with a reduced dose.', 'Take sulfasalazine with an increased dose.']	Proceed taking sulfasalazine as normal. There is no recommendation.	For individuals who are deficient in Glucose-6-Phosphate Dehydrogenase (G6PD), it is generally recommended to avoid the use of sulfasalazine due to the increased risk of hemolytic anemia. If sulfasalazine is deemed essential, close monitoring for signs of hemolysis and regular blood tests should be conducted to ensure patient safety.	0.5816652326720794	0.45414919805192566	0.3405395869011502	0.5523684830658294	0.6172953	0.52118164	0.3195448	0.611733	0.65431756	0.41196546	0.20937979	0.6132706	0.53768206	0.40591288	0.31599605	0.62386346	0.529856	0.47757724	0.3531666	0.5773218	0
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfasalazine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfasalazine. Take an alternate therapy.', 'Take sulfasalazine with a reduced dose.', 'Take sulfasalazine with an increased dose.']	Proceed taking sulfasalazine as normal. There is no recommendation.	For a patient who is indeterminate for G6PD deficiency, caution is advised when prescribing sulfasalazine. It is recommended to closely monitor for hemolytic anemia, particularly if the patient has any symptoms suggesting hemolysis, as sulfasalazine can trigger oxidative stress in individuals with partial G6PD deficiency. Alternative medications may be considered based on a risk-benefit analysis.	0.6098515716424568	0.36064598496889816	0.3043393466122006	0.5682508010242504	0.58963114	0.24025097	0.27568257	0.5514416	0.6584232	0.2746681	0.19229503	0.5798222	0.55782205	0.21604884	0.20274766	0.58398575	0.55041057	0.41990238	0.38604203	0.54752964	0
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfasalazine? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfasalazine. Take an alternate therapy.', 'Take sulfasalazine with a reduced dose.', 'Take sulfasalazine with an increased dose.']	Proceed taking sulfasalazine as normal. There is no recommendation.	For individuals with Central Nervous System Hemolytic Anemia (CNSHA) due to G6PD deficiency, the use of sulfasalazine should generally be avoided. G6PD deficiency can lead to hemolytic anemia when exposed to certain medications, and sulfasalazine is known to be one of those agents that can trigger this adverse reaction. Therefore, it is recommended to consider alternative treatments that do not pose a risk of hemolysis in these patients.	0.42580151077012224	0.37181440721667336	0.4071991464188911	0.48184085625986794	0.5179458	0.46588907	0.47853336	0.62311697	0.5198862	0.43297756	0.3773636	0.56733644	0.5250909	0.42473748	0.38877127	0.584604	0.5122133	0.4163239	0.4607291	0.5428112	0
sulfasalazine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfasalazine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfasalazine. Take an alternate therapy.', 'Take sulfasalazine with a reduced dose.', 'Take sulfasalazine with an increased dose.']	Proceed taking sulfasalazine as normal. There is no recommendation.	For a patient with normal glucose-6-phosphate dehydrogenase (G6PD) levels, taking sulfasalazine generally does not pose an increased risk of hemolytic anemia. Clinical guidance would allow for the administration of sulfasalazine as usual, with standard monitoring for any potential side effects not related to G6PD deficiency. Always consider comprehensive patient evaluation and consult with healthcare providers for personalized advice.	0.587752786989787	0.38844933425038086	0.26983996255999126	0.6220051796783039	0.51011926	0.38723883	0.19100541	0.62023044	0.4450469	0.2594812	0.10531064	0.62286323	0.3096214	0.16246428	0.0971451	0.5919032	0.49524617	0.40873238	0.2822446	0.6065303	1
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking sulfisoxazole? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid sulfisoxazole. Take an alternate therapy.', 'Take sulfisoxazole with a reduced dose.', 'Take sulfisoxazole with an increased dose.']	Proceed taking sulfisoxazole as normal. There is no recommendation.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), the use of sulfisoxazole is generally contraindicated. This is because sulfisoxazole, being a sulfonamide, increases the risk of hemolytic anemia in G6PD-deficient patients. Therefore, alternative antibiotics that do not pose such risks should be considered.	0.5953859529897093	0.4776743438477429	0.35735344684994286	0.5780703416016344	0.61746615	0.5210062	0.3172041	0.5839341	0.61839575	0.41421923	0.21777086	0.6399545	0.5721173	0.41013873	0.3025953	0.56640583	0.55142605	0.47607088	0.3507196	0.6136587	0
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking sulfisoxazole? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid sulfisoxazole. Take an alternate therapy.', 'Take sulfisoxazole with a reduced dose.', 'Take sulfisoxazole with an increased dose.']	Proceed taking sulfisoxazole as normal. There is no recommendation.	Individuals who are Indeterminate for G6PD deficiency should exercise caution when using sulfisoxazole due to the risk for hemolytic anemia, a condition that can be precipitated by certain medications in those with G6PD deficiency. It is generally advised to consider alternative treatments that do not carry this risk, and consultation with a healthcare provider is essential for personalized guidance.	0.6105763120127125	0.3796073106364989	0.3080894529598767	0.5702772487848055	0.50169283	0.2145626	0.24269111	0.5566908	0.55577105	0.24887794	0.16867988	0.5715673	0.5694993	0.23579319	0.20944285	0.5806013	0.53164375	0.43196598	0.4036893	0.5891344	0
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking sulfisoxazole? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid sulfisoxazole. Take an alternate therapy.', 'Take sulfisoxazole with a reduced dose.', 'Take sulfisoxazole with an increased dose.']	Proceed taking sulfisoxazole as normal. There is no recommendation.	For individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency and chronic nonspherocytic hemolytic anemia (CNSHA), sulfisoxazole is contraindicated due to the increased risk of hemolysis. Clinical guidance would recommend avoiding sulfisoxazole and considering alternative antimicrobial agents that are safer for G6PD-deficient patients.	0.42906544231057997	0.3792948412140978	0.4165373432995317	0.5697397546549675	0.5757436	0.46666816	0.47050497	0.63722956	0.5215567	0.44608787	0.3861443	0.62613744	0.52575576	0.4554475	0.4092426	0.5715429	0.49295416	0.39744294	0.45411095	0.5840416	0
sulfisoxazole	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking sulfisoxazole? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid sulfisoxazole. Take an alternate therapy.', 'Take sulfisoxazole with a reduced dose.', 'Take sulfisoxazole with an increased dose.']	Proceed taking sulfisoxazole as normal. There is no recommendation.	For an individual with a normal glucose-6-phosphate dehydrogenase (G6PD) enzyme activity, there are no specific contraindications or additional precautions needed when taking sulfisoxazole based on their G6PD status. They can be prescribed sulfisoxazole as per standard dosing guidelines, since the risk of hemolytic anemia, which is a concern in those with G6PD deficiency, is not increased in these patients.	0.6454101073462903	0.41961966394729994	0.28820550906011466	0.6395766260545075	0.523689	0.38482714	0.1886669	0.63508004	0.48069793	0.26523647	0.11324822	0.6530796	0.44554147	0.16146283	0.09198319	0.5798265	0.57330716	0.4195235	0.29587674	0.61291105	1
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for CYP3A5 with regards to taking tacrolimus? Give a 2-3 sentence summary.	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.	['Proceed taking tacrolimus as normal. There is no recommendation.', 'Avoid tacrolimus. Take an alternate therapy.']	Take tacrolimus with an altered dose.	For a patient identified as a possible intermediate metabolizer for CYP3A5, clinical guidance would suggest that tacrolimus dosing might need adjustment. These patients may have some functional CYP3A5 enzyme activity, potentially resulting in faster metabolism and lower drug levels. It is typically recommended to initiate tacrolimus at a higher dose than standard and to closely monitor blood levels to ensure therapeutic targets are met, adjusting the dose as needed.	0.5316295635672565	0.4617509196947866	0.4362723264956664	0.7170573721576776	0.62138903	0.5866445	0.47952396	0.60739857	0.57126236	0.4991196	0.47183126	0.56588304	0.5549319	0.5063754	0.40307593	0.5677915	0.5365434	0.4840051	0.3148978	0.71645147	1
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Indeterminate for CYP3A5 with regards to taking tacrolimus? Give a 2-3 sentence summary.	No recommendation	['Avoid tacrolimus. Take an alternate therapy.', 'Take tacrolimus with a reduced dose.', 'Take tacrolimus with an increased dose.']	Proceed taking tacrolimus as normal. There is no recommendation.	For patients with an indeterminate CYP3A5 genotype, there is insufficient information to predict their enzyme activity regarding tacrolimus metabolism. Consequently, standard dosing regimens should be initiated with close therapeutic drug monitoring (TDM) to ensure optimal drug exposure and to minimize the risk of toxicity or therapeutic failure.	0.2316980904910156	0.4432376615961127	0.19623655170047397	0.6215468162732755	0.20078902	0.34102392	0.2006446	0.5534207	0.10692349	0.24524473	0.14249896	0.5765215	-0.017783063	0.3217527	0.09869816	0.58098257	0.29704243	0.52993387	0.40260878	0.5902838	0
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP3A5 with regards to taking tacrolimus? Give a 2-3 sentence summary.	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.	['Proceed taking tacrolimus as normal. There is no recommendation.', 'Avoid tacrolimus. Take an alternate therapy.']	Take tacrolimus with an altered dose.	For patients identified as intermediate metabolizers of CYP3A5 (i.e., carrying one functional and one non-functional allele), clinical guidelines recommend starting tacrolimus at a standard dose. However, due to their potentially increased clearance of the drug compared to nonexpressers, closer monitoring of drug levels and potentially adjusting doses based on therapeutic drug monitoring is advised to achieve the desired pharmacologic effect.	0.5387765570284182	0.4617509196947866	0.4362723264956664	0.6830048320138734	0.5695209	0.5866445	0.47952396	0.53169596	0.4685118	0.4991196	0.47183126	0.50101984	0.4994618	0.5063754	0.40307593	0.5890889	0.5061776	0.4840051	0.3148978	0.7343945	0
tacrolimus	CYP3A5	What would be the clinical guidance for someone who is Normal Metabolizer for CYP3A5 with regards to taking tacrolimus? Give a 2-3 sentence summary.	Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.	['Proceed taking tacrolimus as normal. There is no recommendation.', 'Avoid tacrolimus. Take an alternate therapy.']	Take tacrolimus with an altered dose.	For individuals identified as normal metabolizers of CYP3A5, clinical guidance suggests initiating tacrolimus at a higher starting dose of 1.5 to 2 times the typical starting dose, based on their actual body weight. This adjustment is recommended because normal metabolizers have more active CYP3A5 enzymes that metabolize tacrolimus more quickly, necessitating a higher dose to achieve therapeutic drug levels. Close therapeutic drug monitoring is also crucial to ensure that target blood concentrations are maintained.	0.63314909834162	0.4617509196947866	0.4362723264956664	0.6790770206783281	0.7046952	0.5866445	0.47952396	0.62843865	0.60718054	0.4991196	0.47183126	0.56185603	0.66095537	0.5063754	0.40307593	0.5715062	0.65603673	0.4840051	0.3148978	0.7178189	1
tafenoquine	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking tafenoquine? Give a 2-3 sentence summary.	Avoid use	['Proceed taking tafenoquine as normal. There is no recommendation.', 'Take tafenoquine with a reduced dose.', 'Take tafenoquine with an increased dose.']	Avoid tafenoquine. Take an alternate therapy.	Individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD) should avoid taking tafenoquine due to the risk of hemolytic anemia. Clinical guidelines recommend screening for G6PD deficiency prior to administering tafenoquine, and alternative medications should be considered for G6PD-deficient patients.	0.21242710583436455	0.2827124306139707	0.2424404925438057	0.6296264988784697	0.32070038	0.36137244	0.27742746	0.63380957	0.17761233	0.15206681	0.16466647	0.64020115	0.14572449	0.19780403	0.19426864	0.5835839	0.4193591	0.5382571	0.44704333	0.6271293	1
tafenoquine	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking tafenoquine? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid tafenoquine. Take an alternate therapy.', 'Take tafenoquine with a reduced dose.', 'Take tafenoquine with an increased dose.']	Proceed taking tafenoquine as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, tafenoquine should be used with caution due to the potential risk of hemolytic anemia. It is generally advised to either avoid tafenoquine in these patients or to closely monitor their hemoglobin levels and for signs of hemolysis if tafenoquine is administered. Obtaining a definitive G6PD status through additional testing is recommended to guide safe use of the drug.	0.6341102422983589	0.3929812325868425	0.33418327677314624	0.6142150464755879	0.45679224	0.19516154	0.21879303	0.6547717	0.49966297	0.17707741	0.10083938	0.6546118	0.5062529	0.18699534	0.14543097	0.59829444	0.5564275	0.43084386	0.4059943	0.521605	0
tafenoquine	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking tafenoquine? Give a 2-3 sentence summary.	Avoid use	['Proceed taking tafenoquine as normal. There is no recommendation.', 'Take tafenoquine with a reduced dose.', 'Take tafenoquine with an increased dose.']	Avoid tafenoquine. Take an alternate therapy.	For individuals with Deficiency-related Chronic Non-Spherocytic Hemolytic Anemia (CNSHA) due to G6PD deficiency, the use of tafenoquine is contraindicated. Tafenoquine can precipitate severe hemolysis in G6PD-deficient patients, which could lead to serious health complications. Clinical guidance would recommend avoiding tafenoquine and considering alternative medications that do not pose risks of hemolysis in G6PD-deficient individuals.	0.2406382294887691	0.2827124306139707	0.2424404925438057	0.5853201114090145	0.33275387	0.36137244	0.27742746	0.57843995	0.18920651	0.15206681	0.16466647	0.577314	0.14493504	0.19780403	0.19426864	0.5172553	0.37973338	0.5382571	0.44704333	0.56730646	1
tafenoquine	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking tafenoquine? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid tafenoquine. Take an alternate therapy.', 'Take tafenoquine with a reduced dose.', 'Take tafenoquine with an increased dose.']	Proceed taking tafenoquine as normal. There is no recommendation.	For individuals who have normal glucose-6-phosphate dehydrogenase (G6PD) activity, tafenoquine can generally be prescribed safely for the prevention and radical cure of malaria. It is important to confirm normal G6PD levels before initiating tafenoquine, as deficiency can lead to hemolytic anemia, a serious side effect. Regular monitoring and adherence to prescribed dosages are recommended to mitigate potential risks.	0.5369014668704506	0.42251388490429764	0.3047752375907677	0.6595239916762892	0.454039	0.3996183	0.2058283	0.51063645	0.37807393	0.26932794	0.11702489	0.5676343	0.29936522	0.13655837	0.06740729	0.5649232	0.53038645	0.42233616	0.30055106	0.60533404	0
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2D6 with regards to taking tamoxifen? Give a 2-3 sentence summary.	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	['Proceed taking tamoxifen as normal. There is no recommendation.', 'Take tamoxifen with a reduced dose.', 'Take tamoxifen with an increased dose.']	Avoid tamoxifen. Take an alternate therapy.	For individuals who are normal metabolizers with an activity score of 2.0 for CYP2D6, tamoxifen can be prescribed at standard dosing. Normal metabolizers are expected to effectively convert tamoxifen to its active metabolite, endoxifen, thereby achieving therapeutic efficacy. No dose adjustments are needed; these patients should follow the typical dosing regimen advised by their healthcare provider.	0.6550277505095222	0.6740667122966364	0.6647729075617884	0.5467134196020422	0.6171347	0.7435187	0.6722197	0.45849696	0.6922034	0.7313674	0.6874337	0.5517751	0.65523094	0.7392634	0.66961265	0.4846478	0.7480176	0.79819137	0.7745025	0.57192874	1
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.5 for CYP2D6 with regards to taking tamoxifen? Give a 2-3 sentence summary.	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	['Proceed taking tamoxifen as normal. There is no recommendation.', 'Take tamoxifen with a reduced dose.', 'Take tamoxifen with an increased dose.']	Avoid tamoxifen. Take an alternate therapy.	For a patient identified as a CYP2D6 ultrarapid metabolizer (activity score = 2.5) taking tamoxifen, clinical guidance suggests that they may convert tamoxifen to its active metabolites more rapidly and extensively than normal metabolizers. This could potentially lead to enhanced therapeutic efficacy, but may also increase the risk of side effects. It is advisable to monitor the patient closely for both therapeutic response and adverse effects, adjusting the dosing if necessary.	0.6786751412833356	0.6740667122966364	0.6647729075617884	0.5541114228397953	0.5568055	0.7435187	0.6722197	0.47844923	0.66195786	0.7313674	0.6874337	0.5799512	0.6493322	0.7392634	0.66961265	0.51252896	0.7260494	0.79819137	0.7745025	0.6111581	0
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.25 for CYP2D6 with regards to taking tamoxifen? Give a 2-3 sentence summary.	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	['Proceed taking tamoxifen as normal. There is no recommendation.', 'Take tamoxifen with a reduced dose.', 'Take tamoxifen with an increased dose.']	Avoid tamoxifen. Take an alternate therapy.	For individuals identified as Ultrarapid Metabolizers (defined by an activity score ≥3.25) for CYP2D6, clinical guidance typically recommends caution with tamoxifen therapy. This is because Ultrarapid Metabolizers may convert tamoxifen to its active metabolites too quickly, potentially leading to variable therapeutic effects or increased side effects. Alternative therapies or dose adjustments may be considered based on the clinical judgment of the healthcare provider.	0.6927103985513948	0.6740667122966364	0.6647729075617884	0.5937001251135465	0.7051519	0.7435187	0.6722197	0.5319218	0.7568795	0.7313674	0.6874337	0.59457624	0.6684221	0.7392634	0.66961265	0.4684283	0.7218216	0.79819137	0.7745025	0.6182269	0
tamoxifen	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking tamoxifen? Give a 2-3 sentence summary.	Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).	['Proceed taking tamoxifen as normal. There is no recommendation.', 'Take tamoxifen with a reduced dose.', 'Take tamoxifen with an increased dose.']	Avoid tamoxifen. Take an alternate therapy.	For a patient who is a normal metabolizer with an activity score of 1.75 for CYP2D6 taking tamoxifen, clinical guidance generally indicates that no dosage adjustment is necessary. This patient's CYP2D6 activity falls within the normal range, suggesting standard tamoxifen therapy should be effective without requiring modifications. Regular monitoring and follow-up are advised to ensure therapeutic efficacy and manage any potential side effects.	0.6944746673589592	0.6740667122966364	0.6647729075617884	0.5574035925162143	0.67380565	0.7435187	0.6722197	0.5303824	0.78467584	0.7313674	0.6874337	0.63681835	0.72579724	0.7392634	0.66961265	0.5001841	0.7462781	0.79819137	0.7745025	0.5848577	1
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Indeterminate for CYP2C9 with regards to taking tenoxicam? Give a 2-3 sentence summary.	No recommendation	['Avoid tenoxicam. Take an alternate therapy.', 'Take tenoxicam with a reduced dose.', 'Take tenoxicam with an increased dose.']	Proceed taking tenoxicam as normal. There is no recommendation.	For individuals who are Indeterminate for CYP2C9, clinical guidance for tenoxicam use suggests proceeding with caution. It is recommended to monitor for signs of toxicity and adjust the dose if necessary, as CYP2C9 plays a role in metabolizing tenoxicam, and variations can impact drug clearance and efficacy. Consultation with a healthcare professional is advisable for personalized dosing and monitoring strategies.	0.26845017326431597	0.45544501341907156	0.24620268973311324	0.6543594232384324	0.13942721	0.2817978	0.14689124	0.58393973	0.09404343	0.14983797	0.07183944	0.6255431	0.021576993	0.34113687	0.11707449	0.56218636	0.32393008	0.5554444	0.41888842	0.60878474	0
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.0 for CYP2C9 with regards to taking tenoxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid tenoxicam. Take an alternate therapy.', 'Take tenoxicam with a reduced dose.', 'Take tenoxicam with an increased dose.']	Proceed taking tenoxicam as normal. There is no recommendation.	For individuals who are normal metabolizers with an activity score of 2.0 for CYP2C9, the clinical guidance for taking tenoxicam typically does not require any dosing adjustments. These patients are expected to metabolize the drug at the standard rate, implying that standard dosing regimens can be followed. However, it remains important to monitor for efficacy and potential adverse effects as with any medication.	0.42578725969423	0.4313908374119596	0.43324661030122247	0.6892511001071716	0.48184973	0.37811542	0.3729336	0.5964441	0.44972172	0.47835606	0.33658275	0.641119	0.42609453	0.39204025	0.40393975	0.5882998	0.4899487	0.48403755	0.4622179	0.673217	1
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Poor Metabolizer and activity score = 0.0 for CYP2C9 with regards to taking tenoxicam? Give a 2-3 sentence summary.	Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).	['Proceed taking tenoxicam as normal. There is no recommendation.', 'Take tenoxicam with a reduced dose.', 'Take tenoxicam with an increased dose.']	Avoid tenoxicam. Take an alternate therapy.	For individuals classified as Poor Metabolizers with an activity score of 0.0 for CYP2C9, the clinical guidance regarding tenoxicam use typically includes avoiding the medication due to increased risk of drug accumulation and potential adverse effects. Alternative non-steroidal anti-inflammatory drugs (NSAIDs) that are not predominantly metabolized by CYP2C9 should be considered. Monitoring for adverse reactions if tenoxicam is used at reduced doses is also recommended.	0.6306689723581563	0.5852785626980536	0.4841586698051486	0.6702794257306869	0.68532854	0.6312462	0.54917926	0.6374543	0.71894014	0.44854808	0.41460106	0.67288107	0.5881212	0.35341328	0.32623732	0.6156416	0.6470617	0.5569535	0.5257347	0.6911572	0
tenoxicam	CYP2C9	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.5 for CYP2C9 with regards to taking tenoxicam? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.	['Avoid tenoxicam. Take an alternate therapy.', 'Take tenoxicam with a reduced dose.', 'Take tenoxicam with an increased dose.']	Proceed taking tenoxicam as normal. There is no recommendation.	For individuals identified as Intermediate Metabolizers with a CYP2C9 activity score of 1.5, the clinical guidance for taking tenoxicam should include a consideration for dose reduction. Intermediate Metabolizers typically have reduced enzyme activity, leading to slower metabolism of the drug, which can increase the risk of adverse effects. Therefore, it is advisable to initiate tenoxicam at a lower dose and monitor the patient closely for efficacy and safety, adjusting the dose as necessary.	0.46043665232834385	0.4313908374119596	0.43324661030122247	0.6210297527826845	0.45626706	0.37811542	0.3729336	0.4820805	0.45608595	0.47835606	0.33658275	0.5710385	0.46306276	0.39204025	0.40393975	0.5539844	0.4948353	0.48403755	0.4622179	0.5568678	0
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Poor Metabolizer for NUDT15 with regards to taking thioguanine? Give a 2-3 sentence summary.	Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).	['Proceed taking thioguanine as normal. There is no recommendation.', 'Avoid thioguanine. Take an alternate therapy.']	Take thioguanine with an altered dose.	For a patient who is a Normal Metabolizer for TPMT but a Poor Metabolizer for NUDT15, clinical guidance suggests considering a significant dose reduction of thioguanine due to the increased risk of toxicity, particularly myelosuppression. Careful monitoring of blood counts and clinical status is recommended to adjust the dose as needed to avoid severe adverse effects.	0.7160274771834375	0.6743468957039827	0.6740747022737905	0.6542866644755055	0.69933677	0.5872117	0.53395724	0.5630833	0.65015566	0.5793222	0.6469989	0.5220703	0.6350131	0.59166956	0.57199407	0.54749763	0.6949359	0.6405852	0.5567079	0.7004876	0
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Possible Intermediate Metabolizer for TPMT and Normal Metabolizer for NUDT15 with regards to taking thioguanine? Give a 2-3 sentence summary.	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	['Proceed taking thioguanine as normal. There is no recommendation.', 'Avoid thioguanine. Take an alternate therapy.']	Take thioguanine with an altered dose.	For a patient who is a Possible Intermediate Metabolizer for TPMT and a Normal Metabolizer for NUDT15, it is recommended to start thioguanine at 30-80% of the normal dose due to the reduced TPMT function, which can increase the risk of toxicity. Close monitoring of blood counts and adjustment based on clinical response and tolerance are essential to avoid adverse effects.	0.7278261049564319	0.693960802757215	0.6669445704553971	0.6411706218611996	0.64356756	0.5512906	0.524428	0.53120273	0.6622114	0.5617465	0.6398816	0.5037864	0.6810525	0.5995758	0.57533205	0.61054635	0.68003255	0.618008	0.5470049	0.6442936	1
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Normal Metabolizer for TPMT and Intermediate Metabolizer for NUDT15 with regards to taking thioguanine? Give a 2-3 sentence summary.	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	['Proceed taking thioguanine as normal. There is no recommendation.', 'Avoid thioguanine. Take an alternate therapy.']	Take thioguanine with an altered dose.	For a patient who is a normal metabolizer for TPMT and an intermediate metabolizer for NUDT15, the clinical guidance would typically involve initiating thioguanine at standard dosing, but with careful monitoring for potential adverse effects. Given their NUDT15 status, there may be an increased risk of toxicity, so clinicians should consider more frequent monitoring of blood counts and adjust the dose based on tolerance and clinical response.	0.6903433368682605	0.693960802757215	0.6669445704553971	0.6272986743492291	0.5724821	0.5512906	0.524428	0.5217185	0.6129636	0.5617465	0.6398816	0.5040558	0.57996756	0.5995758	0.57533205	0.5763057	0.6261303	0.618008	0.5470049	0.6451583	0
thioguanine	TPMT;NUDT15	What would be the clinical guidance for someone who is Intermediate Metabolizer for TPMT and Possible Intermediate Metabolizer for NUDT15 with regards to taking thioguanine? Give a 2-3 sentence summary.	Start with reduced doses (50% to 80% of normal dose) if normal starting dose is ≥ 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).	['Proceed taking thioguanine as normal. There is no recommendation.', 'Avoid thioguanine. Take an alternate therapy.']	Take thioguanine with an altered dose.	For a patient who is an Intermediate Metabolizer for TPMT and a Possible Intermediate Metabolizer for NUDT15, thioguanine therapy should be initiated at a reduced dose, typically 30-70% of the standard dose, with close monitoring for myelosuppression and other adverse effects. Both TPMT and NUDT15 variants can lead to reduced enzyme activity, increasing the risk of toxicity from thioguanine. Adjustments should be based on the patient's blood counts and clinical response.	0.7740351813412036	0.693960802757215	0.6669445704553971	0.6792778816800256	0.7292198	0.5512906	0.524428	0.5341302	0.7079111	0.5617465	0.6398816	0.5111455	0.67047787	0.5995758	0.57533205	0.57276076	0.72666025	0.618008	0.5470049	0.68949974	1
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is increased risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin? Give a 2-3 sentence summary.	Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.	['Proceed taking tobramycin as normal. There is no recommendation.', 'Take tobramycin with a reduced dose.', 'Take tobramycin with an increased dose.']	Avoid tobramycin. Take an alternate therapy.	For individuals with a known MT-RNR1 genetic variant associated with increased risk of aminoglycoside-induced hearing loss, the clinical guidance would be to avoid the use of tobramycin and other aminoglycosides if possible. Alternative antibiotics that do not carry the same risk of ototoxicity should be considered to prevent potential hearing loss.	0.7465144456877929	0.5475422207939777	0.43225890762247005	0.5598648955292133	0.7960219	0.5954209	0.47497988	0.63532805	0.7539426	0.48701888	0.47801676	0.5920494	0.7930981	0.40880653	0.39415658	0.4786342	0.6522524	0.6295727	0.51017684	0.56490463	1
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is normal risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid tobramycin. Take an alternate therapy.', 'Take tobramycin with a reduced dose.', 'Take tobramycin with an increased dose.']	Proceed taking tobramycin as normal. There is no recommendation.	For individuals who are at normal risk for aminoglycoside-induced hearing loss based on MT-RNR1 genetic testing, standard dosing and monitoring protocols for tobramycin can be followed. It is still important to monitor renal function and hearing during therapy as a precaution, given the general risks associated with aminoglycoside antibiotics.	0.6941173757368168	0.4627909569010701	0.461227017383046	0.5943042609576052	0.63478804	0.4660062	0.48141852	0.541993	0.65975296	0.54020387	0.5372823	0.62220013	0.7387597	0.46048647	0.47000632	0.51769865	0.6136928	0.5228594	0.5528628	0.49264532	1
tobramycin	MT-RNR1	What would be the clinical guidance for someone who is uncertain risk of aminoglycoside-induced hearing loss for MT-RNR1 with regards to taking tobramycin? Give a 2-3 sentence summary.	Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.	['Avoid tobramycin. Take an alternate therapy.', 'Take tobramycin with a reduced dose.', 'Take tobramycin with an increased dose.']	Proceed taking tobramycin as normal. There is no recommendation.	For patients with uncertain risk of aminoglycoside-induced hearing loss due to MT-RNR1 genetic variants, it is recommended to avoid tobramycin and other aminoglycosides if possible, as these individuals may be at increased risk of developing irreversible hearing loss. Alternative antibiotics that do not pose this risk should be considered, and if aminoglycoside use is unavoidable, careful monitoring of hearing function is essential.	0.6580636330393531	0.4627909569010701	0.461227017383046	0.5116662933883794	0.5301654	0.4660062	0.48141852	0.6241264	0.67532855	0.54020387	0.5372823	0.62111896	0.7432301	0.46048647	0.47000632	0.439987	0.5691932	0.5228594	0.5528628	0.50328934	0
tolbutamide	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking tolbutamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid tolbutamide. Take an alternate therapy.', 'Take tolbutamide with a reduced dose.', 'Take tolbutamide with an increased dose.']	Proceed taking tolbutamide as normal. There is no recommendation.	For individuals with normal G6PD (Glucose-6-Phosphate Dehydrogenase) activity, there are no specific pharmacogenomic concerns regarding the use of tolbutamide. Since tolbutamide does not have reported interactions with G6PD deficiency, it can be prescribed without adjustments or additional precautions related to this enzyme. However, as always, monitoring for any drug-specific adverse effects is recommended.	0.6484402548179053	0.397843642689905	0.2663080969358227	0.6055376743694929	0.5715039	0.39871132	0.21813254	0.6323487	0.48250598	0.28900236	0.15585119	0.66640496	0.47744885	0.18447715	0.12374249	0.5111175	0.61756116	0.438312	0.33092445	0.55310124	1
tolbutamide	G6PD	What would be the clinical guidance for someone who is Variable for G6PD with regards to taking tolbutamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid tolbutamide. Take an alternate therapy.', 'Take tolbutamide with a reduced dose.', 'Take tolbutamide with an increased dose.']	Proceed taking tolbutamide as normal. There is no recommendation.	For individuals with variable G6PD (glucose-6-phosphate dehydrogenase) enzyme activity, caution is advised when prescribing tolbutamide. While there is no specific guideline requiring the avoidance of tolbutamide in G6PD-deficient individuals, monitoring for signs of hemolytic anemia is recommended due to the potential risk of oxidative stress-induced hemolysis.    	0.676735883354036	0.47955131885230384	0.34817622643350393	0.5942207831767348	0.6908823	0.5720664	0.4160348	0.5986106	0.6908425	0.51813734	0.3704994	0.63889307	0.69733614	0.43208066	0.34731165	0.5097846	0.6056653	0.51916754	0.40989122	0.49677116	0
tolbutamide	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking tolbutamide? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid tolbutamide. Take an alternate therapy.', 'Take tolbutamide with a reduced dose.', 'Take tolbutamide with an increased dose.']	Proceed taking tolbutamide as normal. There is no recommendation.	Clinical guidance for a patient who is deficient in glucose-6-phosphate dehydrogenase (G6PD) would advise caution when prescribing tolbutamide. Due to the risk of hemolytic anemia in G6PD-deficient individuals, alternative medications with a lower risk for hemolysis should be considered, and close monitoring for signs of hemolysis is recommended if tolbutamide is used. Regular follow-ups and blood tests might be necessary to ensure patient safety.	0.6345045443598568	0.47955131885230384	0.34817622643350393	0.5454356284380771	0.64507794	0.5720664	0.4160348	0.61794525	0.6137302	0.51813734	0.3704994	0.6213994	0.59276587	0.43208066	0.34731165	0.5498974	0.5840151	0.51916754	0.40989122	0.5026542	0
tolbutamide	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking tolbutamide? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid tolbutamide. Take an alternate therapy.', 'Take tolbutamide with a reduced dose.', 'Take tolbutamide with an increased dose.']	Proceed taking tolbutamide as normal. There is no recommendation.	Individuals with an indeterminate G6PD status should exercise caution when taking tolbutamide, as they may be at risk for hemolytic anemia. It's recommended to monitor for signs of hemolysis and consult with a healthcare provider for potential alternative medications or additional genetic testing to clarify G6PD status.	0.6436557479194617	0.36735251477112596	0.29119224497557256	0.5557611718412064	0.5255074	0.263307	0.34012333	0.6432109	0.53993624	0.3410755	0.3203219	0.7286685	0.57084113	0.24749403	0.24025302	0.6240198	0.5640968	0.43693373	0.41461122	0.54325104	0
toluidine blue	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking toluidine blue? Give a 2-3 sentence summary.	Avoid use	['Proceed taking toluidine blue as normal. There is no recommendation.', 'Take toluidine blue with a reduced dose.', 'Take toluidine blue with an increased dose.']	Avoid toluidine blue. Take an alternate therapy.	For individuals who are deficient in glucose-6-phosphate dehydrogenase (G6PD), the use of toluidine blue should be approached with caution or avoided. G6PD deficiency can increase the risk of hemolysis when exposed to certain medications and oxidative agents, including toluidine blue. Therefore, it is advisable to consult with a healthcare provider to evaluate the risks and consider alternative diagnostic or therapeutic options.	0.2495462256810199	0.29805891440684995	0.25843775268165065	0.6281051377165685	0.31824595	0.37050304	0.28443623	0.6731543	0.16934945	0.14705402	0.1672533	0.6906286	0.18869054	0.18024419	0.18333055	0.64830506	0.44897556	0.62642556	0.5362361	0.65165097	1
toluidine blue	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking toluidine blue? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid toluidine blue. Take an alternate therapy.', 'Take toluidine blue with a reduced dose.', 'Take toluidine blue with an increased dose.']	Proceed taking toluidine blue as normal. There is no recommendation.	For individuals with an indeterminate G6PD status, clinical guidance typically recommends caution with the use of medications that can trigger hemolysis in G6PD-deficient patients. Toluidine blue is known to be a potential trigger for hemolytic events in G6PD deficiency. Therefore, it would be prudent to avoid toluidine blue or to conduct further testing to clarify the patient's G6PD status before considering its use.	0.6354725634431669	0.3804564666263044	0.3318767126545907	0.5862449090801695	0.5047614	0.2505031	0.29103777	0.6383933	0.5718912	0.29739717	0.25317508	0.6474585	0.48660898	0.17507727	0.15172209	0.6464476	0.5410068	0.44400328	0.4172858	0.55671453	0
toluidine blue	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking toluidine blue? Give a 2-3 sentence summary.	Avoid use	['Proceed taking toluidine blue as normal. There is no recommendation.', 'Take toluidine blue with a reduced dose.', 'Take toluidine blue with an increased dose.']	Avoid toluidine blue. Take an alternate therapy.	For someone who has Central Nervous System Hemolytic Anemia (CNSHA) and is deficient in glucose-6-phosphate dehydrogenase (G6PD), toluidine blue should be used with caution or avoided. G6PD deficiency can increase the risk of hemolytic anemia when exposed to oxidizing agents, and toluidine blue is one such agent known to trigger hemolysis in G6PD-deficient individuals. It is advisable to discuss alternative diagnostic options with a healthcare provider.	0.2100475793471048	0.29805891440684995	0.25843775268165065	0.5948595672282551	0.28290606	0.37050304	0.28443623	0.687011	0.1442696	0.14705402	0.1672533	0.70427257	0.17198814	0.18024419	0.18333055	0.64326173	0.413367	0.62642556	0.5362361	0.61106503	1
toluidine blue	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking toluidine blue? Give a 2-3 sentence summary.	No reason to avoid ased on G6PD status	['Avoid toluidine blue. Take an alternate therapy.', 'Take toluidine blue with a reduced dose.', 'Take toluidine blue with an increased dose.']	Proceed taking toluidine blue as normal. There is no recommendation.	For individuals who are normal for G6PD (Glucose-6-Phosphate Dehydrogenase), there are generally no specific contraindications or unique clinical concerns related to taking toluidine blue. Since G6PD deficiency is linked to increased risk of hemolysis with certain drugs and chemicals, those who are not deficient do not share this elevated risk and can use toluidine blue following standard clinical guidelines appropriate for the condition being treated. However, it is always advisable to consult with a healthcare provider before starting any new medication.	0.5863644826465725	0.3834674688079002	0.27447796406486497	0.6352018659575115	0.51778215	0.33329457	0.17082961	0.65762013	0.4521738	0.20651565	0.10903176	0.7031718	0.35496	0.14985672	0.09597399	0.6577126	0.51540357	0.39933273	0.3031793	0.6283645	1
tramadol	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 2.25 for CYP2D6 with regards to taking tramadol? Give a 2-3 sentence summary.	Use tramadol label recommended age- or weight-specific dosing.	['Avoid tramadol. Take an alternate therapy.', 'Take tramadol with a reduced dose.', 'Take tramadol with an increased dose.']	Proceed taking tramadol as normal. There is no recommendation.	For an individual who is a normal metabolizer with an activity score of 2.25 for the CYP2D6 enzyme, standard dosing of tramadol is typically appropriate. This metabolic profile indicates that the patient will most likely metabolize tramadol effectively into its active form, providing the intended analgesic effect. However, it is still important to monitor the patient for any adverse reactions or signs of suboptimal pain control, as individual responses to medication can vary.	0.5527546342273242	0.603821425948993	0.6140241180146866	0.5608276678310546	0.5879691	0.54410535	0.6003253	0.4898179	0.6333233	0.7159647	0.6857438	0.60091853	0.6363895	0.7178659	0.62632537	0.60802734	0.61355	0.64960617	0.6656348	0.62383705	1
tramadol	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking tramadol? Give a 2-3 sentence summary.	Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.	['Proceed taking tramadol as normal. There is no recommendation.', 'Take tramadol with a reduced dose.', 'Take tramadol with an increased dose.']	Avoid tramadol. Take an alternate therapy.	For an individual identified as a CYP2D6 ultrarapid metabolizer (activity score 2.75), the use of tramadol is generally not recommended. This is due to the increased risk of severe side effects from rapid conversion of tramadol into its active metabolite, which can lead to higher levels of opioid toxicity. Alternative pain management strategies should be considered to avoid these risks.	0.6317726957244996	0.6514804598095224	0.6042306389294846	0.5908070086651115	0.7397142	0.7926299	0.6635243	0.5826115	0.7763778	0.8252406	0.698061	0.68256587	0.73409945	0.70845735	0.6453412	0.6442897	0.7237532	0.80707586	0.6973669	0.6547246	1
tramadol	CYP2D6	What would be the clinical guidance for someone who is Indeterminate for CYP2D6 with regards to taking tramadol? Give a 2-3 sentence summary.	No recommendation	['Avoid tramadol. Take an alternate therapy.', 'Take tramadol with a reduced dose.', 'Take tramadol with an increased dose.']	Proceed taking tramadol as normal. There is no recommendation.	For a patient with an indeterminate CYP2D6 status taking tramadol, clinical guidelines suggest exercising caution. Tramadol’s analgesic effect depends on its metabolism to the active metabolite O-desmethyltramadol by CYP2D6, and variability in CYP2D6 function can affect efficacy and safety. It may be advisable to monitor the patient closely for pain control and adverse effects, and consider alternative analgesics if necessary.	0.19630784156654732	0.46005817611129435	0.19719534892637594	0.5715284684904397	0.10306354	0.29108876	0.15411814	0.58775306	0.032631025	0.15144758	0.060812023	0.63456964	0.012245058	0.33317629	0.09190321	0.5827456	0.28827375	0.51242226	0.40023422	0.5738775	0
tramadol	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking tramadol? Give a 2-3 sentence summary.	Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.	['Avoid tramadol. Take an alternate therapy.', 'Take tramadol with a reduced dose.', 'Take tramadol with an increased dose.']	Proceed taking tramadol as normal. There is no recommendation.	Individuals who are Intermediate Metabolizers with a CYP2D6 activity score of 0.5 may have reduced conversion of tramadol to its active metabolite, leading to potentially decreased analgesic efficacy. Clinical guidance typically suggests cautious use of tramadol, considering alternative pain management strategies or adjusting the dose as necessary. Close monitoring for therapeutic response and adverse effects is recommended.	0.5473468892618603	0.5871659934617327	0.5905429760518003	0.5462191526053334	0.59203655	0.66825503	0.6443484	0.6024705	0.6017851	0.7324383	0.6762671	0.66648674	0.5828822	0.63700956	0.54356027	0.598165	0.5495502	0.5737988	0.51630276	0.6150387	0
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine? Give a 2-3 sentence summary.	Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking trimipramine as normal. There is no recommendation.', 'Take trimipramine with a reduced dose.', 'Take trimipramine with an increased dose.']	Avoid trimipramine. Take an alternate therapy.	For an individual who is an intermediate metabolizer (activity score = 0.75) for CYP2D6 and a rapid metabolizer for CYP2C19, the clinical guidance for taking trimipramine would typically involve closer monitoring for therapeutic efficacy and adverse effects. Due to reduced CYP2D6 activity, there may be higher plasma levels of trimipramine, potentially leading to increased side effects. Additionally, the rapid metabolism through CYP2C19 might alter the balance of trimipramine’s metabolism, warranting careful dose adjustment and clinical monitoring.	0.809367970068781	0.7205231255562611	0.696732847165468	0.6325228342727579	0.7300006	0.6132038	0.50847274	0.5547634	0.82451296	0.6125775	0.52288413	0.6790608	0.79374224	0.6041246	0.5893733	0.6007567	0.76601607	0.67121416	0.63971174	0.63089126	0
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.25 for CYP2D6 and Poor Metabolizer for CYP2C19 with regards to taking trimipramine? Give a 2-3 sentence summary.	Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.	['Proceed taking trimipramine as normal. There is no recommendation.', 'Take trimipramine with a reduced dose.', 'Take trimipramine with an increased dose.']	Avoid trimipramine. Take an alternate therapy.	For someone who is an Intermediate Metabolizer with an activity score of 0.25 for CYP2D6 and a Poor Metabolizer for CYP2C19, caution should be exercised when prescribing trimipramine. Given the involvement of CYP2D6 in the metabolism of trimipramine, reduced metabolic activity could lead to higher plasma levels and an increased risk of side effects. Dose adjustments and careful clinical monitoring for adverse reactions are recommended.	0.7427681178619513	0.7767418278826546	0.7676794963632974	0.6303228123303142	0.6700361	0.66774267	0.5540744	0.5410032	0.6444861	0.66593623	0.58458406	0.60076153	0.5997313	0.62257737	0.58406955	0.6103303	0.59950304	0.67260265	0.58920425	0.62489897	0
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is No Result and activity score = No Result for CYP2D6 and Rapid Metabolizer for CYP2C19 with regards to taking trimipramine? Give a 2-3 sentence summary.	Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.	['Proceed taking trimipramine as normal. There is no recommendation.', 'Take trimipramine with a reduced dose.', 'Take trimipramine with an increased dose.']	Avoid trimipramine. Take an alternate therapy.	For someone with no available CYP2D6 results and a rapid metabolizer status for CYP2C19, it is important to closely monitor the individual if they are prescribed trimipramine, a tricyclic antidepressant primarily metabolized by CYP2D6. Enhanced metabolism by CYP2C19 may slightly alter the drug's pharmacokinetic profile, but the primary concern remains the unknown CYP2D6 status, which could significantly impact drug efficacy and safety. Consider alternative treatments or adjust dosages with careful therapeutic monitoring.	0.6746423517094547	0.5792983766510217	0.5271287649830944	0.6274251267725762	0.65221375	0.5267595	0.43399522	0.547895	0.6306084	0.4459792	0.3908306	0.6065891	0.6125131	0.52155083	0.50305086	0.6144594	0.6022849	0.59707284	0.51390237	0.5653397	0
trimipramine	CYP2D6;CYP2C19	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.5 for CYP2D6 and No Result for CYP2C19 with regards to taking trimipramine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid trimipramine. Take an alternate therapy.', 'Take trimipramine with a reduced dose.', 'Take trimipramine with an increased dose.']	Proceed taking trimipramine as normal. There is no recommendation.	For a patient who is classified as a Normal Metabolizer with an activity score of 1.5 for CYP2D6 and no result for CYP2C19, standard dosing of trimipramine is generally recommended. Since CYP2D6 primarily metabolizes trimipramine, the normal metabolizer status suggests that the patient should have typical drug metabolism and response, reducing the need for any dosing adjustment based solely on their CYP2D6 status. However, monitoring for efficacy and side effects is always prudent in the absence of complete pharmacogenomic data for CYP2C19.	0.4251114568445125	0.4863172961483083	0.4991211252321241	0.6801195706316051	0.45117185	0.3432085	0.4081172	0.56480247	0.35388893	0.47519082	0.3911544	0.6599995	0.33763146	0.4700804	0.48130813	0.55906063	0.42511687	0.54109067	0.59783524	0.6181296	1
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥6.0 for CYP2D6 with regards to taking tropisetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking tropisetron as normal. There is no recommendation.', 'Take tropisetron with a reduced dose.', 'Take tropisetron with an increased dose.']	Avoid tropisetron. Take an alternate therapy.	For individuals who are ultrarapid metabolizers with a CYP2D6 activity score of ≥6.0, the clinical guidance would indicate that they are likely to metabolize tropisetron very quickly. This may result in lower plasma concentrations of the drug, potentially reducing its efficacy in preventing nausea and vomiting. As a result, alternative antiemetic agents that do not rely on CYP2D6 metabolism should be considered.	0.5854034326188543	0.583343884658839	0.47300642609087323	0.5965131184221028	0.5134768	0.47649997	0.44190633	0.5513764	0.70413685	0.36477798	0.40524283	0.525767	0.677555	0.4630484	0.50664824	0.57113653	0.6125856	0.60423833	0.5602826	0.62540627	1
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking tropisetron? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid tropisetron. Take an alternate therapy.', 'Take tropisetron with a reduced dose.', 'Take tropisetron with an increased dose.']	Proceed taking tropisetron as normal. There is no recommendation.	For a patient who is a normal metabolizer with an activity score of 1.75 for CYP2D6, standard dosing of tropisetron is generally recommended. This metabolic status indicates that the patient has typical enzyme activity, so the drug's efficacy and safety profile are expected to align with standard guidelines. Adjustments to dosage are typically unnecessary unless other patient-specific factors or medications suggest otherwise.	0.440217166192857	0.5165294017567229	0.5168800195862228	0.6403120811893513	0.50834435	0.41645193	0.5192624	0.61177236	0.4631388	0.50086075	0.49158564	0.74152553	0.4348106	0.49092487	0.5058729	0.63770676	0.4636969	0.46484816	0.5646644	0.6137567	1
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking tropisetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking tropisetron as normal. There is no recommendation.', 'Take tropisetron with a reduced dose.', 'Take tropisetron with an increased dose.']	Avoid tropisetron. Take an alternate therapy.	For a patient identified as an ultrarapid metabolizer with an activity score of 2.75 for CYP2D6, the standard clinical guidance suggests avoiding the use of tropisetron. Due to the increased enzymatic activity, tropisetron may be metabolized too quickly, leading to decreased efficacy. An alternative antiemetic that is not significantly metabolized by CYP2D6, such as ondansetron or granisetron, should be considered.	0.6535542346447432	0.583343884658839	0.47300642609087323	0.6633819995854207	0.6664519	0.47649997	0.44190633	0.63180274	0.7541642	0.36477798	0.40524283	0.55024326	0.782197	0.4630484	0.50664824	0.5516836	0.69382846	0.60423833	0.5602826	0.6535252	1
tropisetron	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥5.0 for CYP2D6 with regards to taking tropisetron? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).	['Proceed taking tropisetron as normal. There is no recommendation.', 'Take tropisetron with a reduced dose.', 'Take tropisetron with an increased dose.']	Avoid tropisetron. Take an alternate therapy.	For individuals identified as Ultrarapid Metabolizers with a CYP2D6 activity score of ≥5.0, the clinical guidance typically involves caution or avoidance of using tropisetron. This is due to the potential for significantly reduced efficacy of the medication as these patients may metabolize the drug too quickly. Alternative antiemetics that are not primarily metabolized by CYP2D6 should be considered for optimal therapeutic effect.	0.6041011266027846	0.583343884658839	0.47300642609087323	0.6326749527731885	0.6917085	0.47649997	0.44190633	0.635362	0.7504644	0.36477798	0.40524283	0.55306935	0.6732626	0.4630484	0.50664824	0.48047343	0.637936	0.60423833	0.5602826	0.6829292	1
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.5 for CYP2D6 with regards to taking venlafaxine? Give a 2-3 sentence summary.	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	['Avoid venlafaxine. Take an alternate therapy.', 'Take venlafaxine with a reduced dose.', 'Take venlafaxine with an increased dose.']	Proceed taking venlafaxine as normal. There is no recommendation.	For an individual identified as a CYP2D6 ultrarapid metabolizer (activity score ≥ 3.5) considering venlafaxine, clinical guidance typically suggests caution. Ultrarapid metabolism may lead to reduced efficacy of venlafaxine due to its rapid conversion into the less active metabolite, O-desmethylvenlafaxine (ODV). Alternative antidepressants that are not primarily metabolized by CYP2D6 may be recommended to achieve better therapeutic outcomes and avoid suboptimal response.	0.6362105056578026	0.6441499444191524	0.5854344068748273	0.6068274495954008	0.4604015	0.5338718	0.3698864	0.58095473	0.5895599	0.65448844	0.5178929	0.51711905	0.5278677	0.6193783	0.52694565	0.521158	0.5100854	0.66103494	0.52958226	0.5700506	0
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Normal Metabolizer and activity score = 1.75 for CYP2D6 with regards to taking venlafaxine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid venlafaxine. Take an alternate therapy.', 'Take venlafaxine with a reduced dose.', 'Take venlafaxine with an increased dose.']	Proceed taking venlafaxine as normal. There is no recommendation.	For an individual who is a normal metabolizer (activity score = 1.75) of CYP2D6, standard dosing guidelines for venlafaxine can be followed. This activity score indicates that the person has normal enzyme function, so the metabolism of venlafaxine is expected to be typical without needing dose adjustments. However, as with any medication, monitoring for efficacy and side effects is recommended.	0.3763943067346086	0.47080652981385346	0.49444252899413793	0.6338189190093589	0.40250355	0.39294922	0.43581223	0.5176943	0.3914789	0.5070596	0.40087876	0.57892954	0.36722597	0.4703526	0.49559283	0.5216942	0.36472857	0.545141	0.5885901	0.6118723	1
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = 2.75 for CYP2D6 with regards to taking venlafaxine? Give a 2-3 sentence summary.	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	['Avoid venlafaxine. Take an alternate therapy.', 'Take venlafaxine with a reduced dose.', 'Take venlafaxine with an increased dose.']	Proceed taking venlafaxine as normal. There is no recommendation.	For an individual identified as an ultrarapid metabolizer with a CYP2D6 activity score of 2.75, clinical guidelines suggest considering alternative medications that are not primarily metabolized by CYP2D6. This is because ultrarapid metabolizers may convert venlafaxine to its active metabolite, O-desmethylvenlafaxine, too quickly, potentially reducing the drug's efficacy and increasing the risk of subtherapeutic response. Should venlafaxine therapy be necessary, close monitoring and possible dose adjustments are recommended.	0.5991043505436132	0.6441499444191524	0.5854344068748273	0.5577575098418955	0.40224853	0.5338718	0.3698864	0.57663023	0.6020677	0.65448844	0.5178929	0.5668274	0.5559259	0.6193783	0.52694565	0.54009575	0.5185908	0.66103494	0.52958226	0.579963	0
venlafaxine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥4.0 for CYP2D6 with regards to taking venlafaxine? Give a 2-3 sentence summary.	No action recommended based on genotype for venlafaxine because of minimal evidence regarding the impact on efficacy or side effects.	['Avoid venlafaxine. Take an alternate therapy.', 'Take venlafaxine with a reduced dose.', 'Take venlafaxine with an increased dose.']	Proceed taking venlafaxine as normal. There is no recommendation.	For an individual who is an ultrarapid metabolizer (activity score ≥4.0) of CYP2D6 taking venlafaxine, clinical guidance typically recommends considering alternative medications not metabolized by CYP2D6. This is because ultrarapid metabolizers may have significantly lower plasma concentrations of venlafaxine, leading to reduced efficacy. Monitoring the patient's response if venlafaxine is used may also be necessary.	0.6257748915427647	0.6441499444191524	0.5854344068748273	0.5936187825979696	0.477298	0.5338718	0.3698864	0.6076509	0.5997103	0.65448844	0.5178929	0.56403285	0.5361216	0.6193783	0.52694565	0.52681285	0.51306665	0.66103494	0.52958226	0.61200887	0
vitamin c	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking vitamin c? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid vitamin c. Take an alternate therapy.', 'Take vitamin c with a reduced dose.', 'Take vitamin c with an increased dose.']	Proceed taking vitamin c as normal. There is no recommendation.	Individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency should generally avoid high doses of vitamin C, as it has the potential to induce hemolysis in some cases. However, normal dietary intake of vitamin C is typically considered safe. It is important for patients to consult their healthcare providers before taking any supplements.	0.653953193872831	0.4530974506176605	0.308718999123623	0.5114667745578525	0.5674228	0.49443787	0.28694376	0.6519212	0.56493586	0.39307263	0.20497374	0.64202607	0.5809014	0.42404637	0.31628388	0.6072871	0.551464	0.466125	0.38801518	0.6131775	0
vitamin c	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking vitamin c? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid vitamin c. Take an alternate therapy.', 'Take vitamin c with a reduced dose.', 'Take vitamin c with an increased dose.']	Proceed taking vitamin c as normal. There is no recommendation.	If an individual has an indeterminate G6PD status, caution is advised with vitamin C supplementation. High doses of vitamin C (more than 1 gram per day) can potentially induce oxidative stress, which may trigger hemolytic episodes in individuals with G6PD deficiency. It is best to consult a healthcare provider for personalized advice and possibly undergo further testing to clarify G6PD status.	0.6496391813278262	0.3463153099166472	0.25405531010652765	0.5196091147553065	0.5074726	0.19731884	0.21267374	0.6253422	0.55657697	0.2273946	0.17187029	0.6471843	0.5638731	0.18388693	0.1550858	0.5456265	0.44830087	0.35586622	0.36363074	0.5291782	0
vitamin c	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking vitamin c? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid vitamin c. Take an alternate therapy.', 'Take vitamin c with a reduced dose.', 'Take vitamin c with an increased dose.']	Proceed taking vitamin c as normal. There is no recommendation.	Individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, particularly those with chronic non-spherocytic hemolytic anemia (CNSHA), should exercise caution when taking high doses of vitamin C. Although low to moderate doses are generally considered safe, high doses can increase the risk of hemolysis. It is essential for these individuals to consult with their healthcare provider before taking vitamin C supplements to determine an appropriate and safe dosage.	0.45277579284061864	0.35131461979769635	0.38166649567999705	0.4882189952995636	0.5086734	0.43449652	0.43427578	0.63321584	0.4473415	0.38109422	0.37049726	0.674416	0.43713346	0.28539318	0.24695508	0.6284056	0.48134503	0.3831393	0.43508223	0.5954105	0
vitamin c	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking vitamin c? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid vitamin c. Take an alternate therapy.', 'Take vitamin c with a reduced dose.', 'Take vitamin c with an increased dose.']	Proceed taking vitamin c as normal. There is no recommendation.	For individuals with normal G6PD (glucose-6-phosphate dehydrogenase) activity, there are no specific restrictions or precautions required regarding the intake of vitamin C. They can safely consume vitamin C within the recommended dietary allowances. However, it is always good practice to follow general dietary guidelines and consult with a healthcare provider for personalized advice.	0.6567551581705807	0.385897769065	0.2336737561771104	0.5870225429151193	0.41594857	0.33424136	0.14917232	0.6157757	0.40647766	0.21868823	0.086595275	0.6469906	0.50833243	0.16924912	0.10133479	0.5775446	0.58474964	0.3842258	0.29911324	0.63904107	1
vitamin k	G6PD	What would be the clinical guidance for someone who is Deficient for G6PD with regards to taking vitamin k? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status at standard doses	['Avoid vitamin k. Take an alternate therapy.', 'Take vitamin k with a reduced dose.', 'Take vitamin k with an increased dose.']	Proceed taking vitamin k as normal. There is no recommendation.	For individuals with Glucose-6-Phosphate Dehydrogenase (G6PD) deficiency, taking vitamin K is generally considered safe as it is not known to cause hemolytic anemia, a common concern in G6PD deficiency. However, patients should always consult with a healthcare provider before adding any supplements to ensure it won't interact adversely with other medications or conditions.	0.6480275049310753	0.475064707519343	0.3319275488877396	0.5651491507513384	0.58330476	0.52705634	0.32932243	0.66581607	0.5787591	0.4385026	0.254809	0.6964586	0.54327875	0.433376	0.34540698	0.619335	0.51697123	0.47779933	0.3998873	0.6063566	1
vitamin k	G6PD	What would be the clinical guidance for someone who is Indeterminate for G6PD with regards to taking vitamin k? Give a 2-3 sentence summary.	To ascertain G6PD status, enzyme activity must be measured. Drug use should be guided per the recommendations based on the activity-based phenotype.	['Avoid vitamin k. Take an alternate therapy.', 'Take vitamin k with a reduced dose.', 'Take vitamin k with an increased dose.']	Proceed taking vitamin k as normal. There is no recommendation.	Clinical guidance for individuals with an indeterminate G6PD status, when considering vitamin K administration, generally involves caution due to the risk of hemolysis in G6PD-deficient individuals. Close monitoring for signs of hemolysis is recommended, and alternative options should be considered if the clinical scenario allows. Consulting a healthcare professional for personalized advice based on the specific context and patient history is crucial.	0.6133583464205105	0.36038475964218825	0.2648181186428211	0.5817048983579275	0.57761395	0.23327231	0.25797138	0.58802456	0.60286605	0.2969514	0.23800898	0.6413664	0.58196586	0.21016856	0.19161744	0.5371219	0.5395158	0.3453314	0.3607073	0.576419	0
vitamin k	G6PD	What would be the clinical guidance for someone who is Deficient with CNSHA for G6PD with regards to taking vitamin k? Give a 2-3 sentence summary.	Use drug cautiously; if used, close monitoring for acute exacerbation of chronic hemolysis is recommended	['Avoid vitamin k. Take an alternate therapy.', 'Take vitamin k with a reduced dose.', 'Take vitamin k with an increased dose.']	Proceed taking vitamin k as normal. There is no recommendation.	Individuals with glucose-6-phosphate dehydrogenase (G6PD) deficiency, particularly those with chronic non-spherocytic hemolytic anemia (CNSHA), should exercise caution with vitamin K administration. While vitamin K itself is not typically harmful, it is essential to avoid formulations that contain oxidizing agents or other additives that could trigger hemolysis. Clinical guidance would typically involve careful monitoring and consultation with a healthcare provider before initiating any new medication.	0.469185261813955	0.37778885201017903	0.4139942524045785	0.527816304788049	0.4867876	0.4314468	0.4303917	0.6624186	0.45645702	0.38260692	0.35706964	0.6634346	0.44117185	0.30072775	0.28885838	0.6066062	0.48258087	0.39884764	0.46758947	0.575219	0
vitamin k	G6PD	What would be the clinical guidance for someone who is Normal for G6PD with regards to taking vitamin k? Give a 2-3 sentence summary.	No reason to avoid based on G6PD status	['Avoid vitamin k. Take an alternate therapy.', 'Take vitamin k with a reduced dose.', 'Take vitamin k with an increased dose.']	Proceed taking vitamin k as normal. There is no recommendation.	For individuals with normal Glucose-6-Phosphate Dehydrogenase (G6PD) activity, there are no specific contraindications or additional risks associated with taking vitamin K. Therefore, they can typically take vitamin K as needed, based on clinical indications such as vitamin K deficiency or certain medical treatments, without concerns related to G6PD deficiency.	0.6222311267655648	0.4027223661759168	0.2574430244618993	0.6150508961605954	0.47212806	0.36030206	0.16898829	0.63681334	0.45808557	0.24453527	0.101157606	0.67194384	0.3908154	0.16376244	0.10161231	0.614877	0.46061462	0.38489196	0.29952312	0.6076258	1
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Indeterminate for CYP2C19 with regards to taking voriconazole? Give a 2-3 sentence summary.	No recommendation	['Avoid voriconazole. Take an alternate therapy.', 'Take voriconazole with a reduced dose.', 'Take voriconazole with an increased dose.']	Proceed taking voriconazole as normal. There is no recommendation.	For someone with an Indeterminate CYP2C19 genotype taking voriconazole, clinical guidance recommends close monitoring for adverse effects and therapeutic drug monitoring to ensure appropriate drug levels, as their enzyme activity is uncertain. Adjustments to the voriconazole dose may be required based on clinical response and tolerability.	0.2191881034539712	0.445532616503986	0.2118958503339906	0.6078830788421846	0.11123786	0.3322562	0.17737852	0.57275844	0.076622844	0.22173272	0.11324041	0.65327233	-0.052407153	0.28892753	0.062933825	0.5294938	0.26313016	0.50118667	0.36249566	0.5724653	0
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Ultrarapid Metabolizer for CYP2C19 with regards to taking voriconazole? Give a 2-3 sentence summary.	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole.	['Proceed taking voriconazole as normal. There is no recommendation.', 'Take voriconazole with a reduced dose.', 'Take voriconazole with an increased dose.']	Avoid voriconazole. Take an alternate therapy.	For someone identified as an Ultrarapid Metabolizer (UM) for CYP2C19, the use of voriconazole is generally not recommended because it is metabolized by CYP2C19. Ultrarapid metabolizers will likely achieve subtherapeutic drug levels, rendering the medication ineffective. Alternative antifungal agents that are less dependent on CYP2C19 metabolism should be considered to ensure effective treatment.	0.7149675640058165	0.736287600762101	0.5719272644518504	0.6263277496197167	0.6013729	0.6985361	0.58659106	0.6526845	0.790437	0.7335008	0.66546136	0.6684154	0.7432845	0.62062985	0.539712	0.53998977	0.7797167	0.6731476	0.5901023	0.6195361	1
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Intermediate Metabolizer for CYP2C19 with regards to taking voriconazole? Give a 2-3 sentence summary.	Initiate therapy with recommended standard of care dosing	['Avoid voriconazole. Take an alternate therapy.', 'Take voriconazole with a reduced dose.', 'Take voriconazole with an increased dose.']	Proceed taking voriconazole as normal. There is no recommendation.	For patients identified as intermediate metabolizers for CYP2C19, voriconazole therapy warrants careful consideration. Clinical guidance suggests monitoring for adverse effects and therapeutic drug levels closely, with dose adjustments potentially necessary to achieve therapeutic efficacy while minimizing toxicity. An alternative antifungal agent may also be considered if optimal dosing and monitoring are not feasible.	0.4587588953881225	0.4988429877538778	0.4739442441060751	0.6206545634279151	0.5191492	0.47210976	0.49840656	0.55556834	0.3965982	0.5359108	0.45065176	0.6206634	0.3498374	0.40004116	0.3325781	0.53082293	0.59853923	0.49174172	0.51202416	0.6006351	0
voriconazole	CYP2C19	What would be the clinical guidance for someone who is Poor Metabolizer for CYP2C19 with regards to taking voriconazole? Give a 2-3 sentence summary.	Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.	['Proceed taking voriconazole as normal. There is no recommendation.', 'Take voriconazole with a reduced dose.', 'Take voriconazole with an increased dose.']	Avoid voriconazole. Take an alternate therapy.	In patients identified as Poor Metabolizers (PMs) for CYP2C19, the clinical guidance for voriconazole typically recommends starting with a lower dose and closely monitoring for adverse effects due to the increased drug levels associated with decreased metabolism. Alternative antifungal therapy may also be considered to avoid potential toxicity. It's essential to conduct therapeutic drug monitoring to ensure proper drug levels and to adjust the dosage accordingly.	0.8036017651790087	0.7293173137227408	0.6248888280841638	0.6364457452514747	0.7261531	0.7191381	0.6085645	0.65244937	0.83605653	0.67237025	0.61847323	0.66333556	0.7736261	0.601125	0.5393539	0.54327387	0.7331107	0.6367208	0.56936806	0.6791559	1
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.75 for CYP2D6 with regards to taking vortioxetine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid vortioxetine. Take an alternate therapy.', 'Take vortioxetine with a reduced dose.', 'Take vortioxetine with an increased dose.']	Proceed taking vortioxetine as normal. There is no recommendation.	For a patient identified as an intermediate metabolizer with an activity score of 0.75 for CYP2D6, the clinical guidance for taking vortioxetine would typically recommend initiating treatment with the standard starting dose. However, due to their reduced metabolic capacity, close monitoring for efficacy and potential adverse effects is advised, as adjustments in dosage may be necessary based on clinical response and tolerability.	0.5390863062193573	0.5076687326867557	0.5233059093373252	0.6323340617678336	0.55800056	0.4053733	0.4411199	0.5849887	0.48305944	0.5120082	0.43013287	0.71047544	0.50435185	0.50170827	0.5267877	0.6163949	0.6309444	0.52290684	0.60683453	0.6560645	1
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Ultrarapid Metabolizer and activity score = ≥3.0 for CYP2D6 with regards to taking vortioxetine? Give a 2-3 sentence summary.	Select alternative drug not predominantly metabolized by CYP2D6. If vortioxetine use is warranted, initiate therapy at standard starting dose and titrate to maintenance dose based on efficacy and side effects. Increasing the target maintenance dose by 50% or more may be needed for efficacy.	['Proceed taking vortioxetine as normal. There is no recommendation.', 'Take vortioxetine with a reduced dose.', 'Take vortioxetine with an increased dose.']	Avoid vortioxetine. Take an alternate therapy.	For individuals who are CYP2D6 ultrarapid metabolizers with an activity score of ≥3.0, clinical guidance typically recommends caution when prescribing vortioxetine. These patients may experience reduced therapeutic efficacy due to increased metabolism of the drug. Therefore, it might be necessary to consider an alternative antidepressant that is not primarily metabolized by CYP2D6 to avoid suboptimal treatment response.	0.8055192873137993	0.7039751405306827	0.6784341321434167	0.6675396221146082	0.73227984	0.61908394	0.5544879	0.68048286	0.7738359	0.6243583	0.57840055	0.6773793	0.8081871	0.660748	0.63511544	0.6234497	0.71483934	0.6137674	0.5884796	0.6990972	1
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 1.0 for CYP2D6 with regards to taking vortioxetine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid vortioxetine. Take an alternate therapy.', 'Take vortioxetine with a reduced dose.', 'Take vortioxetine with an increased dose.']	Proceed taking vortioxetine as normal. There is no recommendation.	Vortioxetine dosage should be adjusted for individuals who are Intermediate Metabolizers (activity score = 1.0) of CYP2D6. Although clinical data specific to Intermediate Metabolizers is limited, it is generally recommended to monitor for adverse effects and consider a lower starting dose or slower dose titration. Intermediate Metabolizers may have somewhat reduced enzyme activity, leading to increased drug exposure and potential for side effects.	0.4775819043271773	0.5076687326867557	0.5233059093373252	0.6084541705073485	0.45652086	0.4053733	0.4411199	0.4875387	0.42035443	0.5120082	0.43013287	0.64430165	0.4357468	0.50170827	0.5267877	0.6016556	0.47227398	0.52290684	0.60683453	0.5596858	0
vortioxetine	CYP2D6	What would be the clinical guidance for someone who is Intermediate Metabolizer and activity score = 0.5 for CYP2D6 with regards to taking vortioxetine? Give a 2-3 sentence summary.	Initiate therapy with recommended starting dose.	['Avoid vortioxetine. Take an alternate therapy.', 'Take vortioxetine with a reduced dose.', 'Take vortioxetine with an increased dose.']	Proceed taking vortioxetine as normal. There is no recommendation.	For an individual identified as an Intermediate Metabolizer with a CYP2D6 activity score of 0.5 who is prescribed vortioxetine, clinical guidance usually recommends starting at the normal initial dose and monitoring for efficacy and adverse effects. Although dose adjustments are not generally required for Intermediate Metabolizers, close monitoring is advised due to the potential for altered drug metabolism, which may affect drug levels and response.	0.5188756093032981	0.5076687326867557	0.5233059093373252	0.6195072336707798	0.5040779	0.4053733	0.4411199	0.60767865	0.46797493	0.5120082	0.43013287	0.6497927	0.47640705	0.50170827	0.5267877	0.5984692	0.4967915	0.52290684	0.60683453	0.6081392	1
